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Abstract
P-glycoprotein (P-gp), a major contributor in multidrug resistance (MDR), is a cell 
surface drug efflux pump restricting the intracellular accumulation of many 
agents used in cancer chemotherapy leading to treatment failure. Over­
expression of P-gp is a significant indicator of poor outcome in cancer including 
acute myelogenous leukaemia (AML). In addition to its primary drug efflux role, 
P-gp over-expression may also exert a protective influence on a cell’s ability to 
undergo apoptosis in response to certain stimuli.
A wide range of P-gp inhibitors have been developed for clinical use in an 
attempt to modulate the MDR phenotype. Zosuquidar Trihydrochloride (Z.3HCL) 
is a potent and specific third generation P-gp inhibitor and functions in a non­
competitive manner.
Z.3HCL was the subject of three phase I clinical trials: two on patients with solid 
tumours and one on 16 patients with AML. Functional and expression assays 
were conducted on CD56+ NK cells isolated from patients enrolled on these 
studies. Safety and efficacy data were also analysed, where available. Z.3HCL 
was also implemented in a number of in vitro assays investigating P-gp 
expression and function in malignant cells isolated from patients with 
haematological malignancies: 48 with AML, 75 with CLL, and 16 with MM. 
Apoptosis assays, utilising normal, patient, and cultured cells were undertaken to 
investigate the putative role of P-gp in apoptotic modulation.
In the solid tumour trials, in vitro assays showed that Z.3HCL infusion was 
associated with rapid inhibition of P-gp mediated efflux in CD56+ NK cells in 
85.2% patients studied. Of the patients enrolled on the AML trial, 11 achieved a 
complete remission and one a partial remission, with a median survival of 559 
(range 38-906) days. Non-haematologic grade 3 and 4 toxicities were observed 
in four patients. The in vitro assays showed that Z.3HCL infusion was 
associated with rapid inhibition of P-gp mediated efflux in CD56+ NK cells in all 
16 patients, and in CD33+ cells from 6/10 patients. The median IC50 for 
daunorubicin (DNR) using a MTT assay, decreased significantly between
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Z.3HCL modulated and unmodulated cells (153 and 247 ng/mL respectively, 
P=0.01).
In vitro studies showed that 38.2% of samples from AML patients, 61.3% from 
CLL and 41.2% from MM over-expressed P-gp. Drug sensitisation studies on 
AML cells showed significantly increased drug sensitivity in P-gp positive co­
incubated with Z.3HCL and DNR, which was not observed for P-gp negative 
cells or for co-incubation with cytarabine. Further studies in CLL patients 
showed that P-gp function and expression did not correlate with other prognostic 
indicators such as Binet stage, ZAP-70 expression or lgVH mutation status.
The intermediately P-gp expressing cell line CEMv showed a significant 
resistance to ionising radiation compared with CEM cells. Apoptosis assays 
demonstrated that modulating P-gp with Z.3HCL was able to increase 
significantly the apoptotic sensitivity above baseline in the highly P-gp 
expressing CEM-VLB10o cells, an effect not seen in the P-gp negative parent 
CEM cells.
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1. Introduction
1.1 General Introduction
Cancers by their very nature are resistant to the death impulse that governs and 
maintains the regulation of cell number in multicellular organisms1,2. For many 
cancers, and in particular the malignancies that affect haematological tissues, 
the front-line therapeutic strategy involves the use of cytotoxic agents to arrest 
and reverse the pathogenic process3. The mechanism of action for many of 
these compounds is the induction of apoptosis, or programmed cell death, in the 
tumour cells whilst leaving normal tissues relatively unharmed4.
The real-world application of chemotherapeutic agents is fraught with a multitude 
of complexities that undermine their efficacy in the treatment of cancer. The 
inherent metabolic heterogeneity of patients affects the clearance rates of the 
drugs, non-specificity of the active compounds leads to systemic toxicity, and the 
innate adaptability of tumour cells gives rise to drug resistance5.
Chemotherapy drugs are toxic to a wide spectrum of cell types and accordingly
tend to have a narrow therapeutic window. Apoptosis is a tightly controlled
mechanism of programmed cell death requiring the activation of appropriate
cellular signalling mechanisms in order to commit the cell to this auto-destructive
path6. Processes that cause perturbations in the apoptotic signal being delivered
by the drug to the target cell will render that signal impotent, allowing the cell to
live and ultimately leading to chemotherapeutic failure. In addition, sub-lethal
doses of the cytotoxic drug will not only apply selective pressure in favour of
cells with resistance mechanisms, but will compound the problem by inducing
further upregulation of those mechanisms7.
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1.2 Apoptosis and Cancer
Cancers can be characterised as the pathological accumulation of abnormal 
cells which invade, subvert and supplant the host tissues8. A clonal expansion 
triggered by a genetic or epigenetic aberration9,10, the accretion of neoplastic 
cells is driven by two important factors: proliferation and immortality, the latter 
principally through the evasion of apoptosis. These two hallmarks of malignancy 
result from a breakdown in the tightly regulated mechanisms of cellular 
homeostasis which normally lead to differentiation and apoptosis - both of these 
being of paramount importance to the understanding of why cancers occur and 
for the development of curative strategies11.
Cellular differentiation involves the attainment from an intrinsically proliferative 
and functionally immature precursor cell to a functionally mature, usually non­
proliferative cell type. Oncogenic processes that arrest a cell at its precursor 
state will give rise to a clonal expansion of sub-functional cells which may 
eventually supplant the normal functioning population of cells, leading to 
disease12. Therapy that can force a tumour cell down its differentiation pathway, 
such as all trans retinoic acid (ATRA), which is used in the treatment of Acute 
promyelocytic leukaemia (APL), can make a significant contribution to achieving 
a cure13.
Apoptosis results from a series of intracellular mechanisms which when 
activated causes target cells to undergo what is commonly known as 
programmed cell death14'16. This type of cell death is distinct from necrotic or 
catastrophic cell death in that it is a strictly regulated and effector driven cascade 
of events leading to intracellular and nuclear degradation while maintaining
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plasma membrane integrity17. This ensures that there is no release of lytic 
agents from the cell’s endosomes that may cause damage to the local tissues 
and trigger an inflammatory response. At the culmination of the apoptotic 
process the cell’s DNA has been digested and condensed, the plasma 
membrane has become contracted and highly blebbed and the cell forms what is 
known as an apoptotic body, which can be safely removed by macrophages or 
absorbed by surrounding cells via phagocytosis18.
The main effectors of the apoptosis pathway are a set of homologous cysteine 
proteases collectively known as the caspases (from cvsteinvl-aspartate-cleavina 
proteases). These are synthesized as enzymically inert zymogens that upon 
activation cleave target substrates (including other caspase precursors) thus 
generating a signal amplifying cascade19. There are thought to be about 12 
caspases involved in apoptosis, and essentially, caspase 9 and caspase 8 can 
be thought of as initiator molecules while caspase 3, caspase 6 and caspase 7 
are the proteolytic effectors20.
The apoptotic pathway can be triggered by a variety of stimuli: DNA damage, 
growth factor deprivation, ligation of the tumour necrosis factor receptor (TNF-R) 
family and the action of cytotoxic drugs. The initiation of apoptosis is modulated 
by families of pro- and anti apoptotic proteins, among the most prominent being 
the essential pro-apoptotic checkpoint molecule, p53, the anti-apoptotic Bcl-2, 
Fas-associated protein with death domain (FADD), and the inhibitor of apoptosis 
proteins (lAPs)21'23.
The evasion of apoptotic signalling is one of the key events in the progression of
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malignant disease, and it is the aim that many chemotherapeutic agents may 
selectively restore apoptotic sensitivity to the tumour cells24.
1.3 Classes of Anti-cancer Drugs
Many cytotoxic agents in use are derived from natural sources such as tree bark 
(Taxol from Yew), microorganisms (Daunorubicin) and flowering plants 
(vincristine from periwinkle). Most enter the cell via passive diffusion across the 
plasma membrane, but some are transported via receptors (such as the folate 
analogue methotrexate25) or are endocytically internalized via pinocytosis (such 
as some classes of immunotoxins26). Generally, their defining feature is that 
they are more toxic to cancer cells than to normal cells; this is often because of 
the higher proliferation rate of malignant cells.
Once they are in the cell, the drugs have to travel to their site of action to 
achieve their cytotoxic effect, which is usually the nucleus since virtually all affect 
DNA synthesis or cell division. The anthracyclines, such as daunorubicin are 
intercalating agents that integrate into the DNA helix. They disrupt DNA 
replication during cell division and inhibit the topoisomerase enzymes resulting in 
cell cycle arrest and cell death via tumour suppressor checkpoint proteins such 
as p53.
The majority of commonly used chemotherapeutics can be divided into functional 
classes such as alkylating agents, anti-metabolites, plant alkaloids and other 
naturally derived agents, anti-tumour antibiotics, and hormones.
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The alkylating agents include the nitrogen mustard analogues, such as 
chlorambucil and melphalan, and the alkyl sulphonates such as busulfan27. The 
anti-metabolites include folic acid analogues (methotrexate), purine analogues 
(mercaptopurine), and pyrimidine analogues (cytarabine)28,29. The plant 
alkaloids and other agents include the vinca alkaloids (vincristine), 
podophyllotoxins (etoposide), and taxanes (paclitaxel)30. The anti-tumour 
antibiotics include anthracyclines such as mitoxantrone and daunorubicin, as 
previously discussed31.
Hormones can also be used as chemotherapeutic agents such as the steroid 
dexamethasone, which can inhibit the growth of some tumours, and hormone 
blocking agents, used in sex-hormone driven malignancies, such as finasteride 
and tamoxifen for prostate and ovarian cancers respectively32. Other anti-cancer 
agents include the platinum compounds, such as cisplatin, and monoclonal 
antibodies such as rituximab, which binds to the CD20 antigen and is used to 
treat certain B cell malignancies33.
1.4 Multidrug Resistance
Multidrug resistance (MDR) is an innate or acquired characteristic describing a 
number of cellular mechanisms that conspire to render a cell impervious to a 
range of structurally and functionally disparate cytotoxic agents34. A hallmark of 
the acquired trait is the ability of a single applied cytotoxin to engender a broad 
spectrum resistance phenotype35. The innate expression of MDR is cell and 
tissue specific, and tumours arising from these cellular sources will be more 
likely to display the MDR phenotype36. Tumours expressing or acquiring the
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MDR phenotype have been shown to be harder to treat with chemotherapy and 
correlate with a less optimistic prognosis37'39.
The best studied MDR mechanism is the expression of membrane efflux pumps. 
Their basic mode of action is to nullify the toxicity of a wide range of unrelated 
anticancer drugs by increasing their cellular efflux across the plasma membrane, 
resulting in reduced drug accumulation at the intracellular site of action40. 
Energy in the form of ATP hydrolysis is required for their operation, and they can 
actively remove compounds against a concentration gradient41. There are 
several different members of drug efflux pumps in this class, the best studied 
and possibly the most clinically significant being the P-glycoprotein (P-gp)42.
Other MDR mechanisms include: detoxification mechanisms (glutathione 
transferase, metallothionein and selenium dependent glutathione peroxidase), 
alteration of drug target site by mutation (e.g., BCR-ABL tyrosine kinase 
resistance to Imatinib Mesylate), enhanced DNA repair, lowered drug activation, 
and cell cycle and apoptosis mediated resistance (BCL-2, p53)43'45. There is one 
family of membrane associated efflux pumps that have become almost 
synonymous with the classical MDR mechanism of reduced drug accumulation, 
and they are the ABC Transporters46.
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1.5 ABC Transporters
The ATP-binding cassette (ABC) transporters are a superfamily of highly 
conserved membrane proteins responsible for the transport of a variety of 
molecules across the plasma membrane, as well as intracellular membranes47. 
There are currently 49 known human ABC transporters, classified into seven 
subfamilies, ABCA, ABCB, ABCC, ABCD, ABCE, ABCF and ABCG4849. They 
use energy from the hydrolysis of ATP to translocate a target substrate molecule 
across their associated membrane from one compartment to another, typically 
against a concentration gradient50.
The characteristic functional structure of ABC transporters is that of two 
homologous halves, joined by a linker region, each with a transmembrane 
domain (TMD) and a nucleotide binding domain (NBD)51 (Figure1.1). Each TMD 
typically comprises of 6-11 membrane spanning a-helices which determine the 
substrate specificity. There are some ABC proteins, however, that comprise of a 
so called half-transporter; consisting of only a single TMD and NBD, they are 
thought to operate functionally as a homodimer, or even in some cases as a 
heterodimer47,52.
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Figure 1.1 Basic structure of three ABC transporters implicated in MDR: P- 
glycoprotein (P-gp), Multidrug resistance associated protein (MRP1), and Breast 
cancer resistance protein (BCRP). TMD -  Transmembrane domain; NBD -  
Nucleotide binding domain.
The NBD’s are located in the cytoplasm and contain three conserved domains: 
the Walker A and B domains and a signature C motif, which is found upstream of 
the Walker B site53,54. The NBD’s translate and transfer energy liberated from the 
catalytic hydrolysis of ATP to ADP into the active transport of the substrate. 
Typically, two molecules of ATP are bound at the NBD’s and the target substrate 
is bound by one of the TMD’s. Energy from one of the hydrolysing ATP’s causes
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a conformation change in the steric state of the ABC molecule, facilitating the 
transport of the substrate across the associated membrane. Energy from the 
second ATP hydrolysis elicits another steric reconfiguration returning the ABC 
transporter to its basal state in preparation for another binding and transport 
cycle55'57.
Several classes of ABC transporters are implicated in human disease, most 
prevalent being mutations to the gene encoding the cystic fibrosis 
transmembrane regulator (CFTR, ABCC7), that disrupts its role as a chloride ion 
channel causing the dysfunctional mucus pathology associated with cystic 
fibrosis58'60. Multidrug resistance, however, is linked to the inappropriate over­
expression of functional ABC transporters: P-gp, MRP1, and BCRP, and several 
other related proteins. The degree of specificity and substrate overlap between 
these three main ABC transporters is shown in Figure 1.2.
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R123
MRP1
BCRP
Key:
BIS -  bisantrene 
CA -  calcein
CA-AM -  calcein-AM ester 
COL -  colchicine 
DNR-daunorubicin 
DOX -  doxorubicin 
EPR -  epirubicin 
LYS -  lysotracker 
MTX -  methotrexate 
MIT -  mitozantrone 
R123-rhodamine123  
TAX -taxol 
VBL -  vinblastine 
VPM -  verapamil 
ETP - etoposide
Adapted from Litman et al, 2001
Figure 1.2 Venn diagram illustrating substrate overlap between the three 
main MDR transporters, P-gp, MRP1 and BCRP. The compounds coloured 
green are efflux dyes commonly used for studying MDR function.
1.6 P-glycoprotein
ABCB1, MDR1, P-gp, PGY1, GP170
The permeability glycoprotein (P-gp) is the best known and most extensively 
studied contributor to the MDR phenotype. It was first described by Juliano and 
Ling in 1976 from work involving colchicine resistant Chinese Hamster Ovary 
cells61, although studies by Dano in 1973 identified active transport of 
daunomycin in Ehrlich tumour cells62. Inappropriate over-expression and
26
upregulation of P-gp in neoplasia as a response to chemotherapy is largely 
recognised to be an obstacle to successful treatment63.
P-gp is a 1280 amino acid, 170 kilodalton glycosylated membrane associated 
protein that exports a wide range of structurally and functionally diverse 
substrates64'66. It is a member of the ATP Binding Cassette (ABC) transporter 
superfamily (sub-family ABCB67) and is encoded by the MDR1 gene which has 
28 exons and maps to the long-arm of chromosome 7 (7q21.1 )47,68.
1.6.1 P-gp Structure
Although its exact crystallographic structure is yet to be elucidated, it is 
commonly believed that the P-gp molecule has a typical ABC transporter 
configuration, consisting of two homologous halves of about 610 amino acids, 
each with six a-helix transmembrane domains and an ATP binding motif (Figure 
1.1). The two homologous sections are joined by a flexible linker region of about 
60 amino acids, and each TMD has four intracellular loops, each made up of 50 
amino acids, connecting the a-helices on the cytoplasmic side of the 
membrane69. It is envisioned that the P-gp molecule resides in the lipid phase of 
the associated membrane and folds spatially to form a pore-like structure with a 
symmetry analogous to a heterodimer, but a single protein coded by a single 
gene (Figure 1.3).
The P-gp molecule is glycosylated at three N-glycosylation sites in the first 
extracellular loop. Mutational and deletion analysis shows that these
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glycosylations are required, not for efflux function, but for the correct trafficking of 
the P-gp protein to the plasma membrane70,71.
Studies using photo affinity substrate analogues to map P-gp substrate binding 
interactions have shown that different substrates have different, but overlapping 
binding sites. All the areas implicated exist within the cr-helix transmembrane 
domains72. Further evidence for the location of the substrate binding domain 
came from site directed mutagenesis studies that showed that mutant P-gp 
molecules that lacked both NBD’s (and so only consisted of the TMD’s) could 
still bind drug substrates73.
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Figure 1.3. Structural diagram of P-gp. The transdomain regions span the 
plasma membrane and the folded structure may be envisioned as pore-like. Also 
shown is the exon sequence relating to amino acid position. From Ambudkar et 
al, 2003
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1.6.2 Mode of Action of P-gp
The plasma membrane forms a differentially permeable partition between the 
interior of the cell and the functional milieu of its tissue environment. The plasma 
membrane is a fluid lipid-protein matrix into which is embedded a multitude of 
receptors, effectors and signalling components all involved in dynamic 
interactions necessary to the function and continuing survival of the cell. P-gp 
interacts with, responds to, and exerts an influence over its immediate lipid- 
membrane environment.
P-gp is concerned with affecting the net permeability of the plasma membrane, 
primarily through the active effluxing against a concentration gradient of 
passively permeating target compounds. The ability of the plasma membrane to 
generate a concentration gradient is dependent upon its ability to effectively 
partition. This in turn is dependent upon the dynamic domains of its lipid-protein 
matrix which affect the kinetics of the permeating target and may exert an 
influence over the efflux kinetics of P-gp74.
P-gp has been shown to act as a flippase, intercepting target compounds from 
the inner leaflet of the plasma membrane lipid bilayer, and ‘flipping’ the target to 
the outer leaflet and thus out of the cell (or compartment)75,76. This has the net 
effect of preventing the intracellular (or intracompartmental) concentration of 
administered cytotoxic drugs reaching an effective therapeutic level.
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1.6.3 P-gp Isoforms and Homologues
There are two P-gp isoforms in humans (MDR1 and MDR3)77 and three in 
rodents (mdrla, m drlb  and m drlc)78. MDR3 (ABCB4 encoded by the MDR3 
gene, mapping to 7q21.1) may have a physiological role in the liver translocating 
phosphatidylcholine into bile, and is most strongly expressed on the hepatocyte 
canalicular membranes79. Mutations arising in MDR3 have been implicated in an 
increased susceptibility to the bile disorders Familial Intrahepatic Cholestasis 
and Intrahepatic Cholestasis of Pregnancy80,81.
Although MDR3 has some substrate overlap with P-gp it has not been shown to 
be significantly involved in drug resistance. However, some studies have 
reported an increase in drug uptake by MDR3 expressing leukaemia cells 
treated with cyclosporine82'84. MDR3 is homologous to the murine mdr285
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Table 1.1 Summary of tissue sites of physiological P-gp expression.
Sites of Elevated P-gp Expression 
Liver
Biliary canalicular membrane
Kidney
Brush border of renal proximal tubules
Gl Tract
Apical surface of intestinal mucosal cells
Endocrine System
Adrenal Gland
Blood - Tissue Barriers
Capillary endothelial cells of:
Brain
T estes
Ovaries
Placenta
Haematological Cells
CD34+ Stem Cells 
CD56+ Natural Killer (NK) 
CD8+ T-cells
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Two proteins closely related to P-gp have recently been described. One is the 
recently characterised ABCB5 P-gp which is an 812 amino acid protein encoded 
on chromosome 7p21-15.3 and whose expression is lineage restricted to the 
plasma membrane of CD133+ human epidermal progenitor cells. Its 
physiological function appears to be concerned with the control of progenitor cell 
fusion to form multinucleate constructs through regulating membrane potential 
depolarisation86. ABCB5 P-gp has been reported to be able to efflux R123, but 
no role in contributing to MDR has been elucidated.
The second is the ‘Sister of P-glycoprotein’ (sPgp, ABCB11), which is a specific 
bile acid transporter expressed only in the liver canalicular membrane87,88. Its 
gene map locus is 2q24, and mutations to this gene are associated with 
progressive familial intrahepatic cholestasis; however, sPgp is not thought to 
play a role in MDR.
1.6.4 Physiological Role of P-gp
P-gp is constitutively expressed by three basic cell types: tissue barrier, 
excretory surface, and haematological cells89. It is found in high levels at the 
apical surface of cells typically associated with transport leading to a proposed 
primary role as a cellular detoxifier through the active secretion of xenobiotics 
and natural toxins90. This theory is supported through murine mdr gene 
knockout studies which show a role for P-gp in drug absorption, disposition, 
elimination, and detoxification pathways72'91,92.
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There is evidence for several secondary regulatory roles. The activity of P-gp is 
highly influenced by the lipid component of the membrane it is embedded. Since 
the make-up of the lipid phase of cells is strongly dependant upon the cell type, it 
is reasonable to assume that the determinants of physiological P-gp function are 
likely to be cell type specific74.
Highest normal physiological expression of P-gp is to be found on the apical 
surface of gut epithelia93, liver cells94, kidney tubules95,96 and blood-tissue 
barriers (brain and testes)97,98. Elevated expression is also found on 
haematopoietic stem cells (CD34+)99'103, Natural killer cells (NK), and T and B 
lymphocytes104. Intestinal expression of P-gp can have a severe limiting affect 
upon the bioavailability of substrate compounds ingested via the oral route and 
so restricting the efficiency of orally administered drugs (Table 1.1 )105,106.
NK cells have highest expression of P-gp of all the leukocytes suggesting that it 
may play a role in it’s cytotoxic function107. Moderate to high expression of P-gp 
is also found in CD8+ T-cells, which are also involved in cell mediated 
cytotoxicity. CD4+ T-cells and B-cells, which are not cytotoxic effector cells, 
show relatively lower P-gp expression.
There is evidence to suggest that P-gp may have a role in protecting against 
some caspase-mediated apoptosis, including apoptosis induced by serum 
starvation and via ligation of Fas90,108,109. The over expression of P-gp by a cell 
has been shown to have an effect on cholesterol metabolism and membrane 
redistribution90,110. There is a possibility that these membrane reorganization 
effects may contribute to the reduction in sensitivity to certain forms of pro-
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apoptotic stimuli. Another little researched function is that P-gp (and MRP1) 
appear to have a role in the migration of dendritic cells from the skin via afferent 
lymphatic vessels111,112.
P-gp expression is associated with regulating the activity of volume-activated 
chloride ion (Cl ) channels, which operate as a defensive response to increased 
cell swelling. There is evidence that phosphorylation (possibly by protein kinase 
C (PKC) or protein kinase A (PKA)) of the linker region that join the two 
homologous halves of P-gp may be involved in regulating Cl" conductance. This 
is analogous to the R-region of CFTR, since the two transporters have similar 
domain structure113,114.
In patients with cystic fibrosis, it has been observed that there is a concomitant 
upregulation of the expression of P-gp in the intestine in the absence of CFTR, 
and that this may be a compensatory effect reflecting the complementary pattern 
of expression shown by the two ABC proteins115.
There appears to be a background ATPase activity associated with P-gp, 
independent of drug binding and efflux. It was initially thought to be stimulated 
by the binding and transmembrane movement of molecules such as small lipid 
molecules76 or cholesterol116, but a subsequent study has demonstrated 
evidence for a basal level of ATPase activity even in the absence of any 
substrate binding117.
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1.6.5 P-gp Substrates
P-gp has a broad range of structurally diverse substrates which gives rise to the 
phenomenon of MDR, whereby the resistance mechanism(s) engendered by a 
single cytotoxic entity is effective against a spectrum of structurally and 
functionally unrelated compounds118. Generally, the target substrates for efflux 
are the natural or semi-synthetic drugs, which are neutral or cationic hydrophobic 
or amphipathic molecules that achieve partition equilibrium via passive diffusion 
across the plasma membrane119. These compounds are not dependent on rate- 
limiting influx mechanisms such as receptors or ion pores (necessary for the 
transport of hydrophilic molecules) so the only way to reduce their intracellular 
accumulation is either to remove them from the cytoplasm or to intercept them in 
the membrane and flip them back into the intercellular medium72.
P-gp has at least two allosterically linked substrate binding sites which are 
associated with the transmembrane domains (TMD’s). These in turn are 
allosterically linked to the nucleotide binding domains (NBD’s), and together 
perform as a unit that is engaged in an ATP powered cycle of substrate binding, 
transmembrane transport and renewal. P-gp has a broad range of structurally 
diverse substrates including the vinca alkaloids, anthracyclines, 
epipodophyllotoxins, taxanes, ATRA, Gleevec (STI571), HIV protease inhibitors, 
steroid hormones, anti-epileptic drugs, and fluorescent dyes (Table 1.2).
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Table 1.2. Examples of chemotherapy drugs affected by P-gp over­
expression in the treatment of cancer and HIV.
Drug Substrates for P-gp
Class Example Action
Alkaloid
Anthracyclins
Colchicine
Daunorubicin
Doxorubicin
Mitoxantrone
Spindle Inhibitor 
Intercalation agent / 
Topoisomerase II 
Inhibitor
Vinca alkaloids Vincristine
Vinblastine
Spindle inhibitor
Epipodophyllotoxins Etoposide Mitotic inhibitor/Topo- 
isomerase II Inhibitor
Taxanes
Targeted Therapies 
Vitamin Analogues
Paclitaxel 
Docetaxel 
Gleevec (STI571)
ATRA
Microtubule stabilizer
BCR-ABL Tyrosine 
Kinase Inhibitor 
Differentiation agent
Steroid hormones 
HIV Drugs
Dexamethasone
Prednisone
Immunomodulators
Saquinavir Protease inhibitors
1.6.6 P-gp and CYP3A4
P-gp exhibits a considerable substrate overlap with the CYP3A4 (cytochrome 
p450) enzyme, which plays a central role in the metabolism and excretion of 
many of the drugs and xenobiotics implicated as substrates120'122. P-gp and 
CYP3A4 are co-expressed in the liver and intestine and their expression can be 
co-ordinately regulated by the steroid and xenobiotic receptor (SXR)123,124.
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1.6.7 P-gp Polymorphisms
There are several known MDR1 gene polymorphisms that occur in the human 
population125. Currently, over the 28 exons, 28 single nucleotide polymorphisms 
(SNP) have been identified at 27 positions126. One of the best studied SNP’s is 
the C3435T substitution on exon 26, which has been shown in some studies to 
result in a lower intestinal P-gp expression. It is interesting to note in the case of 
the C3435T substitution that although there is a DNA base change between the 
polymorphic genotypes, which appear to produce some degree of functional 
variability, the SNP does not result in an amino-acid change. The inherent 
redundancy in the generic coding sequence means that both codons involved 
translate the same amino-acid. The functional variability may occur because of 
some difference between the polymorphic mRNA transcripts, such as unequal 
processing efficiencies. Another possibility is that the C3435T is linked to 
another gene which is co-inherited and which does have the ability to affect P-gp 
expression or function72.
The resultant deficiency in P-gp expression has been shown to be associated 
with a greater susceptibility to the development of ulcerative colitis in some 
populations. This demonstrates the important role played by P-gp as part of the 
defence mechanism against intestinal bacteria and toxins, and that pathologies 
can occur when this barrier function endowed by P-gp is compromised127'129.
It has also been observed, however, that several polymorphisms, including the 
C3435T genotype do not affect the ability of that P-gp to exclude fluorescent 
dyes, such as rhodamine123 (R123) from cells expressing it, implying that the 
functional capability of the expressed P-gp protein is not impaired130. Hitzl et al
showed CD56+ cells isolated from C3435T homozygous (TT) and heterozygous 
carrier (CT) did show a significantly decreased (TT) and intermediately 
decreased (CT) P-gp mediated R123 efflux compared to normal (CC) 
individuals131. No distinction was given as to whether this was a result of 
reduced function or reduced expression.
The exon 26 genotype has been shown to be an independent prognostic 
indicator for acute persistent rejection in lung transplants. It is thought that 
because many of the immunosuppressive drugs necessary for the prevention of 
rejection are P-gp substrates, the drug distribution phenotype of the patient may 
play a role in rejection status. The wild-type CC genotype was found to be 
associated with a significantly higher risk of organ rejection than the TT 
polymorphism. The increased P-gp function associated with the CC genotype is 
thought to contribute to rejection by lowering the efficacy of the 
immunosuppressive drugs by altering their tissue distribution or by altering T-cell 
resistance in some way132.
However, a meta-analysis by Chowbay, et al of studies investigating C3435T 
influence on P-gp expression and digoxin pharmacokinetics ultimately found no 
causal link between the polymorphism and the attributed effects. They suggest 
that the previously observed results may be due to a more complex interaction 
between SNP haplotypes and/or other polygenic traits, which in combination 
may influence expression and distribution. The conclusion advocated that 
further studies should avoid focusing on single SNPs in order to avoid spurious 
pharmacogenetic associations133'135.
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Another polymorphism associated with a clinical significance is the G2677T SNP 
in exon 21. Renal transplant patients homozygous for this substitution have 
been shown to exhibit a 40% increased dose requirement compared with the 
wild type population for the oral immunosuppressant tacrolimus. Furthermore, 
genotype analysis by haplotype analysis of the MDR1 gene reliably predicted 
which patients would require optimum dose modification136.
1.6.8 Regulation of P-gp Expression
The expression of P-gp can be regulated at the DNA, mRNA, or protein levels, 
and the predominate control modality varies between cell types137'139. The 
homeostatic signalling feedback pathways that determine P-gp expression and 
function have been difficult to elucidate due to the varying levels of expression 
and function in the range of different cell types involved.
The protein activation regulator Protein Kinase C (PKC)140'146, the cell cycle 
checkpoint protein p53147'155 and the nuclear transcription factor NF-kB156'160 
have all been implicated with at least some level of control over P-gp expression 
levels. Signalling via the phosphoinositol-3 kinase (PI3K) pathway has also 
been shown to upregulate P-gp expression161. In enterocytes, P-gp expression 
and function can be upregulated by NO and pro-inflammatory cytokines in a 
PI3K dependent manner. It can be hypothesised that this effect may be part of 
an adaptive mechanism to limit epithelial injury during response to inflammatory 
conditions162.
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1.6.8.1 PKC
PKC describes a group of at least 12 calcium and phospholipid dependent 
isoenzymes, which exhibit their mode of action by phosphorylating serine and 
threonine residues of target proteins. The 12 isoenzymes are divided into three 
subgroups: conventional (calcium dependent), novel (calcium independent) and 
atypical. Generally, ‘PKC’ usually refers to the PKCa isoenzyme, which is a 
member of the conventional subgroup. Through this modulatory phosphorylation 
action PKC plays a pivotal role in cell signal transduction and the regulation of 
protein and enzyme activity144,163.
It has been observed that in the creation of many MDR cell lines that there is a 
concomitant increase in PKC levels, and there is evidence to suggest that a 
complex relationship exists between P-gp expression, function and PKC. This 
interaction appears to exist both at the gene level, through PKC mediated 
regulation of MDR1 transcription, and at the protein level through PKC 
phosphorylation of key P-gp serine residues. The role PKC plays in the 
regulation of MDR1 at the transcription level is poorly understood and evidence 
for it is based mainly on correlative expression levels in cell lines. Higher levels 
of PKC do correlate with increased P-gp expression, but again this is 
complicated by factors such as cell type, environmental conditions, time scale 
and the interaction of PKC isoenzymes under consideration164,165.
Studies examining the post-translational modification of P-gp by PKC have 
shown that positioned throughout its primary sequence P-gp possesses up to 35 
potential sites for PKC phosphorylation. However, of these only three serine 
residues have been recognised to be phosphorylated by PKC in vivo: residues
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661, 667 and 671, which reside in the inter-TMD linker region. It is postulated 
that phosphorylation of these sites by PKC can regulate the activity of P-gp in 
several ways: phosphorylation of serine 671 has been linked to a stimulation in 
the activity of P-gp’s ATPase, so increasing its ability to act as drug 
transporter166. Phosphorylation of residue 667 has been shown to correlate with 
the suppression of P-gp associated volume-activated chloride channel activity. 
Cell volume increase appears to lead to a pattern of phosphorylation that 
decreases ATPase activity and activates the chloride channel. It would thus 
appear that PKC represents a flexible mechanism by which the cell may respond 
adaptively to a range of stimulatory circumstances114.
It is interesting to note that even though there are three serine residues in the P- 
gp linker region that are PKC phosphorylation sites it has been shown that 
deletion mutants lacking these sites exhibit normal MDR efflux characteristics167. 
This would suggest that phosphorylation activity at this region is involved with 
the regulation of some primary efflux-function independent mechanism, or at 
least that the action of PKC is a cell type and condition dependent mechanism. 
Other studies, however, have reinforced the link between PKC and P-gp 
function, demonstrating that elevated levels of PKC and P-gp are concomitant in 
MDR cell models168, and that PKC inhibitors, such as PKC412 have been shown 
to reduce MDR activity in P-gp expressing cells143.
1.6.8.2 P53
The tumour repressor protein p53 can modulate the expression of P-gp by 
repressing the transcription of the MDR1 gene. This is achieved by direct
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binding of p53, in a novel tetrameric conformation, to a proximal binding element 
within the MDR1 promoter169,170. Certain p53 mutations can cause a functional 
volte-face so that it becomes an inducer of P-gp, though probably not through a 
direct promoter interaction171. The loss of p53, either through deletion or through 
functional mutation, is considered to be one of the key oncogenic cellular 
changes and has been shown to be correlated with P-gp expression151,153,172.
1.6.8.3 NF-kB
NF-kB, a critical cellular mediator of immune and inflammatory response, has 
been shown to be able to upregulate P-gp expression in kidney proximal tubule 
cells as part of a protective mechanism in response to the generation of reactive 
oxygen species (ROS)156. It is thought that certain forms of cellular insult such 
as cadmium poisoning, ionizing radiation or some other carcinogen can cause 
the generation of the highly reactive and damaging ROS, which in turn trigger 
upregulation of NF-kB via activation of the l-kappa B kinases (IKK). The IKK 
kinases promote NF-kB mediated transactivation by the phosphorylation of its 
inhibitor IkB, which flags IkB for ubiquination and subsequent degradation via the 
26S proteasome173,174. IkB is constitutively bound to NF-kB and prevents it 
entering the nucleus, but once IkB is removed, NF-kB translocates to the 
nucleus and binds to its target gene promoters. One of the proteins to be 
affected is MDR1 and upregulation of its expression is initiated160.
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1.6.8.4 Constitutive Expression
The MDR1 promoter region has been shown to contain Sp1 binding motifs and 
so called Y-boxes (CCAAT elements), which are essential for basal expression. 
The Y-box sequence is recognised and bound by the nuclear transcription factor 
NF-Y, which is a complex of three sub-units, A, B, and C. Inhibiting NF-Y with 
agents, such as the anti-tumour agent HMN214 (via its metabolite HMN-176), 
has been shown to actively down regulate expression of P-gp while also 
imparting a chemotoxic function175,176.
1.6.8.5 St John’s Wort
St. John’s wort is a commonly used and apparently effective herbal 
antidepressant which has been shown to be an inducer of P-gp (and CYP3A4) 
and is therefore contraindicated for use in conjunction with cancer or HIV 
chemotherapy177'179.
1.6.9 P-gp Role in Apoptosis
Previous studies suggest a non-drug efflux role for P-gp in cellular resistance to 
caspase mediated apoptosis108,109,180,181. However, P-gp expression in HL-60 
cells selected to overexpress P-gp was not found to correlate with apoptotic 
sensitivity when apoptosis was induced by curcumin or UVC182.
The apoptosis preventing mechanism involved is unclear, but one hypothesis 
proposed involves the P-gp mediated transmembrane trafficking of 
sphingomyelin, thus affecting endogenous levels of ceramide, which has been 
shown to be a potent trigger of apoptosis in cell lines183,184. P-gp has also been
43
shown to alter intracellular calcium ion (Ca2+) levels, and cytoplasmic pH, both of 
which contribute to the cell’s response to apoptotic stimuli185,186. P-gp could also 
change cytoplasmic concentrations of other, as yet unidentified apoptotic factors. 
P-gp has also been shown to inhibit FAS and other death domain activation of 
Caspase 8187. Molecules involved in the control of apoptosis such as p53 and 
NF-kB have been shown to alter P-gp expression in certain
circumstances147 149 150,154,157'159,171'188. The interaction of P-gp with several of 
these cell growth and apoptotic control factors is summarised in Figure 1.4.
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Figure 1.4 P-gp and Apoptosis. Simplified diagram demonstrating factors 
affecting P-gp expression and the hypothetical influence of P-gp on apoptotic 
pathways.
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1.6.10 Contribution to Minimal Residual Disease
Morphological remission is considered to have been achieved in patients with 
leukaemia if there are <5% blasts observable in the patient’s bone marrow. 
Even if the numbers of malignant cells that have evaded chemotherapeutic 
killing are too low to detect, a subset of resistant cells may remain as minimal 
residual disease (MRD). These cells can then go on to proliferate and cause a 
resurgence or relapse of the disease, often hallmarked by an increased drug 
resistance phenotype. P-gp expression in tumour cells, especially in AML, has 
been correlated to the likelihood of MRD and subsequent premature relapse189'
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It may be hypothesised that even if the bulk of the tumour cells do not 
overexpress P-gp, there may be a small but significant subset that does. It is 
this subset of MDR competent cells that are more likely to survive the initial 
therapy as MRD and seed the next generation of disease at relapse. And in this 
scenario, the relapsed disease is harder to treat because now the majority of 
tumour cells, like their MRD progenitors, are P-gp expressing. This is especially 
problematic if combined with another resistance marker45.
1.6.11 Immunological Resistance
In P-gp over expressing cell line models it has been observed that in addition to 
the drug pump function of cellular protection, an additional level of resistance to 
complement mediated cytotoxicity (CMC) is generated192. Complement fixation 
is primarily an anti-microbial defence mechanism which utilizes a cascade model 
of inactive subunits to generate a membrane perforating pore, (membrane attack
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complex), which results in cell lysis. Complement is often triggered by the 
process of opsonization, which is essentially the binding of antibody to the target 
cell. The Fc portion of the bound antibody recruits and initiates the complement 
fixing cascade193,194.
CMC may play a role in the body’s fight against cancer, and immunological 
therapies that utilize it may be an alternative route to treating tumours with 
classical MDR, so P-gp engendered resistance to CMC would seem a logical 
component of the tumour cell’s MDR armamentarium. The mechanism whereby 
P-gp could bestow CMC resistance is unclear, but it has been hypothesised that 
the concomitant increase in intracellular pH that accompanies P-gp over­
expression may contribute to CMC resistance, as well as to other phenomena 
associated with P-gp, such as decreased apoptotic sensitivity195, which are not 
adequately explained by its primary efflux function185,196.
1.6.12 Factors Associated with P-gp Expression in Leukaemia
P-gp over-expression in haematological malignancies has been widely 
recognised as an adverse prognostic factor. In AML, P-gp over-expression has 
been shown to be associated with unfavourable cytogenetic karyotypes, the AML 
M1 FAB subtype, and increasing age, all of which are indicators of poor 
response. The association between advancing age and increased P-gp 
expression in AML, in combination with a greater likelihood of adverse 
cytogenetic features, lead some to label AML in the elderly (>50 years) as a 
distinct biologic subgroup associated with a significantly poorer outcome than 
younger patients197'199.
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The MDR phenotype associated with P-gp over-expression has also been shown 
to be frequent in myelodysplastic syndrome and in the blast crisis of chronic 
myeloid leukaemia (CML), both of which are diseases with a poor prognosis200. 
In the latter, P-gp expression may well compound the treatment failure due to 
imatinib mesylate resistance, since it is an avid substrate for drug efflux in cell 
line models201.
In acute lymphoblastic leukaemia (ALL), P-gp expression is again associated 
with other poor prognosis markers, especially BCR-ABL and the CD7+CD4'CD8' 
subgroup. P-gp expression was not found to be an indicator of treatment failure 
in childhood ALL, but was a prognostic signifier in adult ALL. This apparent 
difference may to be due to a higher use of non-effluxed corticosteroids in the 
childhood regimen202,203.
Another haematological disease where P-gp expression is associated with an 
adverse subgroup is in multiple myeloma (MM). Here a higher frequency of P-gp 
over-expression has been observed in relapsed MM compared to that seen in de 
novo patients, especially where there has been prior treatment with the P-gp 
substrates doxorubicin or vincristine. As a consequence to this, P-gp expression 
has only limited impact on response in de novo MM, but has been recognised as 
a contributing factor in treatment failure200,204.
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1.7 MDR in Non-malignant Disease
1.7.1 HIV/AIDS
Acquired Immunodeficiency Syndrome (AIDS) is a progressive, debilitating and 
ultimately fatal disease caused by infection with the human immunodeficiency 
virus (HIV). There are two main strains of the virus, HIV1 and HIV2 and they 
mainly differ in their epidemiological characteristics205. AIDS is characterized by 
the progressive deterioration of the immune system which results in multifarious 
pathologies, especially rare secondary fungal infections and skin tumours more 
commonly associated with patients who are immunosuppressed206.
The primary target of HIV has been shown to be T-lymphocytes of the CD4+ (T- 
helper) lineage and in so doing destroys one of the linchpins coordinating the 
efficient functioning of the immune system. HIV avoids effective elimination by 
the body’s immune mechanisms by attacking one of the cells responsible for 
orchestrating an antiviral response207.
Several components of the combined drug therapies available for the 
suppression of HIV activity are known avid substrates for P-gp efflux, leading to 
the possibility of therapeutic impairment in individuals who over-express P-gp. 
The HIV protease inhibitors included in therapeutic regimens such as HAART 
(highly active antiretroviral therapy) include amprenavir, indinavir, nelfinavir, 
ritonavir and saquinavir, and they are all P-gp substrates208,209. Classical MDR 
expression of P-gp on the target T-CD4+ cells may result in sub-efficient 
intracellular levels of drug accumulation, but also ectopic expression of P-gp 
could lead to reduced tissue deposition of the drugs and cause the formation of
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sanctuary zones (such as in the CNS or testes) for HIV drug evasion and 
subsequent systemic reseeding210211.
1.7.2 Parasitic Worms
P-gp expression in the tissues of certain disease causing parasitic worms 
confers resistance to anti-helminthic drugs used in the treatment of helminth 
infestation. It has been demonstrated that co-treatment with MDR reversal 
agents such as verapamil ameliorates this effect and could help to eliminate the 
infestation212,213.
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1.8 Other MDR Transporters
1.8.1 Multidrug Resistance-Associated Protein 1
MRP1, ABCC1
MRP1 is a 190 kilodalton organic ion efflux transporter consisting of 1531 amino 
acids encoded by the MRP1 gene located on chromosome 16 (16p13.1 )38,46,214. 
It is widely expressed on many human tissues and cancers and it is located on 
the plasma membrane and on the endoplasmic reticulum and post-golgi 
vesicles, suggesting an additional intracompartmental efflux role, removing drugs 
from their intracellular targets38,215.
MRP1 has a broad efflux substrate spectrum similar to P-gp including 
daunorubicin, vincristine, and colchicine, but unlike P-gp it can transport 
compounds that are conjugated to glutathione. Many drugs, including 
chlorambucil and melphalan, are detoxified and deactivated by the glutathione 
reductase pathway216,217. MRP1 can also transport drugs modified by 
glucosylation, sulfation and glucuronylation giving it a direct link to other forms of 
drug modification based resistance218.
MRP1 may have a role in MDR in several cancers, especially small and non­
small cell lung cancer219, but is not thought to have any individual significance in 
AML since it is only expressed in 10% of new cases38,199. The MRP1 gene 
expression has been found to be greater in acute lymphoblastic leukaemia (ALL) 
patients when compared to normal individuals or AML patients, but the 
prognostic significance of its expression remains unclear220'222. It has been 
suggested that MRP1 may contribute to MDR in AML when co-expressed with P- 
gp223,224 Efflux can be inhibited in vitro by CsA, and probenecid and biricodar46.
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1.8.2 Other MRP Family Transporters
ABCC2 (MRP2, cMOAT), ABCC3 (MRP3), ABCC4 (MRP4, MOATB), ABCC5 
(MRP5, MOATC), ABCC6 (MRP6), ABCC10 (MRP7). ABCC11 (MRP8), 
ABCC12 (MRP9)
MRP2 maps to chromosome 10q24 and is associated with the export of organic 
anions from the liver into bile. It is expressed by canalicular cells and may be 
involved in conferring drug resistance if overexpressed, although its 
physiological significance has not been elucidated. Knockout mice for MRP2 
develop similar pathologies to the human genetic disease Dubin-Johnson 
syndrome225,226. MRP3 is similar in expression and function to MRP2, and maps 
to chromosome 17q21.3. Its significance as a contributor to MDR is 
undetermined227,228 (Table 1.3).
MRP4 maps to chromosome 13q32 and has a low level of expression in many 
tissues and cell types and may play a role in MDR in the transport of nucleoside 
analogues, such as fludarabine and the antiretroviral PMEA, which may lead to 
resistance to both anticancer and anti-HIV therapies229'231. MRP4 has also been 
identified as being an exporter of prostaglandins and that this function may be 
inhibited by the action of non steroidal anti-inflammatory drugs232. MRP5 gene 
maps to chromosome 3q27, and is similar to MRP4 in expression and 
function231.
MRP6 is expressed in the liver and kidney and maps to chromosome 16p13.1, 
and although it is involved in the translocation of glutathione conjugates, it has 
not been shown to be directly involved in MDR233,234. However, MRP6 (and 
MRP2) mRNA has been detected in blasts from AML patients, particularly in
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those where the MRP1 gene had been deleted, suggesting a compensatory 
MDR function223. MRP7 maps to chromosome 6q21.1, and has been reported to 
act as a lipophilic anion transporter, but as yet its function remains unclear235'237.
MRP8 and MRP9 both map as a cluster to chromosome 16q21.1, and although 
a human T-cell leukaemia cell line over-expressing MRP8 shows resistance to 
certain nucleoside drugs, its function is largely unknown238,239. MRP9 has two 
transcripts, one leading to a truncated protein and has been observed being 
expressed in breast cancer240
Table 1.3 Summary of MRP Family ABC Transporters
MRP Alias Chromosome Expressed Substrates Include Role in MDR?
MRP1 ABCC1 16p13.1 Ubiquitous Glutatione conjugates Yes
MRP2 ABCC2 10q24 Canalicular cells Organic anions Yes
MRP3 ABCC3 17q21.3 Liver Organic anions Yes
MRP4 ABCC4 13q32 Ubiquitous Nucleotides & nucleoside analogs ?Yes
MRP5 ABCC5 3q27 Ubiquitous Nucleotides & nucleoside analogs ?Yes
MRP6 ABCC6 16p13.1 Liver/Kidney Glutathione conjugates ?No
MRP7 ABCC10 6q21.1 Ubiquitous Lipophilic anion ?
MRP8 ABCC11 16q21.1 Most Tissues ?Nucleotide analogs ?No
MRP9 ABCC12 16q21.1 Testes/Prostate/Ovaries ? ?No
1.8.3 Breast Cancer Resistance Protein
BCRP, ABCG2, MRX
BCRP is a half-transporter and is encoded by the ABCG2 gene located on
chromosome 4 (4q22)46,241. It is distinctive from the other MDR ABC proteins in
that it has only one TMD of 6 a-helices and one associated NBD, analogous to
half a standard P-gp molecule52. BCRP was discovered in MDR cell lines that
did not over express P-gp or MRP1 and is associated with mitoxantrone
resistance in the breast cancer cell line MCF-7242, and with methotrexate
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resistance243. BCRP has been found to form a component of the blood brain 
barrier244, is expressed in tissues as diverse as the placenta, intestine and 
liver245, and is one of the distinguishing markers for the so called side-band 
population of haemopoietic stem cells246.
Studies have been conducted to determine the clinical relevance of BCRP 
expression in malignant disease245. BCRP was found to have no clinical 
significance in childhood Acute Lymphoblastic Leukaemia (ALL)247, but studies 
into its relevance in AML have been mixed: some report a strong association 
with disease248'250, while others saw only a negligible correlation191,251.
1.8.4 Lung Resistance Protein
Lung resistance protein (LRP) is a 110 kilodalton protein, which is encoded on 
chromosome 16 (16p13.1 )252. Unlike the previously described MDR 
transporters, it is not an ABC transporter, but is comprised of a major vault 
protein subunit complexed with a small RNA molecule and at least two other 
proteins. LRP is thought to be located on the nuclear membrane and confers 
resistance by redistribution rather than efflux of drug substrates38,253.
LRP over-expression has been shown to correlate to shorter progression-free 
and overall survival in patients with advanced testicular germ-cell tumours254 and 
in advanced ovarian carcinoma255. LRP over-expression has also been 
observed in acute leukaemias (AML256 and ALL257), but its prognostic 
significance remains unclear258.
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The normal physiological role of LRP has not been firmly established. It has 
been found to be expressed in the kidney, adrenal, heart, lung, muscle, thyroid, 
prostate, bone marrow and testis, showing considerable overlap with P-gp and 
MRP1, advancing the case fora xenoprotective function252,259.
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1.9 P-gp Modulation
The current strategy for attempting to ameliorate the effects of P-gp expression 
in malignant disease is to co-administer a non-cytotoxic P-gp inhibiting agent as 
an adjuvant to a conventional chemotherapy drug regimen. The P-gp inhibitor, 
through effective disabling (or modulating) of the P-gp efflux function, can then 
act as a chemosensitizer by enabling increased net drug uptake by the target 
cells and so increase cytotoxic efficacy.
P-gp can be modulated by a large range of compounds that can function in two 
basic modes of action: either to block its function by binding to it allosterically, 
such as vanadate260, or to competitively inhibit by acting as a high avidity 
substrate, such as verapamil261,262. Numerous in vitro studies have investigated 
the ability of these substances to modulate MDR, mostly using cell lines and 
fluorescent dye efflux flow cytometry263. Some of these compounds, such as 
cyclosporin A and its non-immunosuppressive analogue PSC833 have been 
evaluated in clinical trials264'266. They are reported to induce undesirable 
pharmacokinetic interactions at concentrations necessary for P-gp 
modulation267,268.
Table 1.4 summarises the main compounds in use for MDR modulation and 
shows the development from 1st generation modulators, which were primarily in 
use for other purposes, such as cyclosporin A. This generation of compounds, 
although effective in vitro could not be readily used in the clinical setting because 
often the concentrations required for in vivo P-gp inhibition were too high and 
caused deleterious side effects. The 2nd generation modulators were developed 
usually as structural analogues of 1st generation compounds, but displaying a
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much reduced toxicity profile. The 3rd generation modulators are novel 
compounds screened or engineered to be specific P-gp inhibitors, they present 
the highest efficacy with the least side effects (Table 1.4).
Table 1.4 Progressive development of P-gp modulators
P-gp Inhibitors
1st Generation (compounds with previous clinical use)
Verapamil 
Cyclosporine A 
Quinine
Calcium channel inhibitor 
Immunomodulator 
Anti-malarial drug
2nd Generation (structural analogues)
R-isomer of Verapamil 
PSC-833
Biricodar (VX-710)
Less toxic than Verapamil 
Non-immunomodulatory analogue of CsA 
Inhibits P-gp & MRP1
3rd Generation (original compounds)
Z.3HCL 
GF120918 
Tariquidar (XR9576)
Specific for P-gp 
Inhibits P-gp & BCRP 
Anthranilic acid derivative
Other
Progesterone 
Rosemary Extract 
Grapefruit and saville 
orange juice extract
Po I y m et h oxyf I a vo n es
For a MDR modulator compound to be effective as a clinical adjuvant to 
chemotherapy there are certain criteria that ideally should be met. First, it 
should be specific as an MDR modulator as accessory pharmacokinetic 
interactions could lead to side effects and contraindications with certain drug 
combinations. Whether the compound should be specific for only one type of
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MDR transporter is a moot point. Zosuquidar trihydrochloride is specific for only 
P-gp and not other transporters, while Biricodar is capable of inhibiting both P-gp 
and another class of MDR transporter, MRP1. The more specific single 
transporter approach has the advantage of possibly having fewer unwanted side 
effects and is certainly more useful from a research point of view, while the multi­
transporter strategy may be clinically more effective in tumours that express 
more than one MDR effector mechanism (Table 1.5). Secondly, the modulator 
should have no cytotoxic effect at the concentrations used.
Table 1.5 MDR modulators and their transporter selectivity. Adapted from 
Dantzig et al, 2003
M od u la to r P-gp MRP1 MRP2 BCRP
Z.3HCL + - - -
PSC-833 + - + -
VPM + - /+ - /+ -
CsA + - /+ - -
Biricodar (VX-710) + + - -
GF120918 + - - +
Tariquidar (XR9576) + - NR NR
FTC - - - +
MK-571 - + + -
Probenecid - + + -
Key: + Inhibition; - no inhibition; -/+ weak inhibition in some 
circumstances; NR not reported.
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1.9.1 CD56+ NK Cells
A valuable tool for evaluating the efficacy of a P-gp modulator in cancer and 
leukaemia patients is the CD56+ Natural Killer cell because of its inherently high 
P-gp expression. It is ideally suited for use as part of a flow cytometric 
fluorescent dye efflux assay to gauge in vitro efflux suppression. A Rhodamine 
123 (R123) assay utilizing the relative fluorescent intensity of patient derived 
CD56+ NK cells was used for the pharmacodynamic arm of the clinical trials that 
formed the core of this research project124,269,270.
Another means of overcoming the MDR effect could involve altering a drug’s 
structure in some subtle way so that it retains its pharmacological efficacy but 
exhibits a reduced avidity for P-gp efflux. The addition of a succinate group at 
the C10 position of paclitaxel produces a new compound that has enhanced 
penetration across the blood-brain barrier (BBB) due to its reduced interaction 
with P-gp compared to the original structure271.
Other techniques, such as the transfection of an anti-MDR1 ribozyme into P-gp 
expressing cells have also been shown to be able to reverse MDR efflux. The 
ribozyme is a RNA molecule (oligonucleotide) with enzymic activity that is able to 
degrade the MDR1 mRNA transcript, thus reducing expression of the P-gp
protein272'274.
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1.10 Zosuquidar Trihydrochloride
Zosuquidar trihydrochloride (Z.3HCL) is a potent and selective third generation 
inhibitor of P-gp. It is a difluorocyclopropyldibenzosuberane quinoline derivative 
((R)-4-[(1aR,6R,10bS)-1,2-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]- 
cyclopropa[c]cycloheptan-6-yl]-a-[(5-quinoloyloxy)methyl]-1-piperazineethanol 
trihydrochloride) and has a molecular formula of C32H31F2N302-3HCI and a 
molecular weight of 637.0 (Figure 1.5). It is produced by Eli Lilly & Company 
with a CAS registry number of 167465-36-3. It was previously known as 
LY335979 and before that as RS-33295-198 and was first described by Slate et 
al in 1995275.
Z.3HCL has been described as possessing many characteristics that qualify it as 
an ‘ideal modulator’ of P-gp: it binds with high affinity and specificity to P-gp and 
it is not a substrate for efflux, ensuring that it is effective over a suitably extended 
timescale276. The exact inhibitory mode of Z.3HCL is still unclear, but it is known 
that it has no significant effect on other multidrug transporters such as MRP1 
and BCRP277. This specificity, in contrast with many first and second generation 
modulators, means there are no, or at least much reduced pharmacokinetic 
interactions with coadministered drugs, thus enabling unaltered dosing 
regimens276,278'280.
60
Cyclopropyl substitutions
Relative stereochemistry
Anti configuration is >10 
times more potent than syn 
configuration \ N.
Piperazin & linker 
f  substitutions
OH
Hydroxy stereochemistry
Heteroaryl substitutions
Figure 1.5 Structure-activity diagram of Z.3HCL
Z.3HCL is thought to bind in an allosteric manner to P-gp and in doing so it 
causes an alteration in the protein’s configuration, thus inactivating P-gp efflux 
function. Z.3HCL binds with a high avidity with concentration of half-maximum 
inhibition (Kj) of 59nM276.
In vitro cell line studies and in vivo investigations using mouse xenograft models 
clearly show that Z.3HCL is highly effective at neutralising the protective benefit 
of P-gp over-expression and enhancing the cytotoxic effects of chemotherapy 
agents known to be P-gp substrates281. For clinical use in human patients, it can 
be administered either orally or via IV.
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1.10.1 Clinical Trials of MDR Modulators
Z.3HCL has been clinically investigated for use as a chemotherapeutic adjuvant 
for overcoming MDR, but the phase III studies are still ongoing. However, there 
have been nine randomised clinical trials to date that have included other MDR 
modulators in conjunction with chemotherapy: 5 on leukaemias (2 AML267,282, 2 
Myeloma283,284, 1 acute leukaemia (AML, ALL, MDS in transformation285), and 4 
on solid tumours (2 breast cancer286,287, 2 lung cancer288,289). Out of these, only 
three trials observed a significant benefit from the incorporation of the MDR 
modulator compared with the unmodulated arm of the study264 (Table 1.6).
Of those that did show a benefit, the SWOG AML study (List et al, 2001) showed 
that, although remission rates were not significantly improved (39% v 33%, 
P=0.14), relapse-free survival (34% v 9% at 2 years, P=0.031) and overall 
survival (22% v 12%, P=0.046) were significantly increased in the CsA arm282. 
The Solary study with quinine again showed no significant difference in the rates 
of OR (52.8% v 45.5%, P=0.19) but did observe a modulator benefit for failure of 
the regimen due to blastic persistence or increase, which was higher in the 
control group (61/154 patients) than in the quinine group (45 / 161, P=0.04)285. 
They concluded that the increased benefit of modulation by quinine could have 
been masked by the concomitant increase in toxicity. However, a later study by 
Solary using quinine in AML did not find any benefit in overall survival, but did 
observe an increase in CR for patients identified as having P-gp efflux290 in vitro. 
The Millward study in lung cancer with VPM showed that the median survival 
from start of treatment was significantly better in the verapamil arm (P=0.02)288.
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There were also negative results arising from the use of a MDR modulator, in 
particular the PCS-833 study in patients with AML reported by Baer et al, 2002. 
In this case, the modulator arm of the study was closed prematurely, after the 
randomisation of 120 patients, due to adverse rates of remission, non-response 
and death compared with the un-modulated arm (P=0.08). However, further 
analysis showed that DFS and overall survival did not differ significantly between 
the two arms and were consistent with historical studies267.
It is interesting to note that when analysis was restricted to a subset of patients 
tested for in vitro P-gp efflux function, those exhibiting efflux function had a 
worse outcome than those with no efflux function in the un-modulated arm 
(P=0.03). However, in the modulated arm there was no difference between the 
two groups. Furthermore, patients who exhibited P-gp efflux function had a 
greater median DFS in the modulated arm than in the un-modulated arm (14 
months and 5 months, respectively), although this difference was not shown to 
be statistically significant (P=0.07)264,267.
The above studies show that although there may have been an overall increase 
in toxicity associated with the use of some modulators, characterised by 
deleterious pharmacokinetic interactions, a positive benefit could be observed by 
restricting the results to outcomes from P-gp expressing patients. It can 
therefore be argued that subsequent trial design should incorporate a targeted 
approach to the administration of MDR modulators to only those patients who 
might gain any benefit: those with primary resistance (P-gp functionally positive 
by in vitro analysis at presentation) with a crossover schedule for those patients 
who develop secondary resistance during the course of the treatment.
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Table 1.6. Randomised clinical trials investigating P-gp reversal in cancer 
and leukaemia, indicating those that found a significant advantage in favour of 
the modulator.
Disease Study Inhibitor n Chemo
Response - 
Inhibitor
Response + 
Inhibitor
Significant 
Benefit Seen
AML
List et al, 
2001
CsA 226 DNR & ARA-C 33% 39%
RFS: P=0.031 
OS: P=0.046
Baer et at, 
2002
PSC833 120 ADE 46% 39% No
Myeloma
Dalton et at, 
1995
VPM 200 VAD 41% 36% No
Sonneveld et 
a/, 2001
CsA 75 VAD 49% 53% No
Breast
Cancer
Wishart et al, 
1994
Quinidine 233 Epirubicin 44% 43% No
Belpomme et 
al, 2000
VPM 99
Vindesine & 5- 
FU
11% 27% No
Acute
Leukaemia
Solary etal, 
1996
Quinine 315 MIT & ARA-C 46% 53% BP: P=0.04
NSCLC
Mi IIward et 
al, 1993
VPM 68
Vindesine & 
Ifosf amide
18% 41% MS: P=0.02
SCLC
Milroy et al, 
1993
VPM 220 CAVE 80% 83% No
Abbreviations: ADE= ARA-C, DNR, Etoposide; CAVE= Cyclophosphamide, 
DXR, VNC, Etoposide; OS= overall survival; RFS= relapse free survival; BP= 
blastic persistance; MS= median survival.
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1.11 Malignant Diseases Involved in Study
1.11.1 Acute Myelogenous Leukaemia -  AML
AML is a group of malignant proliferative diseases affecting the myeloid lineage 
of leukocytes. It is characterized by an accumulation of immature haemopoietic 
cells in the bone marrow and blood, and the malignant infiltration of tissues and 
organs, particularly the liver and spleen. Although patients often present with a 
normal or elevated leukocyte count, the underlying pathophysiology results in 
the decreased production of normal blood cells leading to varying degrees of 
anaemia, thrombocytopenia, neutropenia,291.
AML can be categorized along morphological criteria into 8 main subsets, using 
the FAB (French, American, British) classification: MO -  M7. The predominant 
focus of this study was with regard to P-gp expression in AML, a disease in 
which MDR is a recognised clinical problem199,292. A general overview of the 
precursor cell lineages leading to the cells affected by the haematological 
malignancies under discussion are shown in Figure 1.6. This diagram is purely 
schematic and does not take into account that in AML the leukaemic event is 
thought to occur in multipotent progenitors largely independent of the observed 
FAB type293,294
1.11.2 Chronic Lymphocytic Leukaemia -  CLL
CLL comprises a group of several malignant disorders affecting leukocytes of 
both lymphoid lineages, as both T and B cells can be involved, although the 
latter is predominant. It is characterised by the appearance of mature looking 
blast cells circulating in the peripheral blood and there is considerable overlap
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with the non-Hodgkin’s lymphomas, depending upon the relative tissue 
distribution295,296.
B-CLL, the most common leukaemia in the Western Hemisphere, is 
characterized by the accumulation of long-lived, relatively mature monoclonal B 
cells, which express CD5, CD19, CD23 and weak surface IgM (or IgD) 
immunoglobulin297.
Relatively few drugs used in the treatment of B-CLL are efflux substrates for P- 
gp and so this mechanism of MDR is not thought to play a major role in the 
development of drug resistance in CLL.
1.11.3 Multiple Myeloma -  MM
Multiple Myeloma is a neoplastic clonal expansion of bone marrow plasma cells 
which is pathologically characterized by lytic bone lesions, accretion of plasma 
cells in the bone marrow, humoral immunodeficiency, anaemia, and the 
presence of monoclonal protein in the serum and urine298,299.
Plasma cells are antibody producing cells derived from terminally differentiated 
B-lymphocytes. Antigenic stimulation causes a small subset of reactive naTve B- 
lymphocytes, or reactivated B-memory cells, to expand clonally, migrate from the 
lymph nodes to the bone marrow and differentiate into plasma cells. Typically 
they express CD38 and CD138 cell surface markers.
Although the disease remains largely incurable, medical intervention has
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increased the median survival of patients from just seven months to five years. 
Contemporary treatment regimens include vincristine, doxorubicin, 
cyclophosphamide and a high dose corticosteroid, either dexamethasone or 
methylprednisolone300. Many of the drugs used for the treatment of MM are P-gp 
efflux substrates, and therefore may benefit from the adaptive use of P-gp 
modulators. Novel agents such as thalidomide and bortezomib are not thought 
to be affected by P-gp expression. Indeed the proteasome inhibitor bortezomib 
has been shown to modulate P-gp expression, possibly by interfering with NF-kB 
signalling pathways301,302.
1.11.4 Non-haematological Tumours
There are numerous solid tumour cancers that are affected by MDR, especially 
those cancers that are derived from tissues that naturally express P-gp in 
significant quantities: cancers of the gastrointestinal (Gl tract), including liver and 
pancreatic cancer; cancers of the genitourinary system, including cancers 
effecting the kidney, ovary and testicle215.
Patients enrolled on the two Z.3HCL solid tumour clinical trials which formed a 
part of this research project (JTAC and JTAM) had either small cell lung cancer, 
non-small cell lung cancer or breast cancer279,303.
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Haematopoiesis of Leukaemia
Adapted from Hoffbrand et al, 2001. and van der Kolk et al, 2002 
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Figure 1.6 Cell lineage haematopoiesis
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1.12 Aims
The inappropriate expression of P-gp by malignant cells has been shown to be 
an independent prognosticator of chemotherapeutic failure and patient 
relapse199304. It has therefore been hypothesized that blockading the function of 
P-gp with a suitable modulating agent may improve the efficacy of the 
therapeutic regimen. Z.3HCL has been developed to fulfil this function, 
selectively and potently and without exacerbating the toxicity of the therapeutic 
procedure305. The aims of this study were threefold:
1. To perform the pharmacodynamic analysis of the in vivo efficiency of Z.3HCL 
on cells isolated from patients participating on three clinical trials conducted by 
Eli Lilly & Co.
2. To characterize Z.3HCL as an inhibitor of P-gp functional efflux in cells 
isolated from patients with a variety of haematological malignancies. It was 
envisioned that the data generated may indicate further avenues of clinical 
investigation.
3. To investigate the putative role played by P-gp in the inhibition of caspase- 
dependent apoptosis, and to discover whether Z.3HCL is effective at modulating 
this effect.
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2. Materials and Methods
2.1 Clinical Trial Assays
2.1.1 Rhodamine 123 Efflux Assay
Peripheral blood samples were taken from the patients using one or, when 
possible, two 9ml Becton Dickinson Cell Preparation Tubes (CPT), which were 
then processed according to the manufacturer’s recommendations. These were 
taken, depending upon the Z.3HCL dosing group at: 0, 1,6, 8, 24 or 0, 0.5, 3, 6, 
12 and 24h. The tubes were centrifuged at 1500g (~2900 RPM in a bench-top 
Centaur centrifuge) for 20 minutes at ambient temperature to allow density gel 
separation of the mononuclear cell fraction.
After three washes with HBSS, the cells were aliquoted into 2 sets of 3 tubes. 
One set of tubes was spiked with 10/yl (100nM final) Z.3HCL, which would 
ensure maximal in vitro P-gp inhibition. The ‘buffer’ set received 10/vl RPMI as a 
control. The cells were then incubated with 50ngml'1 R123 (Molecular Probes, 
R-032) for 90min at 37°C, washed with ice cold wash buffer (PBS + 0.1% BSA) 
and incubated for 15min at 37°C with anti-CD56 Cy-chrome antibody 
(Pharmingen, 31668X). After red cell lysis, (1ml ddH20  for 30 seconds followed 
by 1ml x2 PBS), fluorescence was read on a Becton Dickinson FACScan using 
CellQuest software, and the data analysed and compensated with Verity Winlist 
4.0 software (Figure 2.1).
The in vivo efficacy of Z.3FICL was measured using CD56+ Natural Killer (NK)
cells as surrogate reporter cells because of their intrinsically high P-gp
expression. This was particularly necessary for the solid tumour trials because,
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due to the nature of the disease, direct sampling of malignant material was not 
practical.
Patients administered oral dose of 
Z.3HCL at 0 and 12 hours
> <
Blood samples taken at 0, 12 and 
13.5 hours
Samples sent to RFH for
analysis
i
Separation of mononuclear cells 
(ficoll)
"Buffer” "Spike"lOOnM Z.3HCL
Incubate with R123 and anti-CD56 
Cy-Chrome
I
Analysis on FACS / Winlist
Figure 2.1 Protocol for mononuclear cell preparation for flow cytometry 
Assay
R123 is a P-gp substrate and the relative brightness of a cell read in a flow 
cytometer is a direct indication of the cell’s accumulation function. For the AML
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study, anti-CD33 labelling was used in parallel to anti-CD56 in the R123 assay 
for direct gating of blast cells where sufficient patient material was
available107’269’270.
2.1.2 In Vitro Assays 
2.1.2.1 Anti-P-gp MRK16 Assay
P-gp expression was measured flow cytometically by using the MRK16 
monoclonal antibody (TCS Biologicals, UK). The blast cells were selected using 
forward scatter (FSC) and side scatter (SSC) gating. It was ensured that a 
discrete, monophasic fluorescent profile was obtained, indicating the selection of 
a homogenous cell population. The results are expressed as a ratio of median 
channel fluorescence (MCF) of the specific antibody relative to the MCF of 
isotype matched control serum306,307. A MCF ratio of >1.1 was considered P-gp 
positive, and samples with a ratios of ^ .1  were considered negative. This value 
was derived from the mean of MRK16 ratios from the MAF've group plus 1 
standard deviation (SD) of 53 AML samples studied as part of on-going routine 
MDR profiling.
2.1.2.2 Calcein-AM Functional Assay
A functional P-gp accumulation assay using the fluorescent dye Calcein-AM 
(Molecular Probes) a acetoxymethyl ester of calcein, co-incubated with either 
Z.3HCL or Verapamil (VPM) was used to assess in vitro P-gp activity. The 
calcein-AM accumulation assay has been widely used to detect P-gp functional 
activity in AML cells308,309. Both the Z.3HCL and the VPM stock solutions were
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stored in DMSO and multiple dilutions in RPMI were used to obtain the final 
working solutions to avoid any cytotoxic effects of DMSO. Once inside cells, 
calcein-AM is cleaved by cellular esterases and the calcein derivate is 
fluorescent. P-gp actively effluxes calcein-AM but not the derivative calcein310. 
The MCF’s of the modulated and unmodulated cells was used to generate a 
Multidrug Activity Factor (MAF), a ratiometric figure (0 -  100, with significance at 
>10.0) denoting the ability of each modulator to correct calcein efflux. The 
higher the MAF, the more effective the inhibitor or the greater amount of P-gp.
MAF = ((MCFm -  MCFc) I MCFm) x 100
Where MCFm is the median channel fluorescence of the modulated cells, and 
MCFc is the median channel fluorescence of the unmodulated control cells. 
Samples with a MAF of ^ 0  were considered to be P-gp positive, and samples 
with a MAF <10 were considered P-gp negative.
MRP1 is able to efflux both calcein-AM and the fluorescent calcein derivative, 
but at a markedly slower rate than P-gp311,312.
Calcein-AM was obtained from Molecular Probes and stored at -20°C at a stock 
concentration of 0.1 mM in DMSO (Sigma) as 10pl aliquots. Immediately prior to 
use, the 10jul was diluted with 190pl sterile saline to obtain a working solution 
(w/s) of 5pM. This was added to a falcon FACS tube of 5 x 105 cells in 1ml 
RPMI to giving a final concentration of 50nM.
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2.1.2.3 MTT Drug Sensitivity Assay
The ability of viable cells to reduce 3,4,5-dimethylthiazol-2,5,-diphenyl 
tetrazolium bromide (MTT, Sigma, UK) was used as a measure of drug 
sensitivity. The amount of purple formazan produced by the process is linearly 
proportional to the number of viable cells when read on a suitable plate reader 
(Anthos Labtec Instruments, Austria)313.
Drug sensitivity profiling against ARA-C, DNR and mitoxantrone (MIT) for AML 
cells by MTT assay was conducted whenever sufficient patient material was 
available. These were performed in 96 well microtitre plates with the patient’s 
cells incubated with 6 concentrations in serial dilution of cytotoxic drugs, with and 
without 100nM Z.3HCL to generate comparative IC50 levels. At 72h 10jul of MTT 
(5mg/ml) was added for an additional 4 hours. The precipitated purple MTT 
formazan was centrifuged for 5 minutes at 600xg. The supernatant was 
removed and the formazan pellet was dissolved in 100pl DMSO (dimethyl 
sulfoxide). The statistical software package Prism 3 (Graphpad) was used to 
perform a one-tailed Wilcoxon Signed Rank Test between modulated and 
unmodulated IC5o curves to determine if any differences in drug sensitivity are 
statistically significant143.
CLL cells were tested against CHL, DNR and FLU. Neither CHL nor FLU are P- 
gp substrates. MM cells were tested against DNR, MELP, and PRED or VNC.
The use of the MTT assay for the apoptosis studies detailed in chapter 5 differed
from the MDR MTT assay in that no drug dilutions were used and no IC50 was
calculated. Cells, typically following y-radiation exposure, were assayed with the
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MTT in order to elucidate relative cell viability in comparison with a control 
population of cells.
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2.2 In Vitro Study Procedures
2.2.1 Mononuclear Cell Preparation Using Lymphoprep™
Peripheral blood or bone marrow aspirate was taken by clinical staff, 
preferentially in 30ml universal tubes containing 200 units of preservative free 
heparin; although 9ml lithium heparin ‘vacutainer’ tubes were also employed, 
depending upon availability. Mononuclear cells were separated by density 
gradient centrifugation on Lymphoprep™ (Nygaard, Norway). Employing sterile 
conditions in a class II flow cabinet, the peripheral blood was diluted with an 
equal volume of HBSS. A 15ml, 30ml or 50ml tube was employed depending 
upon the sample volume, into which was poured an amount of Lymphoprep 
equal to the sample volume. The sample blood was then carefully pipetted down 
the inside wall of the tube so that it formed a layer on top of the Lymphoprep and 
maintaining a clearly defined interface. The sample was then spun in a bench- 
top centrifuge (MSE Centaur) at x600g (2500 rpm) for 20 minutes at room 
temperature.
The mononuclear cell population (i.e. lymphocytes, monocytes and blast cells) 
was then carefully removed from the interphase layer to a fresh tube using a 
syringe or pipette ensuring minimal contamination with Lymphoprep. The cells 
were then in resuspended HBSS and spun at x480g (2000 rpm). The cell pellet 
was then inspected for red cell contamination, in which case a Red Cell Lysing 
solution was employed, followed by a wash in HBSS. If no significant RBC 
contamination was present, the cells were washed twice in HBSS and then 
resuspended in RPMI + 10% FCS, at a volume appropriate to the cell pellet size 
(typically 10ml -  20ml). The cell solution was kept for up to 4 hours at 4°C to 
minimize cell deterioration until use.
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Figure 2.2 Mononuclear cell preparation from Lymphoprep
2.2.2 Other MDR Transporter Measurement
MDR Transporter expression was studied on a FACScan (Becton Dickinson) 
using the following monoclonal antibodies:
MRP1 - MRP6 antibody, IgGi Isotype 
LRP - LRP56 antibody, lgG2b Isotype 
BCRP - BXP21 antibody, lgG2a Isotype
The results were expressed as a ratio of MCF of the specific antibody relative to 
the MCF of isotype matched control serum.
2.2.3 Trypan Blue Cell Viability Assay
The viability status of cells was analysed using a trypan blue dye exclusion 
assay. 10jul of the 1x106ml'1 cell suspension was mixed with an equal volume of
0.1% trypan blue (Sigma, UK) and viewed microscopically using a 
haemocytometer (Improved Neubauer). Non-viable cells were unable to exclude 
the dye from their cytoplasms and consequently became an easily 
distinguishable blue in colour. All viable and non-viable cells in each of the four 
haemocytometer compartments (or at least 200 cells) were counted and used to 
calculate a percentage of viable cells.
2.2.4 JC-1 Assay
JC-1 is a biphasic fluorochrome used to determine mitochondrial membrane 
potential (4\n) as an indicator of apoptotic modulation by P-gp and the inhibition 
of that effect by Z.3HCL. It emits at two concentration dependent spectra, 
corresponding to a green signal (cytoplasm - FL1) and a red signal (mitochondria 
-  FL2). A ratio of the red signal to the green signal (from FL1 / FL2 quadrant 
percentages) gives a measurement of the relative strength of the T V
At low relative concentrations, JC-1 exists as a monomer (green fluorescent 
signal), but beyond a certain concentration threshold, the monomers begin to 
form aggregated stacks called J-aggregates (red fluorescent signal). Since J- 
aggregate formation increases linearly with applied membrane potential over the 
range of 30-180mV, this phenomenon can be exploited for potentiometric 
measurement of apoptotic mitochondrial depolarization314"316.
One distinctive feature of the early stages of apoptosis is the disruption of active 
mitochondria (via BAX, BID etc). This mitochondrial disruption includes changes
in AT'm and alterations to the oxidation-reduction potential of the mitochondria.
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Changes in AT'm are presumed to be due to the opening of the mitochondrial 
permeability transition pore allowing passage of ions and small molecules. The 
resulting equilibration of ions leads to the decoupling of the respiratory chain and 
the release of cytochrome C into the cytosol.
In healthy cells, JC-1 enters the negatively charged mitochondria where it forms 
concentration dependent liquid crystal aggregates that emit a red fluorescence. 
In cells undergoing apoptosis, where the mitochondrial potential has collapsed, 
JC-1 exists monomerically throughout the cell, and when dispersed in this 
manner JC-1 fluoresces green. Using flow cytometry, changes in T'Am are 
indicated by measuring the red / green intensity ratio.
JC-1 (Molecular Probes, UK) was stored at a stock solution of 1 mM in DMSO.
A working solution (w/s) of 50 //M was prepared fresh from 10/yl stock + 190/vl 
saline. 10/vl of w/s was used in 1ml cells (0.5 x 106 cells) making a final 
concentration of 0.5/yM. This was then incubated at 37°C / 15min in dark (water 
bath). The cells were then washed twice in ice cold PBS, and kept on ice away 
from direct light until analysed on FACScan with 2-colour online compensation.
The flow cytometry data was reported as the ratio of percentage red signal 
against the percentage green signal as ascertained from a quartered dot plot 
displaying FL1 (green) against FL2 (red) along each axis.
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2.2.5 Western Blots
The caspases, and in particular caspase 3, can be considered to be the effector 
molecules of the apoptotic process. They exist as inert or low activity precursors 
within the cell. On activation, a cascade of proteolytic action leads to the 
cleavage of numerous intracellular components essential for normal function. 
This renders the cell a condensed and fragmented apoptotic body readily 
absorbed by surrounding cells or macrophages.
One of the first recognised and most commonly cleaved substrate is the enzyme 
poly-ADP-ribose-polymerase (PARP, 116kDa) whose proteolytic cleavage into 
24kDa and 85kDa fragments early during the apoptotic process is one of the first 
detectable events. PARP plays a role in DNA repair and replication, cell 
proliferation, and differentiation, and its cleavage has a deleterious effect on its 
function. PARP is known to be cleaved by the apoptotic effector caspase-3.
PARP cleavage, considered to be a hallmark of apoptosis, was measured using 
western blotting by taking a ratio of the apoptosis specific p85 fragment against 
the uncleaved PAPR p116 expression. Caspase 3 activation, another hallmark 
of apoptosis, was also measured initially in the study, and normalised against p- 
actin.
Protein lysate was obtained from prepared cells using 1ml whole cell lysing 
solution (WCL) (20mM Hepes-KOH [pH 7.5], 50mM NaCI, 2% nonidet P40, 0.5% 
sodium deoxycholate, 0.2% sodium dodecyl sulfate (SDS), 1mM sodium 
vanadate, 10mM sodium fluoride, 1mM ethylene glycol tetra-acetic acid (EGTA)) 
with 2pl DTT and 10jul PMSF. It was added at 80pl WCL per 10x106 washed
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cells, incubated on ice for 15 min and then spun in a benchtop refrigerated 
microfuge at 4°C for 15 min at 14000 rpm. The supernatant was removed and 
the lysate stored at -80°C until use.
A protein standard curve was performed in order to determine 20pg protein 
loading from cell lysate for loading onto SDS PAGE gel lane. Protein 
concentration was quantified using the Bio-Rad protein assay kit (Bio-Rad, UK), 
which utilized the proportional colour change of a dye in response to the 
concentrations of protein and measured using a spectrophotometer at 595nm. 
Bovine serum albumin (BSA) (Sigma, UK) was used as a protein standard for 
the making of a standard curve.
Tris Glycine 4-12% precast gradient gel plates were assembled according to the 
manufacturer’s instructions (Invitrogen). The protein concentration was 
measured, and 20/yg of protein samples were made up with 1 x SDS sample 
buffer (Invitrogen), 80mM DTT reducing agent and ddH20. Samples were heat 
denatured for 10 minutes at 80°C in boiling water bath, centrifuged briefly and 
loaded into gels using a Hamilton syringe. NuPAGE (Polyacrylamide gel 
electrophoresis) Gels (Invitrogen) were run at 200V using 1x MOPS (N- 
morpholino propanesulfonic acid) running buffer (Invitrogen) and NuPAGE 
running buffer antioxidant (Invitrogen) for approximately 45mins.
Two Whatman filter papers and one nylon membrane (Hybond C, Amersham) 
per gel, cut in the same dimension as the gel were soaked individually in blotting 
buffer (Bicine 25mM, Bis Tris 35mM, Ethylene diamine tetra-acetic acid (EDTA) 
1mM, 10-20% methanol, pH7.2 and 200//I of antioxidant per 200ml of transfer
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buffer). The gel was placed on top of one filter, followed by nylon membrane 
then another filter paper, with care taken to avoid trapping air bubbles between 
layers. The gel, membrane and filter papers sandwiched with blotting pads pre­
soaked in transfer buffer were placed in a blot module (Invitrogen) with transfer 
buffer. Transfer of proteins was carried out at 25V for approximately VAh.
After blotting, the nylon membrane was stained with Ponceau-S stain (Sigma, 
UK) to ensure equal and satisfactory transfer of proteins. The membrane was 
carefully agitated at room temperature in polyvinylpyrrolidone (PVP) blocking 
buffer (0.02M Tris, 0.14M NaCI, 2% new-born calf serum and 5% PVP (Sigma) 
[pH 7.6]) for 1 hour. After blocking, the membrane was placed on top of a plastic 
sheath, rolled up and placed in a 50ml Falcon tube with 10ml fresh blocking 
buffer containing primary antibody. The tube was placed in a rotisserie overnight 
(16-18h) at room temperature.
The blots were probed with rabbit anti-p85, (goat anti-rabbit 2° HRP antibody) 
and mouse anti-p116 (goat anti-mouse 2° HRP antibody), p-actin and caspase 3 
were also probed for in the initial experiments.
After primary antibody incubation, the blot was washed in 1x washing buffer 
(0.02M Tris, 0.14M NaCI and 0.02% Tween 20) for two 5 min washes followed 
by one 1 hour wash and finally two 5 min washes. The membrane was incubated 
with horseradish peroxidase linked secondary antibody (DAKO Denmark, 1/5000 
dilution) in blocking buffer for at least 1 hour at room temperature. The 
membrane was finally washed thoroughly in washing buffer for two 5 min 
washes, a 1 hour wash and two final 5 min washes to reduce background.
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The ECL (enhanced chemiluminescence) method (Amersham) was used to 
detect immunoreactive protein bands: the two solutions were mixed in equal 
proportions (0.5ml each per blot) and pipetted onto the blot, covered, and 
towelled off after 1min. The blots were then exposed onto x-ray film using a 
Kodak developer and these films were scanned using a Bio-Rad densitometer 
using the Quantity One software package, which also calculated the band 
intensity.
For further antibody staining the blots were stripped by incubation in stripping 
buffer (162mM Tris [pH 6.7], 2% SDS, 100mM p-mercaptoethanol) for 30 
minutes at 50°C.
2.2.6 Annexin-V Assay
The Annexin-V assay kit was used (Caltag MedSystems) to quantitate early 
apoptotic events flow-cytometrically. This assay uses a FITC conjugated 
monoclonal antibody specific to externalized membrane phosphatidylserine, 
which is externalized to the outer membrane surface following apoptotic initiation 
and is a readily discernable hallmark of early apoptotic changes. The Annexin-V 
was used in combination with propidium iodide (PI), and the results measured 
flow-cytometrically on a Becton Dickinson FACScan. Cells, both cell lines and 
patient PBMC’s were treated with varying levels of y-radiation and incubated for 
up to 48 hours with and without Z.3HCL. For some experiments utilizing B-CLL 
cells, the drug CHL was used as the apoptotic initiator. The assay was then
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used to look for differential apoptotic sensitivities between control and Z.3HCL 
modulated samples.
The protocol was adapted from the manufacturer’s standard protocol. 0.5 x 106 
cells per tube were prepared, spun (x1500 rpm / 3mins) and pelleted. The cells 
were then washed with x1 binding buffer (from kit stock, diluted 1/5 with ddH20), 
spun (x1500 rpm / 3mins) and resuspended in 195jnl of x1 binding buffer. Then, 
5jnl of Annexin-V FITC (from kit) was added to the cells, and they were incubated 
in the dark at room temperature for 15mins. The cells were then washed in 
0.5ml x1 binding buffer, spun (x1500 rpm / 3min) and resuspended in 190jul of x1 
binding buffer. After this, 10pl propidium iodide (from kit) was added and the 
solution mixed. The cells were kept on ice away from direct light until analysed 
on the flow cytometer using preset FSC, SSC & compensation settings, 
adjusting as necessary.
The proportion of apoptotic cells was determined by gating on the main cell 
population and then dot-plot sub-gating with annexin V (FL1) intensity along one 
axis and PI (FL2) intensity along the other axis. This plot was then quartiled and 
the percentage of annexin V+ / PI- cells taken. When the flow cytometry data 
was acquired for all the samples, the data was transferred to a Microsoft Excel 
spreadsheet file for basic data manipulation and normalisation before being 
visualised graphically using Prism 4.03, which was also used for the basic 
statistics and one-tailed paired t-tests. For the CEM/CEMv/VLB cell lines, each 
experiment contained three replicates for each point and each experiment was 
repeated on three separate occasions.
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2.2.7 Purification of Plasma Cells
Plasma cells (PC) were purified by use of a MACS magnetic bead column 
system. Paramagnetic microbeads coated with anti-human CD138 (Miltenyi 
Biotec, UK) were incubated with PBMC’s isolated from MM patients (10/yI beads 
per 5x106 total cells, pelleted) and incubated at 4°C for 30 mins. The cells were 
then washed and resuspended in 3ml cold media and passed through a 
proprietary magnetic column which retains bead bound plasma cells and allows 
unbound non-CD138 cells to pass through. The bound plasma cells were then 
recovered from the column by removing it from the magnetic source and flushing 
through with ice cold media. A small aliquot of the purified cells was taken and a 
cell count was determined in a counting chamber (Improved Neubauer 
Haemocytometer). A morphological test of PC purity was performed from 
cytospins (1x104 cells) stained with May-Grunwald-Giemsa (MGG)
2.2.8 Cell Morphology Analysis
Cytospin preparations of no more than 1x104 cells were prepared on glass 
microscope slides at x400rpm for 2mins on a Shandon Cytospin 2 centrifuge and 
air dried for a minimum of 10 minutes, but preferably for 1 hour. These were 
then stained with MGG and viewed microscopically. Apoptotic cells could be 
distinguished from unaffected cells by morphological changes characteristic of 
apoptosis such as membrane blebbing and apoptotic bodies. This was used for 
apoptosis scoring and also for plasma cell purity analysis following MACS 
magnetic purification.
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2.2.9 Cell Line Studies
The human T-cell lymphocytic leukaemia non-MDR cell line CCRF-CEM (CEM) 
and its P-gp over expressing sub-line CEMA/LB10o (VLB) were used for in vitro 
investigation of the efficacy of Z.3HCL and for the preliminary calibration of the 
assays implemented in the monitoring of patient material. An intermediately P- 
gp expressing cell line, denoted CEMv, was also established by growing CEM 
cells in the presence of escalating doses of vincristine (VCR), a cytotoxic drug 
recognised as an inducer of P-gp upregulation and over expression. A similar 
strategy was employed in an attempt to produce a P-gp expressing variant of the 
human acute myeloid leukaemia cell line HL-60 which, despite several attempts 
was not sucessful.
2.2.10 Statistical Methods
Basic statistic inferences were performed using Microsoft Excel for Windows, 
which was also used to create the tables. Graphpad Prism 3.03 and 4.03 
software for Windows was used to calculate Student’s t-tests, Wilcoxon signed 
rank and Mann-Whitney non-parametric tests for the MTT assays and apoptosis 
assays, linear regression and correlations for the P-gp and Calcein-AM data and 
for creating all of the graphs shown. All data sets were tested for normality using 
the inbuilt function in Prism. Verity Winlist 4.0 for Windows was used for the 
analysis and off-line compensation of the R123 flow cytometry data. CellQuest 
software by Becton-Dickenson for Macintosh OS9 was used for the acquisition of 
all flow cytometry data.
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3. Results - Clinical Trials
3.1 AML Trial
3.1.1 Introduction & Study Design
3.1.1.1 Introduction
Several clinical trials have been previously undertaken to investigate the efficacy 
of MDR modulation, both in solid tumours and in haematological malignancies. 
These trials studied first generation modulators, in particular cyclosporine A 
(CsA), and its second generation analogue, PSC-833. Most, if not all of these 
studies concluded that P-gp modulation was of little or no benefit. However, one 
study evaluating CsA in elderly patients with AML showed some benefit from 
modulating P-gp282, and another evaluating PSC-833 in AML in a phase III trial 
suggested some benefit, but only in those patients exhibiting P-gp efflux. 
However, the inhibitor arm of this trial was curtailed prematurely because of 
increased early mortality associated with PSC-833 combination therapy267.
The focus of this chapter will concern a phase I trial of Z.3HCL in patients with 
AML, which was conducted at the Royal Free Hospital. The blood samples for 
pharmacodynamic (PD) analysis were delivered directly to the lab as soon as 
they were acquired. The pharmacokinetic (PK) samples were frozen and sent 
off-site for analysis. Pre-trial samples were also taken from patients at 
enrolment prior to chemotherapy induction for the purpose of MDR 
characterisation and drug sensitivity assays. The well-established MDR inhibitor 
Verapamil (VPM) was used in vitro as a standard against which the efficiency of 
Z.3HCL was contrasted.
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The trial was designated JTAN -  (B3T-MC-JTAN) by Eli Lilly and was entitled: A 
Phase 1 Study of Intravenous Z.3HCL in Combination with Daunorubicin and 
Cytarabine in Patients with Acute Myelogenous Leukaemia or Myelodysplastic 
Syndrome.
3.1.1.2 Primary Objective of JTAN Trial
To determine a dose of Z.3HCL that can be administered safely, with acceptable 
toxicity, as a short intravenous infusion (6 hours or less) in combination with 
DNR and ARA-C in patients with AML or MDS.
3.1.1.3 Secondary Objectives of JTAN Trial
To evaluate the toxicity of Z.3HCL administered in combination with DNR and 
ARA-C and to determine the pharmacokinetics of Z.3HCL (and its metabolites) 
and DNR and its metabolite daunorubinicinol when given together and when 
DNR is given alone. Also to determine any relationship between plasma levels 
of Z.3HCL and P-gp inhibition as measured in vitro.
The study was approved by the Royal Free Hospital Ethics Committee and all 
patients entered gave written informed consent.
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3.1.1.4 Inclusion Criteria
De novo and relapsed patients aged between 18 and 80 years age with 
morphologically confirmed AML or MDS were eligible for inclusion. All patients 
had a performance rating of 0-2 on the ECOG (Eastern Co-operative Oncology 
Group) scale, unless their performance was judged to be a direct consequence 
of AML/MDS. Any prior chemotherapy must have been completed at least three 
weeks before enrolment, except for hydroxyurea, in which case the time elapsed 
should have been six weeks.
Other inclusion criteria included: a negative pregnancy test if female and 
appropriate contraceptive measures for both females and males to minimise 
childbearing potential, adequate organ function (Hepatic-bilirubin <1.5 times 
upper limit of normal (ULN), aspartate transaminase <2.5 times ULN, Renal- 
serum creatinine <1.5mg/L or greater than calculated creatinine clearance 
>40ml/min (calculated by Cockcroft and Gault Formulae), multiple-gated 
acquisition (MUGA) scan or echocardiogram with ejection fraction of >45%.
3.1.1.5 Exclusion Criteria
Newly diagnosed APL (AML FAB M3) were not considered for enrolment 
because of the associated coagulation complications of chemotoxic therapy and 
the preferred use of ATRA therapy13. Patients were not to have had the use of 
any investigational agent within four weeks prior to enrolment or any serious 
systemic disorder incompatible with the study, or to have shown any previous 
cytarabine related neurotoxicity. Other exclusion criteria included pregnancy or
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Table 3.1.1 Demographics and Z.3HCL dosing schedule of patients
Z.3HCL dose age sex diagnosis Cytogenetics
1 200mg/m2 @6h 44 F de novo M5a Complex
2 200mg/m2 @6h 30 M de novo M5 Normal
3 200mg/m2 @6h 36 M de novo M4 Trisomy 22 inv(16)
4 200mg/m2 @6h 54 M relapsed M4 Trisomy 21
5 300mg/m2 @6h 53 M refractory M1 t(14:21)
6 300mg/m2 @6h 36 F de novo M2 Trisomy 8
7 300mg/m2 @6h 24 M de novo M6 Normal
8 400mg @ 3h 54 M relapsed M2 *(6:9)
9 400mg @ 3h 56 M de novo M1 Normal
10 400mg @ 3h 47 M de novo M5a Normal
11 400mg @ 3h 63 M relapsed M4 Normal
12 400mg @ 3h 25 M relapsed M1 Trisomy 4
13 400mg @ 3h 69 M de novo M1 Failed
14 400mg @ 3h 68 M de novo M1 Normal
15 400mg @ 3h 52 M de novo M2 Monosomy 7
16 400mg @ 3h 70 F de novo M2 Trisomy 11, del(X)
breast feeding, unstable angina, myocardial infarction in previous six months, 
atrial or ventricular arrhythmia or congestive heart failure (CHF).
3.1.1.2 Patient Recruitment
Sixteen AML patients were entered onto the trial: 13 Male and 3 Female with a
median age of 52.5y (range 24 - 70y). Six patients had normal cytogenetics,
nine had cytogenetic aberrations including two with an unfavourable pattern and
one failed the analysis. The median WBC at the start of treatment was 3.4
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x 109/L (range 0.9 - 45.4 x109/L). The patient demographics and inclusion criteria 
are shown in Table 3.1.1 and Table 3.1.2 respectively.
3.1.1.3 Treatment schedule
ARA-C was infused via a central line at 200mg.m'2 for 7 - 10 days. DNR was 
infused by slow push IV at 50mg.m"2 on days 1, 3 and 5. Z.3HCL was given on 
days 3 and 5 prior to the DNR, as either a 3 or 6h IV infusion to allow 
assessment of the effect of Z.3HCL on DNR pharmacokinetics (Figure 3.1.1). 
The patients were split into 3 dosing groups for Z.3HCL: 4 patients received 
200mg.m'2 over a 6hr infusion; 3 patients at 300mg.m'2 over 6hrs, and 9 patients 
at 400mg flat dosing given over 3hr. The flat dosing of 400mg was derived from 
initial pharmacokinetic data gathered from earlier phase I solid tumour studies303.
Patients were monitored for response and adverse events continuously during 
their in-patient stay for 27 to 74 days and thereafter at intervals of once or twice 
weekly dependent on clinical status. Bone marrow aspirates were performed at 
3-4 weeks when evidence of regeneration was obtained. Complete remission 
(CR, CR1, CR2) during follow-up was defined as a bone marrow aspirate with 
less than 5% blasts with subsequent normalisation of blood counts prior to the 
next course of treatment. Partial remission is defined as the presence of a bone 
marrow which is regenerating normal haematopoietic cells and contains 5-20% 
leukaemic blast cells. Toxicity and adverse events were assessed daily using 
the NIH-NCI Common Toxicity Criteria317. Patient follow-up was performed 
independently of the sponsor of the protocol.
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PK analyses were performed on blood samples taken before and at various time 
intervals at the end of Z.3HCL IV push. These samples were centrifuged 
according to the protocol and the plasma collected, labelled and frozen at -70°C, 
before being sent off-site for analysis. These data were collated and discussed 
by Callies et a/318.
Table 3.1.2 Inclusion and exclusion criteria for the JTAN AML clinical trial.
Inclusion Criteria Exclusion Criteria
Morphological diagnosis AML or MDS
Prior chemotherapy completed >4 weeks 
ago
Performance status 0-2
Adequate organ function
Age 18-80 years 
Negative pregnancy test and/or 
adequate contraception where 
appropriate
Acute promyelocytic leukaemia 
No chemotherapy in the last 4 weeks No 
previous study involving modulation of
P-gp
Previous cytarabine related 
neurotoxicity
Unstable angina, uncontrolled AF or 
arrhythmias
Serious concomitant disease 
Pregnancy or breast-feeding
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Figure 3.1.1 JTAN Drug and modulator dose schedule. The arrows 
represent the times when the different drugs were administered. Z.3HCL was 
given prior to DNR on days 3 and 5, while DNR was given without Z.3HCL on 
day 1.
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3.1.2 Results
3.1.2.1 Clinical Response
Sixteen patients were entered into the treatment schedule of which 11 had de 
novo AML, 4 had relapsed AML and one refractory AML. None of the patients 
had previously received any resistance modifying treatment. Eleven patients 
achieved complete remission by the defined criteria including one patient who 
achieved a bone marrow with regenerating haematopoietic cells and less than 
5% blasts but who then died of a probable pulmonary embolus prior to the 
normalisation of blood counts (ANC 1.7x109/L and platelets 31x109/L). One 
other patient achieved a partial remission. These data, along with the in vitro 
assay results, are summarised in Table 3.1.3.
The median survival for the 12 patients was 559 (range 38-906) days. Five of 
the 11 patients later died: 3 of progressive disease post relapse and 2 of 
infection post mini bone marrow transplant. All 6 patients still alive with a 
median survival of 722 (range 510-906) days in CR had de novo AML. There 
were 3 deaths prior to assessment of remission status: 2 related to AML (both 
patients had poor risk cytogenetics) and one, as described above, of probable 
pulmonary embolus. The median time to neutrophil recovery (>0.5x109/L) was 
21 days and to platelet recovery (>50x109/L) was 23 days.
3.1.2.2 Toxicity Assessment
In general, Z.3HCL was reported to be well tolerated in combination with DNR 
and ARA-C. Toxicities and adverse events were graded by NIH-NCI Common 
Toxicity Criteria and are shown in Table 3.1.4
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Table 3.1.3 Results of the in vitro  studies: P-gp expression (MRK16 assay); 
accumulation function (calcein-AM assay); and drug sensitivity (MTT assay). Also shown 
is the corresponding initial response to treatment (CR = complete remission, PD = 
progressive disease, ND = not done). + in the MTT column denotes a significant 
sensitisation to DNR observed in the presence of Z.3HCL
MRK16 Calcein-AM MTT
Patient P-gp Z.3HCL VPM DNR Response
1 - + + - CR1 - PD - Died
2 - + - - CR1
3 + + + - CR1
4 - - - ND PD - Died
5 - ND ND ND Fungal Infection - Died
6 - - - ND CR1
7 - - + ND CR1
8 - - + - CR2
9 + + + + CR1
10 - + - - CR1
11 + + + - PD - Died
12 - + + + CR1
13 - - + - PE - Died
14 + + + + CR1
15 + + + ND PD - Died
16 + - + + CR1
% Positive 37.5% 60.0% 73.3% 36.4%
Four patients experienced Grade 3 and Grade 4 toxicities and there were no on- 
study deaths. Adverse events not attributed to Z.3HCL were mostly predictable 
following chemotherapy. All patients experienced neutropenic fever, 7 patients 
experienced nausea and vomiting, 4 had mucositis, 5 diarrhoea and 6 patients 
exhibited abdominal pain. Palmar rash was observed in 6 patients (2 both
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palmar/plantar) with plantar pain experiences in 2 individuals. One additional 
patient had palmar pain in the absence of any rash. Three other patients had a 
macular body rash; one had anorexia and one exhibited peripheral oedema. 
Significant laboratory abnormality was experienced in 2 patients in the form of 
hyperbilirubinaemia. Both resolved spontaneously though one was reported as 
a serious adverse event (SAE). This patient also had a SAE of renal failure; 
however baseline renal and liver functions had been elevated.
The main toxicity seen with the combination therapy of ARA-C and DNR with 
Z.3HCL was neurological. Two patients experienced grade 3 hallucinations or 
confusion during the 24h after infusion of Z.3HCL. These patients consequently 
received only the first dose of Z.3HCL. The first (patient 8) was a patient with 
relapsed AML who developed vivid hallucinations, bad dreams and fatigue: the 
patient had never experienced similar symptoms during his previous 4 courses 
of chemotherapy and anti-emetic therapy. The second (patient 14) described 
mildly distressing visual hallucinations. This patient had fever at the time of 
confusion which may well have exacerbated the adverse event. Symptoms 
resolved completely after 24h in both patients.
In general, the incidence of palmar/plantar syndrome was higher than expected 
and it is possible that Z.3HCL may have exacerbated this reaction. Abdominal 
pain experience was also higher than expected but this could be the result of 
enhanced monitoring in the trial setting. However, it was considered that the 
inclusion of Z.3HCL did not significantly increase the toxicity of the induction 
regime, with all individuals having average times for both engraftment and 
inpatient stay.
96
Table 3.1.4 Adverse Events to Z.3HCL. Table showing patient grade 3 toxicity 
reactions associated with drug combination
Patient
4
200mg/
2m
6h
Patient
6
300mg/
m
6h
Patient
7
300mg/
2m
6h
Patient
8
400mg
3h
Patient
9
400mg
3h
Patient
11
400mg
3h
Patient
14
400mg
3h
Hallucinations
Grade 3 Grade3
Syncope
Grade 3 Grade 3
Confusion/
vagueness
Grade 3 Grade 3
Short term memory 
loss
Grade 2
Increased anxiety
Grade 3
Hand tremor
Grade 1 Grade 1
Abnormal dreams
Grade 3
Lightheaded/
dizziness
Grade 2 Grade 2
Vomiting
Grade 3
Fatigue Grade 2 Grade 3
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3.1.2.3 P-gp Expression
Blast cells isolated from 6 of the 16 (37.5%) patients assayed positivity for P-gp 
over-expression (MRK16 / Isotype ratio >1.1). These results are illustrated in 
Table 3.1.3.
3.1.2.4 R123 Efflux Assay
In the R123 assay, P-gp activity was completely inhibited in all 16 patients in the 
CD56+ cells with a median percentage inhibition of 98% (range 73 -111%) at 0.5 
- 1h after start of Z.3HCL infusion. Similar inhibition of P-gp activity was also 
demonstrated at 2 - 3h (mean 90.5%, range 63-106%), with gradual loss in 
inhibition post 8h, as demonstrated by an increase in R123 MCF ratio (Figure.
3.1.2 A). This data is also represented on a per patient basis in Figure 3.1.2 B
Similarly, in CD33+ cells in 6/10 patients where Z.3HCL induced P-gp efflux 
modulation was demonstrated, the mean inhibition was 85.25% (range 64- 
105.5%) at 0.5-1 hr. The modulation by Z.3HCL in P-gp+ and P-gp' patient cells 
are shown in Figure 3.1.2 C and E (mean) and D and F (individual). In the P-gp+ 
cells, there was a decrease in mean modulation post 8h, similar to that seen in 
CD56+ cells. However, this data is somewhat distorted by the fact that only one 
of the four in this group of CD33+ cells (Patient 9) responded with an efflux 
profile similar to that seen in the CD56+ cells (Figure 3.1.2 D).
Data were made available from the pharmacokinetic analysis performed off-site 
by Eli Lilly. The Z.3HCL plasma concentration-time curves for the three dosing 
patient groups relating to these data are shown in figure 3.1.3.A-C A direct
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concentration-effect relationship between Z.3HCL plasma concentration and 
inhibition of R123 efflux in CD56+ lymphocytes has been reported previously318. 
Based on this relationship all patients achieved plasma concentrations in excess 
of the IC90 value (figure 3.1.3).
The CD56+ results can be further illustrated in Figure 3.1.4, where the data is 
displayed for the three dosing groups (A, B, C). This figure indicates that 
maximal P-gp inhibition was rapidly achieved and that inhibition was still active at 
approximately half-maximal at 24h irrespective of which dosing schedule were 
undertaken by the patient.
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Figure 3.1.2 Results of the Pharmacodynamic R123 efflux assay: A - CD56+ 
cells mean; B - CD56+ cells individual; C - CD33+ cells, P-gp+ mean; D - CD33+ 
cells, P-gp+ individual; E - CD33+ cells, P-gp' mean; E - CD33+ cells, P-gp' 
individual.
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Figure 3.1.3 Plasma concentration-time curves forZ.3HCL in the 3 patient 
cohorts. A - 200mg/m2/6h, B -  300mg/m2/6h, and C -  400mg/3h.
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Figure 3.1.4. CD56+ cell response to P-gp inhibition by Z.3HCL, stratified by 
dosing group: A -  200mg.m2 / 6hr; B -  300mg.m2 / 6hr; C -  400mg / 3hr.
102
3.1.2.5 Calcein-AM Accumulation Correction Assays
Cells isolated from 9/15 patients and blast-gated using forward and side scatter 
showed functional P-gp calcein-AM efflux correction of MAF>10 with Z.3HCL 
with a median MAF of 13.4. Similarly, 11/15 patients showed efflux correction 
with VPM with a mean MAF of 18.7. Seven patients exhibited an efflux 
correction by both compounds (Table 3.1.3). The median calcein-AM efflux 
correction was greater in those cells that over expressed P-gp (median MAF 
37.9 for Z.3HCL and 35.4 for VPM). A significant correlation was found between 
P-gp expression with MRK16 and P-gp function by calcein-AM (Fig 3.1.6).
3.1.2.6 MTT Assay
The median IC50 levels for DNR show significant difference between cells 
modulated and not modulated in vitro with Z.3HCL (median IC50= 246.9ngml'1 
control vs 153.0ngml'1 +Z.3HCL, p= 0.012) implying that P-gp mediated efflux of 
DNR can be reversed by the addition of Z.3HCL. This effect was also seen for 
MIT, which is also a P-gp substrate (median IC50= 141.1ngml'1 control vs 
57.0ngml'1 +Z.3HCL, p= 0.037). There was no significant difference between the 
IC50 levels for ARA-C with and without Z.3HCL (median IC50= 1571ngml'1 vs 
2313ngml"1, p= 0.313). Figure 3.1.5A
Further analysis showed that the patient cohort data could be subdivided and 
stratified as two separate groupings determined on functional P-gp performance 
(calcein-AM assay) shown in Figure 3.1.5B and P-gp expression (MRK16 assay) 
shown in Figure 3.1.5C.
103
Figure 3.1.5B shows the median IC50 results from the subset of patients (n= 9) 
that were shown to have a positive calcein-AM efflux function. The ARA-C 
results showed no significant drug sensitisation between the unmodulated and 
modulated group (2175ngml'1 and 2516ngml'1 respectively, p=0.3672). The DNR 
and MIT groups both show significant sensitisation between the median IC50’s: 
DNR, 471.2ngml'1 unmodulated against 271.5ngml'1 modulated, (p=0.0371); 
MIT, 168.6ngml'1 unmodulated against 141.3ngml'1 modulated, (p=0.0273). 
These results are essentially similar to the results from the total median group.
Figure 3.1.5C shows the IC50 results from the subset of patients found to be P- 
gp+ by the MRK16 flow cytometry assay. Again, the pattern of sensitisation is 
similar to the efflux positive and total groups, only differing in the results for the 
MIT. Although showing a reduction in IC50 levels between the unmodulated and 
modulated groups (130 ngml'1 and 42.69ngml'1 respectively) this reduction was 
not found to be significant (p=0.1875). This could be due to the small sample 
size (n=4). The ARA-C showed no significant change (3303 ngml'1 unmodulated 
against 2516ngml'1 modulated, p=0.3125) and the DNR did demonstrate 
significant sensitisation (160.3ngml'1 against 135.6ngml'1, p=0.0313).
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Figure 3.1.5 MTT Assays. The median IC50 values with and without Z.3HCL 
assayed against ARA-C, DNR and MIT. A - shows the median results from all 
the patients assayed; B - from calcein-AM efflux+ patients; C - from MRK16 P- 
gp+ patients. * Denotes a significant difference.
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Figure 3.1.6 Correlation between P-gp expression by MRK16 MoAb and P-gp 
efflux function by calcein-AM accumulation assay in blast gated PBMC cells 
isolated from AML patients enrolled on the JTAN study. A shows the correlation 
for the P-gp inhibitor Z.3HCL, and B shows the correlation for VPM.
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3.2 Solid Tumour Trials
There were two solid tumour trials participated in during the course of this study: 
JTAC and JTAM. For JTAC, peripheral blood samples were taken from patients 
based at sites in Glasgow (UK), Oxford (UK) and Amsterdam (The Netherlands), 
typically four samples over a period of 24 hours. These samples were shipped 
to the Royal Free Hospital by courier for pharmacodynamic analysis using the Eli 
Lilly R123 assay. For the JTAM study the patients were based at The Royal 
Marsden (UK) and UCL Middlesex Hospitals (UK).
Due to the limited amount of patient material, study design and lack of informed 
patient consent, no accessory in vitro studies were carried out on cells isolated 
from JTAC and JTAM patients.
3.2.1 JTAC
3.2.1.1 Introduction and Study Design
Designated JTAC -  (B3T-MC-JTAC(d)) by Eli Lilly, the investigation was titled, A 
Phase 1 Dose Ranging Study of Z.3HCL (LY335979) Administered in 
Combination with Paclitaxel in Patients with Metastatic or Locally Advanced 
Cancer.
3.2.1.1.1 Objectives
The primary objective was to determine a dose of Z.3HCL that can be 
administered safely, with acceptable toxicity, in combination with paclitaxel.
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The secondary objectives were to evaluate the toxicity of Z.3HCL administered 
in combination with paclitaxel; to compare the pharmacokinetics of paclitaxel 
with and without Z.3HCL; to determine the pharmacokinetics of Z.3HCL (and its 
metabolites) when administered in combination with paclitaxel; to identify a dose 
of Z.3HCL that could be used in combination with paclitaxel in future Phase 2 
efficacy studies. The data from sixteen patients were collected during the course 
of our participation in the study.
3.2.1.1.2 Inclusion Criteria
Eligible patients were to be male or female of at least 18 years age exhibiting 
metastatic or locally advanced cancer not amenable to surgery or radiation. 
Prior surgery or radiation treatment should have been completed at least 3 
weeks prior to study enrolment. Prior chemotherapy was allowed providing there 
had been no more than two regimes and that they had been completed 3 weeks 
before enrolment. Eligible candidates were to have a performance rating of 0 -  
2 on the ECOG scale, adequate organ function, contraceptive measures to be 
taken for both females and males to minimise childbearing potential, and have 
an estimated life expectancy of at least 12 weeks.
3.2.1.1.3 Exclusion Criteria
Patients with unstable angina, myocardial infarction in previous six months, atrial 
or ventricular arrhythmia or congestive heart failure (CHF) were not considered 
eligible for enrolment. Other criteria for exclusion included: serious systemic 
infection; pregnancy or breast feeding; the use of any investigational agent within
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four weeks prior to enrolment; diagnosis of a haematological malignancy; 
patients with seizure disorders; history of brain metastases.
3.2.1.1.4 Dosing
The Z.3HCL was administered orally, with seven dose escalation cohorts in total. 
The doses were given 12hr apart for between 2 and 7 days, except for cohort 1, 
where the dosing was administered every 8hrfor 10 days. The dosing schedule 
for Z.3HCL started at 100mg/m2 in cohort 1, increasing to 200mg/m2 for cohort 2, 
300mg/m2 for cohorts 3 and 4, 250mg/m2 for cohort 5. Cohorts 6 and 7 received 
450mg and 500mg total respectively. The paclitaxel dose was 175mg/m2 for 
cohorts 1 to 5, and 225gm/m2 for cohorts 6 to 7.
3.2.1.1.5 Patient Demographics
There were sixteen patients studied: 13 female and 3 male, with a median age of 
55 years (range 31 -  77 years). There were 6 lung cancers (5 non-small cell 
lung cancer (NSCLC), 1 adenocarcinoma); 3 breast cancers (2 ductal, 1 lobular); 
3 ovarian cancers; 1 endometrium; 1 melanoma; 1 oesophagus; and 1 stomach 
cancer. The median time from diagnosis was 15 months (range 2 - 1 6 6  months) 
(Table 3.2.1).
3.2.1.1.6 Pharmacodynamic Assay
The Eli Lilly protocol R123 accumulation flow cytometry assay was used to 
measure the degree to which Z.3HCL inhibited the P-gp efflux function in CD56+
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NK cells isolated from patient peripheral blood, sampled during the course of 
Z.3HCL administration.
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3.2.1.2 Results
3.2.1.2.1 Clinical Data
The available clinical data made available by Eli Lilly shows that of the 16 
patients involved with the in vitro study at the Royal Free, 10 patients achieved a 
best response of stable disease (SD). One patient showed progressive disease, 
while a further 5 were not evaluated. No analysis was performed on the clinical 
benefits of P-gp modulation in these patients (Table 3.2.1).
3.2.1.2.2 Pharmacodynamic Assay
In the CD56+ flow cytometry assay 1 4 / 1 6  patients showed inhibition of R123 
efflux in response to the oral Z.3HCL. This inhibition was denoted by a greater 
than two-fold reduction in percentage efflux from the Oh time sample (Figures
3.2.1 and 3.2.2).
3.2.1.2.3 Adverse Events
Toxicity data was not made available for individual patients and therefore cannot 
be broken down to apply to the patients whose samples were analysed at the 
Royal Free. However Eli Lilly report that for the study overall, non- 
haematological toxicities associated with the modulator combination therapy 
were mainly neurological and included hallucinations, alopecia, myalgia, fatigue, 
neuropathy, visual disturbances, tremor, and ataxia319.
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Figure 3.2.1 Results of the R123 Accumulation Assay for JTAC Clinical 
Trial. Demonstrating the mean P-gp inhibition in CD56+ isolated from 16 patient 
samples.
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patient samples.
JTAC - P-gp Inhibition
(0a:
LLo
CMT—
O'
10-1
8
6
4
2
0
4 12 240 8 16 20
Time After Treatment (hours)
113
Q)
Months No. Z.3HCL Paclitaxel Best Study
Patient Center Gender Age Diagnosis Stage From Diag Prior Rx Dose (mg/m2) Dose (mg/m2) Response Reason Discontinued
1 157 Amsterdam M 31 Stomach Metastatic 11 1 239 174 SD Lack of Efficacy
2 158 F 60 Oesophagus Metastatic 8 1 238 177 SD Lack of Efficacy
3 159 F 67 Melanoma Metastatic 120 1 237 226 SD Lack of Efficacy
4 160 F 52 Lunq, NSCLC Metastatic 10 1 268 225 SD Lack of Efficacy
5 161 F 47 Lung, Adeno Metastatic 70 1 300 229 SD Fatigue
6 162 F 43 Lung, NSCLC Metastatic 11 1 286 225 NE Death from study disease
7 163 F 53 Endometrium Metastatic 41 272 225 NE Peripheral Neuropathy NOS
8 164 F 54 Lunq, NSCLC Metastatic 9 1 258 225 SD Lack of Efficacy
9 165 M 72 Lung, NSCLC Metastatic 15 1 250 175 SD Fatigue
10 166 M 56 Lung, NSCLC Metastatic 2 1 303 170 PD Lack of Efficacy
11 198 Glasgow F 70 Breast, Ductal Metastatic 92 2 260 175 SD Lack of Efficacy
12 199 F 69 Ovary, Epithel Metastatic 8 1 316 225 SD Personal conflict or other pat decision
13 200 F 47 Breast, Lobular Metastatic 166 5 . 226 NE Physician decision
14 254 Oxford F 47 Ovary Metastatic 52 4 250 175 NE Spinal cord compression NOS
15 255 F 77 Ovary Metastatic 17 2 347 222 NE Physician decision
16 256 F 61 Breast, Ductal Metastatic 15 1 298 173 SD Satisfactory Response
Table 
3.2.1 
JTAC 
patient 
dem
ographics 
and 
clinical inform
ation 
for the 
JTAC
3.2.2 JTAM - Introduction and Study Design
Designated JTAM -  (B3T-MC-JTAM) by Eli Lilly, the investigation was entitled, A 
Phase 1 Dose Ranging Study of Z.3HCL (LY335979) plus Doxorubicin and 
Z.3HCL (LY335979) plus Doxorubicin and Cyclophosphamide in Patients with 
Metastatic or Locally Advanced Cancer.
3.2.2.1 Objectives
The primary objective of this study was to determine a dose of Z.3HCL that could 
be administered safely and with acceptable toxicity in combination with 
doxorubicin (DXR) alone (dose schedule part A), and with doxorubicin plus 
cyclophosphamide (CPM) (dose schedule part B) in patients with metastatic or 
locally advanced cancer. The secondary objectives were to evaluate the toxicity 
of Z.3HCL when administered in combination with DXR alone, and when 
administered with DXR plus CPM; to determine the pharmacokinetics of Z.3HCL 
and its metabolites alone and in combination with DXR, and DXR plus CPM; to 
determine the pharmacokinetics of DXR and its metabolite doxorubicinol 
(DXRL), with and without Z.3HCL; to determine the pharmacokinetics of DXR 
and DXRL administered in combination with CPM with and without Z.3HCL.
Due to difficulties encountered implementing the study and problems with slow 
enrolment Eli Lilly decided to prematurely terminate the JTAM study. All patients 
enrolled participated in dosing schedule part A (DXR & Z.3HCL). Dosing 
schedule part B (DXR & CPM & Z.3HCL) was not implemented.
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3.2.2.2 Inclusion Criteria:
Patients to be enrolled had metastatic or locally advanced cancer, not amenable 
to surgery or radiation. Any prior surgery or radiation treatment was to have 
been completed at least four weeks prior to study enrolment. Prior 
chemotherapy treatment was allowed only if the candidate had received no more 
than 2 courses of therapy and that they had been completed at least 3 weeks 
before enrolment.
Prospective patients were to have had a performance rating of 0 -  2 on the 
ECOG scale with adequate organ function and an estimated life expectancy of at 
least 12 weeks. Patients were also to show a MUGA (Multiple Gated 
Acquisition) scan or echocardiogram with an ejection fraction of >50%, and to 
utilise appropriate contraceptive measures for both females and males to 
minimise childbearing potential.
3.2.2.3 Exclusion Criteria
Patients were not considered eligible for enrolment if they’d had use of any 
investigational agent within 4 weeks prior to enrolment or had a >300mg/m 
doxorubicin cumulative lifetime exposure. Other exclusion criteria included: a 
serious systemic infection; pregnancy or breast feeding; unstable angina, 
myocardial infarction in previous 6 months, atrial or ventricular arrhythmia or 
congestive heart failure (CHF). Patients were also excluded if they had a 
diagnosis of a haematological malignancy; concomitant hormonal or other anti­
cancer therapy; known or suspected CNS metastases; or any previous 
involvement with a Z.3HCL trial.
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3.2.2.4 Patient Demographics
Of the 11 patients enrolled that had samples analysed, 4 patients were 
diagnosed with sarcoma (3 metastatic, 1 locally advanced), 3 patients with lung 
cancer (1 bronchial, 1 large cell (LCLC), and 1 adenocarcinoma), 1 with adenoid 
cyst carcinoma, 1 colon cancer, 1 liver cancer, and 1 patient diagnosed with 
oesophageal cancer. All the non-sarcoma tumours were diagnosed as 
metastatic except the bronchial lung cancer and the LCLC which were locally 
advanced (table 3.2.2). The median time from diagnosis was 10.5 months 
(range of 2 -  32 months) and the median number of previous therapies was 2 
(range of 1 -  3).
3.2.2.5 Dosing
The Z.3HCL was administered as an oral capsule, with an initial dose of 200mg 
every 12 hours. The escalation of Z.3HCL was in 100mg steps until the 
achievement of the maximally tolerated dose (MTD). The median Z.3HCL dose 
was 400mg/m2 (range 200 -  500mg/m2) and the DXR dose was 75mg/m2 (no 
escalation).
3.2.2.6 Study Amendment
There were originally planned to be 2 parts to the dose regimen, schedule A and 
schedule B, but because of the early termination of the study, only schedule A 
was implemented. For dosing schedule A, on cycle 1, 3 and any subsequent 
cycles, Z.3HCL was given on Day 1 for a total of 2 doses (12 hours apart) with
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75mg/m2 DXR given as 30 minute infusion 2 hours after the first dose of Z.3HCL. 
For cycle 2, 75mg/m2 DXR was given alone on day 1.
3.2.2.7 Sample Schedule
Blood samples were taken at 0, 2, 4 and 24h after the commencement of 
Z.3HCL therapy. The first three samples were sent via courier at the end of the 
first day, and the remaining 24h sample sent on the second day straight after 
being taken. The samples were processed and analysed immediately upon 
receipt at the Royal Free Hospital.
3.2.3 Results
3.2.3.1 Pharmacodynamic Assay
It can be seen from figure 3.2.3 that P-gp efflux function, as demonstrated using 
the Eli Lilly R123 flow cytometry assay, was completely and rapidly inhibited in 9 
/ 11 assessable patients. Significant inhibition was denoted by a greater than 2 
fold reduction in R123 MCF ratio. This data is also shown for individual patients 
in Table 3.2.4.
3.2.3.2 Clinical Results
Data provided by Eli Lilly report that 3 / 1 1  patients demonstrated a study best 
result of stable disease (SD), 5 with progressive disease (PD), and 3 patients 
that were unevaluated (NE). No modulator benefit analysis was conducted.
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Patient Centre Gender Age Diagnosis Stage
Months 
From Diag
No.
Prior Rx
Z.3HCL 
Dose (mg/m2)
DXR
Dose (mg/m2)
Best Study 
Response Reason Discontinued
1 8001 Royal Marsden M 63 Sarcoma Metastatic 12 2 200 75 PD Physician Decision
2 8003 Royal Marsden M 54 Sarcoma Locally Advance 15 2 200 75 SD Physician Decision
3 8004 Royal Marsden F 57 Sarcoma Metastatic - 2 200 75 PD Physician Decision
4 8005 UCL Middlesex M 53 Sarcoma Metastatic 2 1 400 75 PD Physician Decision
5 8026 Royal Marsden M 67 Lung, Bronchial Locally Advance 11 2 400 75 NE Evidence of diminishing cardiac function
6 8027 UCL Middlesex F 58 Liver Metastatic 8 2 400 75 PD Death from study disease
7 8028 UCL Middlesex M 65 Lunq, Lq Cell Locally Advance 10 2 400 75 SD HvDoaesthesia
8 8030 UCL Middlesex M 48 Lung, Adeno Metastatic 23 3 500 75 NE Pancytopaenia
9 8031 UCL Middlesex M 52 Colon Metastatic 32 3 500 75 SD Evidence of diminishing cardiac function
10 8032 UCL Middlesex M 63 Oesophagus Metastatic 4 2 500 75 PD Death from study disease
11 8034 UCL Middlesex M 36 Adenoid Cyst Ca Metastatic 8 1 500 75 - Neutropenia
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Figure 3.2.3 Results of the R123 Accumulation Assay for JTAM Clinical 
Trial. Demonstrating the mean P-gp inhibition in CD56+ isolated from 11 patient 
samples.
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Figure 3.2.4 Results of the R123 Accumulation Assay for JTAM Clinical 
Trial. Demonstrating the individual P-gp inhibition in CD56+ isolated from 11 
patient samples.
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3.2.4 Variation Between Trials
Even though the three clinical trials involved different drugs, times and tumour 
types, the two constants were the use of NK cells as a reporter for P-gp inhibition 
and the time Oh sample. It can be seen from the data that there is a range of 
initial R123 MCF ratios seen between individual patients. By comparing the 
means of the R123 MCF ratios between each trial an indication of the 
reproducibility of the assay may be ascertained.
Figure 3.2.5 shows the mean and individual points of the pre-Z.3HCL (Oh) 
samples for each of the three trials. It can be seen that the mean and spread of 
the data for JTAN and JTAC are very similar (Mean = 3.852 for both) and this is 
reflected in the result of the t-test performed between the two (P=1.000). The 
variation between patients in JTAM is by contrast much larger, and the mean of 
the data is higher (7.117), and that this difference although not statistically 
significant, does however approach significance (JTAN, P=0.0531, and JTAC, 
P=0.0527)
JTAN/C/M - CD56+ - Oh
JTAN v JTAC: P= 1.0000 
JTAN v JTAM: P= 0.0531 .
JTAC v JTAM: P= 0.0527
* • • • •  • • • *
JTAN JTAC JTAM
Figure 3.2.5 Inter-Trial Assay Variability.
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3.3 Discussion
The pharmacodynamic data from all three trials show a corresponding pattern of 
in vivo P-gp inhibition in circulating CD56+ cells, with almost complete efflux 
inhibition being demonstrated very rapidly after commencement of treatment, 
regardless of the dosing regimen or route of administration. It can be seen that 
when only a single dose regimen was implemented P-gp inhibition begins to 
diminish at 8-12h, but still retaining approximately half-maximal efficacy at 24h. 
The two-dose regimen demonstrated a maximal inhibition up to 24h.
3.3.1 JTAN AML Trial
The R123 accumulation flow cytometry data clearly show Z.3HCL to be a 
significant P-gp inhibitor in patients with AML. R123 efflux from CD56+ cells was 
completely and rapidly inhibited in all the patients studied, often by 0.5 hours 
from the start of infusion of the modulator. A similar trend was seen for the 
CD33+ cells confirming inhibition of P-gp in the AML cells in vivo. However, 
CD33+ cells tend to express significantly less P-gp than CD56+ cells and the 
observed inhibitory effect was therefore less pronounced. It is this inherently 
high P-gp expression and their relative abundance in peripheral blood that 
qualifies CD56+ cells as a convenient in vitro surrogate marker for use in 
fluorescent dye accumulation assays measuring in vivo P-gp modulation. 
However, some AML blasts are known to express CD56, and since in most 
cases blasts cells express a much lower level of P-gp than NK cells, this may 
have had the effect of reducing the observed sensitivity of the assay. In a Phase 
II trial with Z.3HCL, in vitro studies on bone marrow myeloblasts also 
demonstrated successful modulation of P-gp efflux320. On hindsight, inclusion of
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CD45 as a co-marker would have made the assay more robust, since this would 
have allowed for more accurate gating of the blast cell population.
The calcein-AM accumulation assay showed Z.3HCL to be as almost as 
effective as VPM at inhibiting functional P-gp efflux in vitro. Although more 
patients showed calcein-AM efflux correction with VPM than with Z.3HCL, 5/6 P- 
gp+ patients exhibited efflux correction with both modulators. The higher 
correction and better correlation by VPM may be attributed to its ability to inhibit 
other drug transporters including, to some extent, MRP1 while Z.3HCL solely 
inhibits P-gp modulated efflux. This lack of selectivity by VPM can however, 
result in deleterious changes to the pharmacokinetics of co-administered drugs, 
a problem not associated with Z.3HCL. The clinical relevance of MRP1 
expression as a significant resistance mechanism in AML is still being debated 
but its expression in this cohort of samples appear not to contribute to the 
results.
The drug sensitivity studies using the MTT assay show that co-incubation with 
Z.3HCL in vitro renders the AML cells from patients more sensitive to DNR and 
MIT. DNR is a recognised substrate for P-gp and MIT can be effluxed by P-gp 
and the related half-transporter, BCRP. Both drugs would therefore be removed 
from the cell by P-gp unlike ARA-C, which is not a substrate and consequently 
there is no sensitisation to ARA-C by the addition of Z.3HCL. The reduction in 
the IC50 for DNR confirms that Z.3HCL treatment in this cohort of patients would 
have inhibited the efflux of the infused DNR in AML cells thereby contributing to 
cell death and consequent treatment response.
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The results suggest that Z.3HCL is well tolerated in combination with standard 
induction agents DNR and ARA-C. The main toxicities manifested as 
neurological events. This is in keeping with the fact that P-gp is expressed in 
brain endothelial cells and may represent direct drug effect, concomitant 
cytotoxic drug effect or effects related to inability to efflux naturally occurring 
toxins or metabolites. There is however, no apparent correlation with plasma 
drug concentrations of Z.3HCL or with the degree of P-gp inhibition as all 
patients achieved maximal inhibition in the R123 assay. Hence the possible 
mechanisms for this remain unknown318.
An additional adverse event with the use of P-gp modulators in vivo is the 
enhanced toxicity of the co-administered cytotoxic agent. Although second 
generation P-gp inhibitors such as PSC833 and CSA are characterised by 
enhanced activity against P-gp, they also affect the pharmacokinetics of the 
cytotoxic agents with which they were administered. However, Z.3HCL has 
been shown to have minimal effect on doxorubicin toxicity or pharmacokinetics 
as shown by a phase I study in patients with advanced malignancies321.
Previous studies have observed that since the bulk of the AML cells do not over 
express P-gp, it is possible that P-gp+ clonogenic AML blast cells may form a 
seed reservoir of resistant cells that contribute to conventional treatment failure. 
It is further suggested that this minor population should be the target for P-gp 
modulation as indeed was done in this study by the infusion of Z.3HCL on the 
third and fifth day post initial treatment with DNR and ARA-C. It was assumed 
that this would have eliminated the sensitive pool of AML cells to be followed by 
an effect on resistant cells consequent to P-gp modulation. The benefits of this
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modulation however may not be seen in a CR but in the DFS or in the time to 
relapse322. However, studies by van der Pol et al suggest that the emergence of 
minimal residual disease (MRD) in AML is not by selection of pre-existing 
resistant subpopulation cells191.
These data suggest that Z.3HCL shows promise as a clinically useful adjuvant 
due to its high specificity, potency and lack of deleterious pharmacokinetic 
interactions. Large scale randomized trials are warranted to assess the clinical 
efficacy of Z.3HCL in AML. Z.3HCL in combination with the C-AM and MTT 
assays is useful in ascertaining specific P-gp functional resistance. Results of 
this trial in AML have been recently published by Gerrard et al in 
Haematologica323, and by Callies et al in Cancer Chemother Pharmacol318.
3.3.2 JTAC Solid Tumour Trial
The focus of this study was the clinical dosing and safety data, which was 
analysed offsite by Eli Lilly. The pharmacodynamic assay showed that CD56+ 
cells isolated from 14 of the 16 patients assayed showed a rapid greater than 
two-fold reduction in P-gp efflux in response to oral Z.3HCL.
It can be seen from figure 3.2.2 that there was a wide range of initial points for 
the individual inhibition ratio graphs, possibly reflecting the wide range of 
variables involved, including variability between the centres concerned, 
differences in acquiring the blood samples, between patient disease, and the 
length of time the samples were in transit before analysis. When taken together,
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these factors may help explain the wide range of heterogeneity in the starting 
assay. The oral route of Z.3HCL administration may also contribute a degree of 
variation due to possible differences in bioavailability.
None of the patients involved were assayed to determine P-gp over-expression 
in their tumour tissues, although all of the tumour types in question have been 
shown to be affected by P-gp mediated MDR324'326.
Overall, the pharmacodynamic results do indicate that oral Z.3HCL at all of the 
dosage regimens implemented appears to be an effective inhibitor of P-gp 
mediated efflux and therefore may contribute positively as an adjuvant to 
chemotherapy where P-gp associated MDR has been indicated as a obstacle to 
successful treatment. The pharmacokinetic data from this trial was published by 
Callies et a?79.
3.3.3 JTAM Solid Tumour Trial
As with the previous solid tumour trial (JTAC), the primary focus of this 
investigation was the safety and pharmacokinetic data, which were analysed off- 
site by Eli Lilly. The pharmacodynamic analysis of the surrogate CD56+ cells 
showed that overall there was a rapid and prolonged response to the oral 
administration of Z.3HCL, with cells isolated from 9 of the 11 patients showing 
significant efflux inhibition.
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It can be seen from Figure 3.2.4 that, as seen previously, there was a wide 
range of initial efflux ratios indicating some degree of variability, which could be 
attributed to the inherent number of variables involved. These include the 
differences in patient condition, sample location and transport. All the samples 
subsequent to the initial pre-dose samples show a level of uniformity in response 
to Z.3HCL, maintaining an effective and prolonged inhibition of efflux function. 
Pharmacokinetic data from this trial was published by Callies et a/278.
It was also observed that there was a wider range of pre-dose (time=0h) CD56+ 
R123 efflux start points for patient samples from the JTAM trial compared with 
samples from the JTAN and JTAC, which were virtually identical (Figure 3.2.5). 
No obvious explanation for this finding can be offered other than some 
unidentified source centre specific variable. All three trials ran concomitantly 
with overlapping sampling durations, with JTAC starting first, then JTAM and 
then JTAN. All patient samples for JTAN were sourced at the Royal Free, while 
all samples for JTAC and JTAN were same-day couriered from external sites. It 
is worth noting, however, that only 3 of the 11 JTAM samples fell outside of the 
range observed for the other two trials, and these 3 samples came from 2 
different centres and were not received contiguously. Since the statistical 
analysis found no actual significant difference, therefore it must be considered 
that the observed difference may well be stochastic in origin.
In summary, three phase I clinical trials of Z.3HCL were conducted: JTAC, 
JTAM, and JTAN. The first two trials were limited in their scope for investigating 
the efficacy of Z.3HCL in the clinical setting, primarily because they were
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conducted on patients with solid tumours, and secondarily because the focus of 
these investigations (and indeed JTAN as well) was to facilitate the acquisition of 
dose range and drug combinational safety data. The third trial, JTAN, was more 
amenable to the attainment of MDR related data and the monitoring of inhibition 
efficacy, notably in surrogate cells, but also in malignant cells. However, the 
sample size of patients was too small to enable a realistic evaluation of benefit 
arising from the use of Z.3HCL in the clinical setting.
In the clinical setting, Z.3HCL is shown to be a relatively safe and effective 
inhibitor of P-gp efflux function, both as an oral (JTAC and JTAM) or IV treatment 
(JTAN). These data add weight to the argument for it’s inclusion in further 
efficacy studies as an adjuvant for leukaemia and cancer chemotherapy where 
P-gp has been shown to be an adverse prognostic signifier.
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4. In Vitro Studies -  Multidrug Resistance
4.1 General Introduction
MDR, and in particular P-gp over-expression has been shown to be a risk factor 
that impacts negatively upon the chemotherapeutic treatment of cancer in 
general, and haematological malignancies in particular. The routine monitoring 
of MDR levels in leukaemia patients using both quantitative and qualitative 
methods has been established and implemented by our laboratory at the Royal 
Free Hospital. Z.3HCL, because of its proven selectivity and potency, was 
utilized as a component of the assays used in this analysis along side the 
established P-gp inhibitor verapamil (VPM), thereby enabling further examination 
of its character and ability as a P-gp inhibitor in patient material and in vitro cell 
line studies.
4.1.1 Patient Sample Material
Cells from patient peripheral blood and bone marrow samples were tested for 
the expression of MDR proteins using monoclonal antibodies and for functional 
P-gp efflux using the calcein-AM assay. MTT drug sensitivity assays were 
performed where appropriate and where sufficient patient material was available. 
The P-gp inhibiting efficacy of Z.3HCL was evaluated in the different disease 
types in order to ascertain the suitability of Z.3HCL as a P-gp modulatory agent 
for future clinical trials in these diseases. Of initial interest was the mature 13- 
lymphocyte malignancy, multiple myeloma, and although this study has shown 
Z.3HCL to be an efficient reverser of P-gp in tumour cells isolated from myeloma 
patients, the inherent difficulties in obtaining sufficient numbers of pure tumour
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cells from small volumes of typically low-cellular marrow samples frustrated most 
attempts to conduct drug sensitivity assays.
4.1.2 Calcein-AM Data
The calcein-AM dye accumulation assay yielded the largest number of data, and 
is conceivably the more useful of the assays performed in indicating the MDR 
status of a sample because it demonstrates P-gp function rather than 
expression, although the two are strongly correlated (Figure 4.1).
4.1.3 Expression Stratification
To give a realistic indication of the P-gp status of an individual patient sample at 
least two parameters should be measured, and in the case of this study, a 
functional P-gp (calcein-AM assay) and a quantitative P-gp expression assay 
(MRK16 MoAb) were utilized. This strategy allows for the stratification of patient 
samples into three expression profiles: negative, intermediate and high. For a 
patient sample to be classified as negative, both tests for P-gp would be below 
the threshold for positivity. For a patient sample to be intermediate one or other 
of the two assays would be positive, and a patient sample to be classed as high, 
both assays would prove positive.
4.1.4 MTT IC50 Data
The MTT drug sensitivity assay when used with and without Z.3FICL is a useful 
indicator of the significance of P-gp in the MDR character of a sample cell
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population. Non-parametric, one-tailed Mann-Whitney tests were performed 
between the median of each data set in order to determine any significant 
sensitisation to the drugs by the presence of Z.3HCL.
Typically, three drugs were utilized in the assay, and these were chosen to 
reflect drugs in clinical use for the treatment of each disease. As seen in 
Chapter 3, ARA-C, DNR and MIT were used in the MTT assay for cells isolated 
from AML patients. DNR and MIT are P-gp substrates and ARA-C is not.
The MTT data for CLL patient cells included only one P-gp effluxed drug, DNR. 
Chlorambucil (CHL) and Fludarabine (FLU) are two of the main first line drugs 
used in the treatment of patients with CLL and neither of these drugs are a 
substrate for P-gp mediated efflux. Although a trend is seen in the combined 
IC50 data towards a sensitisation in the presence of Z.3HCL, none of the results 
proved to be significant at the 95% confidence level, even for DNR in the P-gp 
efflux selected group. This again may be a consequence of the low sample 
numbers. Less priority was given to the comparative study of CLL patients with 
Z.3HCL because of the fact that most of the drugs used in its treatment are not 
P-gp efflux substrates.
Due to the difficulties associated with the attainment of sufficient numbers of 
viable MM plasma cells, no meaningful MTT results were obtained for these 
samples.
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4.2 Results
4.2.1 AML Patient Samples
Over a period of three years AML patient samples were collected, prepared and 
analysed (see Appendix 1). Of these, 55 samples (26 PB, 29 BM) from 48 
patients yielded useful results for both the calcein-AM functional assay and 
MRK16 quantitative P-gp assay. There were 35 males and 13 females and the 
median age of the patients was 60 years (range of 11 to 82 years), with a 
median WBC of 12.2 x 109L'1 (range of 0.7 to 242.0 x 109L'1) and a median bone 
marrow blast count (where available) of 79% (range of 10 to 100%).
There were 29 presentation samples from de novo patients, 8 samples from 
previously relapsed patients and 9 samples from patients following treatment, 
with another 9 samples where the patient status was unknown. There were 6 
patients from whom we received both an initial and a follow-up sample (including 
one patient who had 2 follow-up samples), with a median interval time of 7.7 
months. There were 4 de novo samples with a follow-up at post treatment, 1 de 
novo sample with a relapse follow-up sample, and 1 relapsed sample with a 
follow-up at post-treatment. Of the first 4 de novo sample group, 3 were positive 
for P-gp function (MAF) at presentation and 2 remained positive post treatment, 
one patient was positive for P-gp expression at presentation, and 3 were positive 
post treatment. The remaining two patients were both positive for P-gp function 
and P-gp expression at both initial and follow-up time points.
Therapeutic response data was available for 33 patients, with 23 achieving a 
complete haematological response (CR), 7 who did not attain a CR (NR), and 3 
showing progressive disease (PD).
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Thirty patients had cytogenetic data available and were stratified into three 
prognostic risk groups197: Favourable (F), Intermediate (I) and Adverse (A). Two 
patients were classified as F, 26 as I, and 2 as A. These groups were too small 
to enable any meaningful correlative statistics, but a descriptive table detailing 
relative median WBC, age and MDR status is given in Table 4.1.
Table 4.1 Cytogenetic Risk Groups in AML patient cohort.
No. % Age WBC MAF P-gp
F
I
A
2
26
2
6.7%
86.7%
6.7%
44.5
55
48
27.15
9.8
1T05
15.70 
10.01 
21.18
1.23 
0.99 
1.11
Risk Group: F= Favourable; l= Intermediate; A= Adverse. WBC = median 
white cell count
4.2.1.1 AML MDR Assay Correlation
Figure 4.1 shows the correlation between P-gp expression, as measured by the 
MRK16 flow cytometry assay, and MDR efflux function, as measured by the 
calcein-AM accumulation assay. The latter assay utilized Z.3HCL (Figure 4.1 A) 
and VPM (Figure 4.1 B) as the P-gp inhibitor, allowing comparison between the 
two and thus enabling a measurement of the efficacy of Z.3HCL in the in vitro 
environment.
It can be seen that for both Z.3HCL and VPM calcein-AM assays the correlations 
with P-gp were highly significant (P<0.0001 for both), but probably due to the 
heterogeneous nature of the disease the r2 (coefficient of determination) is 
relatively low (0.4224 for Z.3HCL and 0.4813 for VPM).
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Figure 4.1 P-gp Expression and Calcein-AM accumulation correlation in 
AML. These graphs show the correlation between P-gp expression measured 
by MRK16 MoAb and functional Calcein dye efflux inhibition, as measured by 
MAF. A p-value is shown to indicate significance, and r2 denotes the coefficient 
of determination.
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4.2.1.2 AML MDR Assays
Table 4.2 shows the basic results for positivity in the two MDR assays (P-gp 
expression and efflux function). Figure 4.2 illustrates the results from the 
MRK16 P-gp expression and calcein-AM functional assays, with the intention of 
stratifying the patient samples into one of four MDR categories: positive (+), 
double positive (+/+), negative (-), and double negative (-/-).
Table 4.2 Basic results of the in vitro  assays. Absolute figures and 
percentages for positivity in the P-gp expression assay (MRK16) and functional 
efflux assay (calcein-AM).
AML
n=55
CLL
n= 75
MM
n= 17
P-gp+
MRK16
21
38.2%
46
61.3%
7
41.2%
Efflux+
Calcein
27
49.1%
42
56.0%
7
41.2%
+ /  + 16
29.1%
31
41.3%
4
23.5%
Figure 4.2A shows the results of the calcein-AM accumulation functional assay 
stratified by P-gp expression (assessed from the MRK16 assay), along with the 
results of Mann-Whitney tests implemented to determine the level of significant 
difference between the groups (denoted by a P number, with <0.05 being 
considered significant). Also shown in Figure 4.2A is a column representing all 
55 AML calcein-AM results to illustrate the spread of the data. The numbers at 
the top of each column shows the median value for those data, and this is also 
demonstrated by the short horizontal bars bisecting each column.
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From these data in Figure 4.2A it can be seen that the P-gp positive group (P- 
gp+) has a higher median MAF than the P-gp negative group (P-gp-) (19.79 and 
3.965 respectively) and that the Mann-Whitney test performed between these 
data sets show that this difference is highly significant (P<0.0001).
Figure 4.2B shows the results of the MRK16 P-gp expression assay stratified by 
P-gp efflux function (MAF). The medians are shown both on the graphs as 
horizontal bars and are given numerically above each column. Statistical 
significance between these groups derived from a Mann-Whitney test is also 
given.
It can be seen in these data that the efflux positive group (MAF+) has a 
substantially higher median P-gp expression than the efflux negative group 
(MAF-) (1.22 and 0.96 respectively), and that this difference is highly statistically 
significant (P<0.0001).
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Figure 4.2 AML Calcein-AM accumulation and P-gp expression data. Graph 
A shows the different levels of calcein accumulation as measured by MAF in 
relation to different categories of P-gp expression. Graph B shows the P-gp 
expression as measured by MRK16 in relation to the different categories of 
calcein accumulation as measured by MAF. The P number denotes the 
significance of a Mann-Whitney test between the P-gp+ and P-gp- groups in 
graph A, and MAF+ and MAF- groups in graph B.
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Figure 4.3 illustrates the P-gp expression and function profiles of patients 
samples grouped according to whether they were de novo presentation samples 
(P), samples from patients that had undergone treatment (T), or from patients 
with secondary or relapsed AML (R). The left-hand three scatter plots show the 
MAF data from calcein assays, the right three illustrate the data from MRK16 
assays, and the bars represent the median of the data.
It can be seen that for the calcein data, there is no statistical difference in P-gp 
function shown between the three groups, although the median MAF for the 
treated patients is higher than that of presentation and relapse patient samples 
(12.62 v 9.45 & 7.29, respectively).
The P-gp expression data shows that samples from treated patients have a 
significantly higher level of P-gp than the presentation samples (1.23 v 1.04, P= 
0.0378). There was no significant difference between either of these two groups 
and the relapsed group (1.05).
Figure 4.4 shows P-gp expression and function in patient samples grouped 
according to outcome: complete haematological remission (CR), no remission 
(NR) and progressive disease (PD). Neither the calcein data nor the MRK16 
data show any significant difference in expression or function between the 
outcome groups.
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Figure 4.3 AML P-gp expression and function grouped according to  
treatm ent. P= presentation sample; T= post treatment sample; R= post relapse 
sample. The P values represent statistical test performed between the groups.
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Figure 4.4 AML P-gp expression and function grouped according to patient 
response. CR= complete remission; NR= no response; PD= progressive 
disease.
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Figure 4.5A shows a linear regression correlation plot performed to investigate 
whether P-gp expression or function varies according to age. It can be seen 
from these data that there is no significant correlation between age and function 
(MAF, P= 0.1933) or expression (P-gp, P=0.0986), although the slopes of the 
regression lines do suggest a general trend towards and increase in MAF and P- 
gp as the age of the patient increases.
Figure 4.5B demonstrates the P-gp function and expression by two age 
groupings: <55 and ^55 years. Compared to the <55 year group, the median P- 
gp function was shown to be increased in the ^ 5  year group, but this was not 
statistically significant (4.40 to 9.45, P=0.0988). The median P-gp expression 
was also higher in the ^ 5  year group, and this increase was statistically 
significant (0.99 to 1.05, P=0.0353).
The proportion of P-gp function positive (MAF ^ 0 )  and expression positive 
(MRK16 ^ .1 )  samples were higher in the ^ 5  year group compared to the <55 
year group. Nine (42.9%) of the <55 year group were P-gp function positive, 
compared to 14 (48.3%) of the ^55 year group. For P-gp expression, only 4 
(19%) of the <55 year group were P-gp positive, compared to 12 (41.1%) in the 
^>5 year group.
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Figure 4.5A AML P-gp expression and function correlated against age. P-
gp functional (MAF) and expression (P-gp) data of patient samples correlated 
using linear regression against patient age.
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Figure 4.5B AML P-gp expression and function measured against age 
group. P-gp functional (MAF) and expression (P-gp) data of patient samples in 
two age groups. The significance of a statistical analysis is denoted by a P 
value.
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4.2.1.3 AML MTT Assays
Figure 4.6 shows the results of the MTT drug sensitivity assays carried out on 
cells isolated from a total of 33 AML patients. The subsections of the figure, 
labelled A -  G illustrate the median IC50’s for each MDR expression group, 
stratified according to the P-gp expression and calcein-AM accumulation assays.
Figure 4.6A shows the overall results from all 33 AML patients. Only MIT shows 
significant sensitisation (p= 0.0223), and although DNR does show a drop in 
IC5o, it is not significant (0.0960). ARA-C is not expected to show significant 
sensitisation; however it quite consistently (in graphs A, B, C, D, and F) shows 
that the cells incubated in the presence of ARA-C and Z.3HCL to have a higher 
IC50 than those with ARA-C alone, though this difference did not approach 
significance.
The results for DNR are generally consistent with what could be predicted from 
the MDR results: all the positive groups (Graph B - P-gp+, D - efflux+, and F - +/+) 
showed significant sensitisation to the drug by Z.3HCL, while all the negative 
groups (Graph C - P-gp', E - efflux', and G P-gp' /Efflux') show no significant 
decrease in IC50.
The results for MIT are not so consistent, with discordance being shown in group 
C (P-gp ), where a significant drop in IC50 in the Z.3HCL cohort is observed 
(p=0.0340). The remaining negative groups show no significance (graphs E and 
G). In groups B (P-gp+) and F (P-gp+/Efflux+) the expected significant 
sensitisation is not observed (in contrast to the DNR), and only in group D
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(efflux+) do we observe concordance with the DNR results with a significant drop 
in IC50 in the presence of Z.3HCL (p= 0.0088).
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Figure 4.6 AML MTT data. IC50 data for the three drugs, ARA-C, DNR, and 
MIT, for different MDR expression stratification groups (Graphs A -  G), in the 
presence and absence of Z.3HCL (continued on next page).
143
(IU1/0U) OSOI
D - Efflux+ AML Samples
AraC
"ft 30000
+Z3HCL-Z3HCL
DNR MIT
750-
246.9
500-
250
+Z3HCL
149.6400-
-Z3HCL +Z3HCL
P= 0.2925 
n= 17
p= 0.0018*
n= 17
p= 0.0088'
n= 16
E - Efflux" AML Samples
AraC
253510000
2500
+Z3HCL-Z3HCL
p= 0.4887 
n= 15
DNR MIT
500
151.5
200-
100-
-Z3HCL +Z3HCL
400-1
136.2
200
1 0 0 -
-Z3HCL +Z3HCL
P= 0.5436 
n= 16
P= 0.5830 
n= 14
F - P-gp+ / Efflux+ AML Samples
AraC DNR
J  20000- 4156
y 10000
+Z3HCL-Z3HCL
p= 0.3848 
n= 10
p= 0.0098 '
n= 10
MfT
400-
300-
200-
100-
-Z3HCL +Z3HCL
93.07 57.00
300-
200
100-
-Z3HCL +Z3HCL
p= 0.2500 
n= 9
G - P-gp" / Efflux' AML Samples
AraC DNR MIT
1776
7500-
5000-
-Z3HCL +Z3HCL
400
71.27
2 0 0 -
100
-Z3HCL +Z3HCL
500-
400
300
200-
100-
-Z3HCL +Z3HCL
p= 0.3054 p= 0.1677 p= 0.6221
144
4.2.2 CLL Patient Samples
Over the course of the study 75 samples from 61 patients yielded useful results 
for both the calcein-AM functional assay and MRK16 quantitative P-gp assay 
(see Appendix 2). The patients were comprised of 48 males and 13 females, 
with a median age of 71 years (range of 53 to 93 years), and a median WBC of 
37.0 x 109L~1 (range of 7.0 to 165.0 x 109L'1). There were 13 follow up samples 
from 10 patients, and of these calcein assays showed that 2 patients 
demonstrated an increase in MAF from negative to positive, 3 showed a 
decrease from positive to negative, and 5 remained the same. The MRK16 
assay showed that 1 patient went from P-gp negative to positive, 1 from positive 
to negative, and 8 remained the same.
Where known, Binet classification showed 31 patients were stage A, 18 stage B, 
and 10 stage C. There were 32 samples from untreated patients and 43 
samples from patients who had received chemotherapeutic treatment. 
Treatment regimens included chlorambucil (26), fludarabine (7), 
cyclophosphamide (6), prednisone (2), and rituximab (2).
Where results were available, 31 patients were found to be ZAP-70 negative and 
10 were ZAP-70 positive; 19 patients were lgVH mutated and 13 were 
unmutated. Both of these are prognostic signifiers relating to CLL disease 
progression, with ZAP-70 negativity and lgVH mutated correlating to better 
outcome. There was 87.5% concordance between the ZAP-70 positivity and 
lgVH mutation status, in the 30 cases where both values were known.
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4.2.2.1 CLL MDR Assay Correlation
Figure 4.7 shows the correlation between P-gp expression and MDR efflux 
function for Z.3HCL (Figure 4.7A) and VPM (Figure 4.7B) as the P-gp inhibitor. 
As with the AML patients, this allows for a comparison between the two inhibitors 
in the in vitro CLL environment.
It can be seen that for both Z.3HCL and VPM calcein-AM assays the correlation 
with P-gp expression was highly significant (P<0.0001 and 0.0003 respectively), 
but due to considerable scatter the r2 is extremely low (0.2549 for Z.3HCL and 
0.1702 for VPM).
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Figure 4.7 P-gp expression and calcein-AM accumulation correlation in 
CLL. Graphs showing the correlation between P-gp expression (MRK16) and 
functional Calcein dye efflux inhibition (MAF). A p-value is shown to indicate 
significance.
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4.2.2.2 CLL MDR Assays
Figure 4.8A illustrates the results of the calcein-AM functional assay, stratified by 
P-gp expression (assessed from the MRK16 assay), and also shows the results 
of Mann-Whitney tests performed in order to determine any significant difference 
between the groups. Also shown in Figure 4.8A is a column representing all 75 
CLL calcein-AM results to show the spread of the data. The numbers at the 
head of each column show the median value for those data, and this is also 
illustrated by the short horizontal bars bisecting each column.
From these data it can be seen that there is a significant difference in median 
MAF between the P-gp+ and the P-gp- groups, with the P-gp+ group having a 
higher median MAF than the P-gp- group (15.52 and 6.10 respectively, 
P=0.0024).
Figure 4.8B illustrates the results of the MRK16 P-gp expression assay stratified 
by P-gp efflux function (MAF). The medians are shown on the graphs as 
horizontal bars and are given numerically above each column. Statistical 
significance between these groups derived from Mann-Whitney tests is also 
shown.
It can be seen that in these data that the efflux positive group (MAF+) has a 
higher median level of P-gp expression than the MAF negative group (MAF-) 
(1.68 and 0.97 respectively) and that this difference is statistically significant
(p<0.0001).
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Figure 4.8 CLL Calcein assay and P-gp expression assay data. Graph A 
shows the different levels of calcein efflux (MAF) in relation to different 
categories of P-gp expression. Graph B shows the P-gp expression (MRK16) in 
relation to the different categories of calcein accumulation as measured by MAF. 
The P number denotes the significance of a Mann-Whitney test between the P- 
gp+ and P-gp- groups in graph A, and MAF+ and MAF- groups in graph B.
149
Figure 4.9 shows the median P-gp expression and function for patient samples 
grouped by Binet stage. It can be seen from the data that there is no significant 
difference either in function (MAF) nor in expression (P-gp) between any of the 
three groups. The P values indicated represent statistical test performed 
between the three stages.
Figure 4.10 demonstrates the median P-gp expression and function between 
samples from patients who either received treatment (T) or were untreated (U). 
It can be seen that the median MAF was slightly lower in the treated group than 
in the untreated group, but not to the level of statistical significance (10.69 v 
13.79, P=0.6753). The P-gp expression of the treated group was also lower 
than the untreated group, but with the difference approaching significance (1.58 
v 1.01, P=0.0545).
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Figure 4.11 shows P-gp expression and function grouped by lgVH mutation 
status. The lgVH unmutated samples (Un) demonstrate a slightly higher median 
MAF than the mutated samples (Mu), but not significantly (12.01 v 8.273, P= 
0.3293). The same is true for the median P-gp expression (1.619 v 1.558, 
P=0.8724).
Figure 4.12 illustrates P-gp expression and function grouped by the ZAP-70 
status of the patients. It can be seen that the ZAP-70 negative patients exhibit a 
slightly higher MAF than the ZAP-70 positive patient, but not to the level of 
statistical significance (12.62 v 8.595, P=0.1563). This is also seen for the P-gp 
expression data (1.709 v 1.278, P=0.3575).
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4.2.2.3 CLL MTT Assays
Figure 4.13 illustrates the results of the MTT drug sensitivity assays carried out 
on cells isolated from a total of 11 CLL patients. The subsections of the figure, 
labelled A -  C illustrate the median IC50 for 3 MDR expression groups, stratified 
according to the P-gp expression and calcein-AM accumulation assays. Due to 
the smaller sample size, it was not possible to carry out analysis for the P-gp' 
sample subsets.
It can be seen that in contrast to the AML MTT data, none of the statistical tests 
performed between the data sets yielded a significant difference, even though a 
clear trend in IC50 is demonstrated by the addition of Z.3HCL for the P-gp 
substrate DNR. This lack of significance may be explained by the relatively 
small number of patient samples analysed.
The results for CHL, which is not a P-gp substrate, are comparable with the 
ARA-C results for the AML patient samples, in that there is not only no 
significance, but no obvious trend in sensitisation by Z.3HCL. Surprisingly, FLU 
which is also known to be unaffected by P-gp efflux does show what appears to 
be consistent trend in sensitisation by Z.3HCL, but this trend does not near 
significance.
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Figure 4.13 CLL MTT data. Graphs A -  C show MTT results from different 
groups stratified according to P-gp and efflux status for the three drugs utilized, 
CHL, DNR and FLU.
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4.2.3 MM Patient Samples
Over the course of the study, 56 MM patient bone marrow samples were 
collected, prepared and analysed (see Appendix 3). Due to the technical 
difficulties of purifying plasma cells from BM, only 17 samples from 16 patients 
yielded useful results for both the calcein-AM functional assay and MRK16 
quantitative P-gp assay. There were 11 males and 5 females, with a median 
age of 72y (range 49 -  88y), and a median percentage of plasma cells in the BM 
of 17% (range 4 -  80%). There were 9 samples known to be presentation 
samples and 6 post treatment samples. No useful MTT data were acquired for 
MM patients.
4.2.3.1 MM MDR Assay Correlation
Figure 4.14 shows a correlation plot showing P-gp expression against MDR 
efflux function (MAF) for Z.3HCL (Figure 4.14A) and VPM (Figure 4.14B) as P- 
gp inhibitor allowing for a comparison between the two inhibitors in the in vitro 
MM environment.
It can be seen that for both the Z.3HCL and VPM calcein-AM assays the 
correlations with P-gp expression were very weak, with no statistical significance 
(P=0.2007 and 0.0939 respectively). The r2 values denoting goodness of fit are 
also extremely low (0.1067 for Z.3HCL and 0.2161 for VPM). Overall, the assay 
results from the MM cohort of patient samples appeared to be even more 
heterogeneous than for the AML and CLL samples. This, coupled with the 
relatively low sample number (n=17 for Z.3HCL, and n= 14 for VPM), may help 
explain the failure to find statistically meaningful correlation.
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Figure 4.14 P-gp expression and calcein accumulation correlation in MM.
These graphs show the correlation between P-gp expression measured by 
MRK16 MoAb and functional Calcein dye efflux inhibition, as measured by MAF. 
A P-value is shown to indicate significance.
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4.2.3.2 MM MDR Assays
Figure 4.15A illustrates the results of the calcein-AM functional assay, stratified 
by P-gp expression (assessed from the MRK16 assay). Also shown in Figure 
4.15A is a column representing all 17 MM calcein-AM results to illustrate the 
spread of the data. The numbers at the head of each column show the median 
value for those data, and this is also illustrated by the short horizontal bars 
bisecting each column.
From these data in Figure 4.15A it can be seen that the P-gp positive group (P- 
gp+) exhibits a higher median MAF than the P-gp negative group (P-gp-) (12.22 
and 5.250 respectively), and that this difference is statistically significant 
(P=0.0351).
Figure 4.15B illustrates the results of the MRK16 P-gp expression assay 
stratified by P-gp efflux function (MAF). The medians are shown both on the 
graphs as horizontal bars and are given numerically above each column.
It can be seen that in these data that although the efflux positive group (MAF+) 
has a higher median P-gp expression than the efflux negative group (MAF-) 
(1.18 and 1.045, respectively), this difference was not found to be statistically 
significant (P= 0.0665).
This finding is discordant with the results obtained from the AML and CLL 
studies; however, a caveat may be made regarding the relatively low sample 
size for this result and it may be reasonable to assume that, since this result
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nears significance, that if more data were to be accumulated the observed 
difference in medians would become significant.
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Figure 4.15 MM Calcein assay and P-gp expression assay data. Graph A 
shows the different levels of calcein accumulation as measured by MAF in 
relation to different categories of P-gp expression. Graph B shows the P-gp 
expression as measured by MRK16 in relation to the different categories of 
calcein accumulation as measured by MAF. The P number denotes the 
significance of a Mann-Whitney test between the P-gp+ and P-gp- groups in 
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Figure 4.16 shows the median P-gp expression and function data for patient 
samples grouped according to treatment status. Presentation samples (P) and 
samples from patients who had undergone chemotherapy (T) were compared 
statistically. It can be seen that there was no significant difference between the 
two groups for function (MAF) (9.830 v 8.065, P=0.2804) or for expression (P- 
gp) (1.020 v 1.135, P=0.2721).
Figure 4.17 illustrates P-gp expression and function correlated against the 
percentage of plasma cells (PC) in the patient BM samples. The results of the 
linear regression show quite clearly that there is no relationship between the 
number of PC’s and MAF (i^= 0.0045, P=0.8277) or P-gp (r^O.090, P=0.3201).
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4.2.4 Level of Calcein-AM Sensitivity
Figure 4.18 displays the results of the calcein-AM accumulation assays for AML, 
CLL and MM (Figure 4.18 A, B, and C respectively). The graphs show the 
median MAF results obtained from both modulators employed in the assay, 
Z.3HCL and VPM, allowing a comparison to be made of the relative assay 
sensitivity achieved. Paired Wilcoxon statistical tests were performed between 
the medians reveal that for CLL samples and MM samples the Z.3HCL 
modulated assays have a higher median than the VPM modulated assays, but 
that difference is not statistically significant (p= 0.1104 for CLL, and 0.0830 for 
MM). The results for the AML however show the converse, the VPM modulated 
assays have a higher median MAF than the Z.3HCL modulated assays, and that 
difference is statistically significant (p= 0.0001).
Z.3HCL appears to be a slightly more sensitive modulator for use in the calcein- 
AM accumulation assay for CLL and MM patient samples, but in the AML setting, 
VPM is a significantly more sensitive modulator.
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Figure 4.18 Differential sensitivity in calcein-AM assay due to modulator.
The results of the calcein-AM assay for each tumour type (A - AML; B - CLL; C -  
MM) showing the median MAF obtained from the two P-gp modulators utilised, 
Z.3HCL and VPM.
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4.2.5 Tests and Statistics
Not all AML, CLL, and MM MDR results were found to be normally distributed, so 
non-parametric Mann-Whitney or Wilcoxon paired tests were used, and since the 
expected outcome could be predicted (i.e., P-gp+ cells to have a higher MAF 
than P-gp' cells), 1-tail unpaired t-tests were performed where appropriate. 
Where t-test were employed, an F-test to test for unequal variances was also 
performed and where the variances between the two data groups were found to 
be significant, Welch’s Correction was implemented to compensate.
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4.3 Discussion
In AML, MDR induced by P-gp over-expression has been shown to be a major 
prognostic signifier of adverse outcome and treatment failure327'329. There is a 
real case for the targeted use of P-gp modulators in those patients for which P- 
gp over-expression has been identified, provided that the active compound is 
specific and has a low toxicity profile. Even when the inherent toxicity has an 
adverse effect overall, it has been shown that for those individuals with high P-gp 
expression, the benefits of modulation may well outweigh the risks267,282.
It is doubtful if P-gp expression plays any meaningful role in drug efflux in CLL, 
mainly due to the use of non-P-gp transported drugs such as chlorambucil and 
fludarabine in its treatment, and it remains to be seen if the non-efflux 
mechanisms attributed to P-gp could exert some influence330. The situation for 
MM is not clear and studies have not shown a clear cut prognostic significance, 
but since P-gp substrates such as daunorubicin and vincristine are utilised in the 
treatment of MM, there may yet be a case for P-gp modulation in the treatment 
of this disease200,284.
The data presented in this chapter show that Z.3HCL is a valuable component of 
two of the three in vitro assays employed to investigate P-gp mediated MDR in 
clinical samples. In order to use P-gp modulating compounds such as Z.3HCL 
as part of a targeted therapeutic regimen, a rapid and accurate assessment of 
the patient’s P-gp status needs to be implemented. Moreover, by combining P- 
gp expression with functional efflux data a more precise evaluation of the 
patients MDR risk can be made. Since both these tests are performed by flow 
cytometry, the evaluation can be done relatively rapidly.
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In the cohort of 48 AML patients there was evidence from the presentation and 
post-treatment samples to support the hypothesis that P-gp expression is higher 
following chemotherapeutic treatment, as this cytotoxic insult should trigger P-gp 
upregulation. P-gp was found to be significantly higher in the post-treatment 
group, and went from a median figure considered negative for P-gp over­
expression (1.04) to one considered positive (1.23). It must also be noted that 
because of the lack of an extra marker for efficient blast gating on the FACS 
(such as anti CD45), the data from post-treatment samples from patients in CR 
are likely to have included a high proportion of normal BM mononuclear cells. It 
is likely that the MDR profile of these BM cells may well have been divergent 
from these patients’ leukaemic blasts, and this represents a potential 
confounding factor when considering these particular results.
The functional calcein assay showed a similar increase in the post-treatment 
group, and although this was not shown to be statistically significant, here too 
the median MAF went from negative (9.45) to positive (12.62). This finding was 
not seen in the equivalent sample groups from CLL and MM patients, which, in 
the case of the CLL patients reinforces the idea that P-gp is not a significant 
factor in the generation of MDR in this disease. It is likely the very low number of 
MM samples eligible for analysis precludes the ability to draw meaningful 
conclusions about the existence of this phenomenon in MM.
Samples from patients with secondary or relapsed AML did not have any 
significant difference in P-gp levels to the presentation sample group. The 
caveat to these data is that the post treatment group was represented by a 
relatively small number of samples (n=9).
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Across the three disease types, there was no other influencing factor that 
significantly altered the expression or function of P-gp that could be measured by 
the calcein and MRK16 assays: lgVH, ZAP-70 and Binet status in CLL, or the 
percentage of plasma cells in MM. Other studies have stated a correlation 
between age and P-gp function that was not found to be of significance in this 
study. Although it can be seen from Figure 4.5A however, that in AML there is a 
trend for increasing P-gp expression and function as patient age increases, and 
that the failure to reach significant concordance with the observations of previous 
studies could possibly be due to factors such as the relatively lower patient 
numbers involved in this study198,199. A greater level of concordance can be seen 
when the MDR data is split into two age groups of <55 and ^55 years of age, as 
is demonstrated in Figure 4.5B. Here we can see that there is a significant 
increase in the median P-gp expression levels for the ^ 5  year age group. It 
was also observed that the relative proportions of P-gp positivity and function 
was increased in the ^55 year age group.
Another factor that must be considered as an inherent weakness in the design of 
the flow cytometry based AML assays is the omission of co-labelling with a blast- 
specifying fluorescent antibody, such as anti-CD45. Its use would have 
increased the confidence with which the tumour cells under examination could 
have been gated and other high P-gp expressing cells, such as NK cells, could 
have been excluded. However, it can also be argued that the use of anti-CD45 
in itself would not be stringent enough to exclude all potentially confounding cell 
types. The use of further markers would render the assay unnecessarily 
complex and could introduce technical errors, such as spectral overlap from 
improperly calibrated channel compensation. It may be worth considering that a
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basic 3-colour FACS is now insufficiently equipped for adequate analysis of 
MDR, and that any future work should make use of more advanced 4 or even 6- 
colour FACS analysers.
Another factor to consider when attempting to assess the impact of patient MDR 
status upon therapeutic response, is what proportion of those patients were 
actually treated chemotherapeutically with curative intent. Out of 55 samples, 
16.4% were post-treatment, but there were only 6 patients (5 de novo and 1 
relapsed) where both a treatment and post-treatment sample were received. 
Since only one of these patients was MDR negative this cohort can only give 
minimal information regarding the impact of P-gp expression and function on 
outcome.
Drug sensitivity data by use of the MTT assay is slower to produce results but it 
can be argued that it is potentially a more accurate indication of the MDR status 
of a patient’s cells since it is a direct measurement of both the level of drug 
efficacy with and without P-gp modulation. It can therefore be reasoned that a 
combination of these tests should be used to stratify patients into levels of MDR 
expression. Since some level of discordance between the tests can arise, most 
probably due to technical limitations, a scoring system based on the number of 
tests found positive may be employed to give an indication of that patient’s 
likelihood of treatment failure due to the effects of P-gp over-expression and the 
MDR effect.
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5. In Vitro Studies -  P-glycoprotein and Apoptosis
5.1 Introduction
P-gp has been implicated as an influencing factor of caspase-dependent 
apoptotic signalling, reducing the sensitivity of P-gp over expressing cells to 
certain forms of apoptotic stimuli. One of the ways in which P-gp may act on this 
pathway is by trafficking sphingomyelin to the outer leaflet of the plasma 
membrane, thus reducing the available cytoplasmic ceramide pool. It is 
suggested that ceramide, a degradation product of membrane sphingomyelin, 
can act as a second messenger for drug or radiation induced apoptotic 
initiation184. Other studies have shown that P-gp expression can inhibit caspase 
8 activation following death receptor ligation (e.g., FAS), and it is hypothesised 
that this may be caused by P-gp induced perturbations in the plasma membrane 
composition local to the action site.
On the cell surface, FAS is partitioned into sphingolipid and cholesterol rich 
membrane rafts. Upon ligation, FAS aggregates to form clusters in a ceramide- 
dependant manner. These FAS clusters then associate with an adapter 
molecule called FADD (Fas-associated death domain protein) and through 
recruitment of inactive caspase 8 forms the death inducing signal complex 
(DISC), which activates caspase 8 and initiates the apoptotic cascade. Since P- 
gp has not been shown to inhibit either the formation of DISC or recruitment of 
caspase 8 to the DISC apparatus, it is thought that it modulates the apoptotic 
signal through interfering with the autocatalysis of caspase 8, possibly through 
the disruption of the sphingolipid and cholesterol rafts187,331.
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Since several studies have suggested that P-gp modulation could reverse the 
anti-apoptotic effect, the inhibitory effect of P-gp on caspase-dependent 
apoptosis and the effect of Z.3HCL to ameliorate this phenomenon was 
investigated. Ionising radiation was primarily used to initiate apoptosis, having 
been shown by previous studies to be affected by P-gp over-expression108,332. 
The use of radiation, as opposed to a cytotoxic drug, obviated the need to 
compensate for MDR efflux.
Initially, the study looked at the cleavage of PARP (poly-(ADP ribose) 
polymerase (p116), a caspase 3 substrate) into the p85 fragment, a process 
considered to be a hallmark of apoptosis. This was attempted through the use of 
western blots to ascertain differential apoptotic signals between P-gp', P-gp+ and 
P-gp+ modulated cells. Cell death was measured using the MTT assay and 
morphologically from cytospins. Later in the study, the JC-1 mitochondrial 
membrane potential flow cytometry assay was employed to try and obtain 
greater sensitivity. Subsequently the Annexin-V flow cytometry assay was used 
because of its sensitivity and ease of use.
5.1.1 P116, P85 and other Apoptotic Protein Markers
Western blotting was used in an attempt to ascertain whether apoptotic 
responses were affected by P-gp expression and if these effects were modulated 
by Z.3HCL. Chapter 2.2.5 refers to the protocol and rationale.
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5.1.2 MTT Cell Viability Assay
An MTT cell viability assay was often used in conjunction with the one or more of 
the other assays in order to verify the results (see Chapter 2.1.2.3 for details).
5.1.3 JC-1 Assay
JC-1 was used to visualise early apoptotic changes to the mitochondrial 
membrane potential in response to various apoptotic stimuli and modulation with 
Z.3HCL (refer to Chapter 2.2.4 for protocol).
5.1.4 Annexin V Assay
The annexin V assay is flow cytometer based and allows the detection of very 
early apoptotic changes. In many cells, phosphatidylserine (PS) residues 
display an asymmetric plasma membrane distribution pattern in that they reside 
only on the inner envelope of the membrane (see Chapter 2.2.6). For the 
purpose of these experiments it was found that measuring the annexin V +, Pl- 
cells provided the most consistent data (Figure 5.1).
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AnV- / Pl+ AnV+ / Pl+
CEMv-R5ZHCL 48HR .006
Annexin V (AnV)
AnV- / PI- AnV+ / Ph
Figure 5.1 Annexin V and PI flow cytometry staining. Showing four quartiles 
of staining intensity in CEMv cells: live cells (AnV' / PI ); apoptotic cells (AnV+ / 
PI'); late stage apoptotic cells (AnV+ / Pl+); and necrotic cells (AnV' / Pl+)
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5.2 Results
5.2.1 Western Blot Data
Figure 5.2 illustrates a typical scan obtained from the densitometer reading of a 
western blot showing PARP cleavage in response to ionising radiation. The 
density of the bands observed is proportional to the level of expression of that 
protein, so relative expression profiles in relation to external stimuli can be 
recorded by taking ratios of the target proteins. In this example, the apoptotic 
marker protein PARP (p116) is shown with its caspase cleaved product p85. 
The higher the ratio of p85 to p116 the more apoptosis is deemed to have 
occurred in that cell population.
+Z
0 Gy 10 Gy 20 Gy
Ratio 0.03 0.62 0.64 0.10 0.53 0.55
Figure 5.2 Western blot data acquisition after 24hr in CEMv cells.
Developed film scanned on densitometer and level of expression determined by 
band intensity. Amount of apoptosis determined from ratio of the cleavage 
product p85 against p116. -Z= no Z.3HCL (control); +Z = cells incubated with 
100nM Z.3HCL. The housekeeper protein /?-actin was used to show any 
variance in loading volume.
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Figure 5.3 shows the differential apoptosis induced in cells isolated from CLL 
patients by exposure to y-radiation. The amount of apoptosis was indicated by 
the ratio of PARP cleavage by effector caspases (p85 / p116). The CLL cells 
were also tested for MDR markers and all were found to be P-gp+ (data not 
shown). The CLL cells were exposed to 0, 5, and 10Gy of y-radiation and then 
incubated at 37°C with and without 100nM Z.3HCL. Protein lysates were made 
at 6hr and 24hr. Paired t-tests on the results show that any differences between 
the -Z  and +Z.3HCL cells are not significant.
PBMCs isolated from normal donors were also used to see if any sensitisation to 
apoptosis could be seen by P-gp inhibition with Z.3HCL. Figure 5.4 shows the 
result of experiments conducted on normal PBMCs, all of which were found to be 
P-gp+. No statistically significant sensitisation was observed from the paired t- 
tests (Figure 5.4).
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Figure 5.3 Western blot apoptosis data for CLL cells treated with radiation.
P-gp+ CLL cells exposed to 5Gy and 10Gy of y-radiation and incubated with and 
without 100nM Z.3HCL for 6 and 24hrs. The results were normalised 
ratiometrically against the non-irradiated control. Paired t-test performed to 
determine significance of any sensitisation to apoptosis that may be caused by 
the P-gp inhibition.
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Figure 5.4 Western blot apoptosis data for normal PBMCs. PBMCs isolated 
from normal donors were exposed to 10Gy and 20Gy of y-radiation and 
incubated with and without 100nM Z.3HCL for 6 and 24hrs. Paired t-test 
performed to determine significance of any sensitisation to apoptosis that may 
be caused by the P-gp inhibition.
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PARP cleavage Western blot data from the P-gp over-expressing cell lines 
CEMv and VLB and their P-gp negative parent cell line, CEM, were analysed 
and the results displayed in Figure 5.5. Data was available at 20Gy and 40Gy 
radiation for the CEM and CEMv cells lines, and at 10Gy and 20Gy for the VLB 
cells.
It can be seen that neither of the P-gp over-expressing cells lines (CEMv and 
VLB) incubated in the presence of Z.3HCL were significantly sensitised to the 
apoptotic effects of radiation. There does appear to be a small trend towards 
higher PARP cleavage in the Z.3HCL group. However, this is also observed in 
the P-gp negative CEM cell line and must be concluded that it is an artefact of 
the experimental setup (Figure 5.5).
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Figure 5.5 W estern  blot apoptosis data fo r CEM, C EM v and VLB  cells  
treated  w ith radiation. Cells were exposed to 10, 20 or 40Gy of y-radiation and 
incubated with and without Z.3HCL for 24hrs. A= CEM, B= CEMv, C= VLB.
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5.2.2 Cell Viability Data
A series of experiments were conducted to show any differences in sensitivity to 
ionising radiation between the three cell lines employed. Since all three are 
CEM cells expressing different levels of P-gp, any differences displayed could 
theoretically be attributed to the level of P-gp expression. The relative P-gp 
expression profiles of the three cell lines are shown in Table 5.1.
P-gp (MRK16) Efflux (MAF)
CEM 0.91 0.00
CEMv 1.67 39.85
VLB 4.27 96.20
Table 5.1 P-gp expression and efflux profiles of the cell lines used.
Figure 5.6 shows a series of MTT assays illustrating the cell viability of the three 
cell lines after exposure to increasing levels of y-radiation and then incubated at 
37°C for 24 and 48hr. In accordance with the current model of P-gp expression 
bestowing a resistance to apoptotic initiation, the P-gp+ CEMv cells are more 
resistant to the effect of radiation than the P-gp' CEM parent cell line. These 
differences are shown to be statistically significant at 48hr and but not at 24hr. 
Unexpectedly, the very highly P-gp expressing VLB cells show a greater 
sensitivity to the apoptotic effects of radiation compared to both the CEM and 
CEMv cells. (Figure 5.6).
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Figure 5.6 MTT assay comparing cell line sensitivity to radiation. CEM, 
CEMv, and VLB cells were exposed to increasing levels of y-radiation and 
incubated for 24hrs and 48hrs. Paired non-parametric tests were performed to 
determine the significance of any differences in sensitivity between the cell lines. 
Non-linear regressions were also employed to illustrate the trend in decreasing 
cell viability.
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Figure 5.7 illustrates the results from MTT cell viability assays, conducted 
concomitantly with the annexin V assays in Figures 5 .12 -5 .14 . The data was 
normalised and expressed as a ratio indicating cell survival at 20Gy and 40Gy of 
radiation at 6hr and 24hr.
It can be seen that there is no sensitisation by Z.3HCL to the detrimental effects 
of irradiation indicated by either of the P-gp expressing cell lines, although as 
previously shown, there are differences in the levels of apoptotic sensitivity 
shown between the three cell types. At 24hr, the CEMv has a relative apoptosis 
ratio of approximately 0.6, whilst the CEM parent line has a ratio of around 0.4. 
The VLB cell line has the greatest reduction in cell viability, with a ratio of 
approximately 0.2, which is in keeping with the previous observations in Figure 
5.6.
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Figure 5.7 MTT Assay with irradiated CEM, CEMv and VLB cells. Cells
exposed to between OGy, 20Gy and 40Gy of radiation and incubated with and
without 100nM Z.3HCL for 6hr and 24hr. Paired statistical analysis was 
performed to establish any significance between groups
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5.2.3 JC-1 Assay Data
Figure 5.8 illustrates the flow cytometry acquisition strategy employed for the JC- 
1 assay from an experiment utilising normal PBMCs. The mitochondrial 
membrane potential de-coupler FCCP (carbonylcyanide p- 
trifluoromethoxyphenyl-hydrazone) was used as a control for the placing of 
acquisition gates and calibrating compensation settings. The main results are 
reported as the ratio of the red signal to green signal (R/G ratio), with a decrease 
in ratio signifying an increase in the amount of cells undergoing apoptosis.
)ORNW.-B1-JC1-6HR.OQ5 N0RM4.-R1 - JC1 -6HR.002N0RWL-R1-JC1-6HR 003
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Figure 5.8 JC-1 flow cytometry data acquisition. Figure illustrating basic 
principle of the JC-1 assay on normal PBMCs. Green cytoplasmic fluorescence 
on FL1 (x-axis); Red mitochondrial fluorescence on FL2 (y-axis) and the dot plot 
is quartered to determine the percentage of cells exhibiting each signal. The 
effect of radiation and the AvFm inhibitor FCCP is shown by the effect on the R/G 
signal ratio.
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Figure 5.9 shows the results of a JC-1 assay on y-irradiated normal CD56+ 
PBMCs, in an attempt to utilize the inherently high P-gp status of CD56+ NK cells 
as a means of investigating the effect of P-gp expression on apoptosis. Prior 
MDR analysis confirmed that the cells isolated from the normal donors were P- 
gp+ (median MRK16= 1.19, range 1.16 -  1.24; median MAF= 15.88, range 13.43 
_ 16.44). The cells were exposed to 10Gy and 20Gy of y-radiation and then 
incubated with and without 10OnM of Z.3HCL for 6hr and 24hr.
The R/G ratios revealed that the T'Am indicating early apoptotic events, dropped 
in response to the y-radiation at both the 6hr and 24hr time points and that the 
drop was more strongly observed in the cells treated with the higher amount of 
radiation. Paired one-tailed t-test showed that the presence or absence of 
Z.3HCL did not significantly sensitise the cells to the apoptotic initiating effects of 
the ionising radiation at either 6hr or 24hr. It can be seen that at 6hr there was a 
small apparent sensitisation by Z.3HCL, but not statistically significant, and at 
24hr this effect had been lost (Figure 5.9).
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Figure 5.9 JC-1 Assay with irradiated NK cells. CD56+ gated PBMCs isolated 
from normal donors were exposed to 10Gy and 20Gy of radiation and incubated 
with and without 100nM Z.3HCL for 6hr and 24hr. Paired t-tests were also 
performed to establish any significant apoptotic sensitisation.
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Figure 5.10 illustrates the JC-1 assay results from the P-gp+ CEMv cell line, 
exposed to 0, 5 and 10Gy of y-radiation and incubated with or without 100nM 
Z.3HCL for6hr and 24hr.
At 6hr the R/G ratios show that the A'Fm decreased slightly in response to y- 
radiation when compared to the un-irradiated control cells. However, by 24hr the 
ratios had increased, suggesting that the A'Pm had become stronger 
(hyperpolarisation). It may be hypothesised that this increase may reflect an 
increase in the energetic state of damaged cells having initiated repair 
mechanisms.
Paired, one-tailed statistical tests performed between the Z.3HCL and non- 
Z.3HCL cohorts revealed no statistical differences in apoptotic response (Figure 
5.10).
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Figure 5.10 JC-1 Assay with irradiated CEMv cells. CEMv cells were 
exposed to 5Gy and 10Gy of radiation and incubated with and without 100nM 
Z.3HCL for 6hr and 24hr. Paired t-tests were also performed to establish any 
significant apoptotic sensitisation.
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Figure 5.11 shows the JC-1 assay results from cells isolated from CLL patients 
that had been irradiated and incubated with and without 100nM Z.3HCL for 6hr 
and 24hr. Prior MDR analysis revealed that the CLL cells were all P-gp+. The 
levels of y-irradiation used were 5Gy and 10Gy.
The results, contrary to expectation, showed an overall increase in A'Frn, 
especially in the Z.3HCL negative cohort at 6hr. By 24hr, the AT'm had returned 
to basal levels. The t-test showed no significant difference to sensitivity made by 
the addition of Z.3HCL (Figure 5.11).
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Figure 5.11 JC-1 Assay with irradiated CLL cells. CLL cells isolated from 
patients were exposed to 5Gy and 10Gy of radiation and incubated with and 
without 100nM Z.3HCL for 6hr and 24hr. Paired t-tests were performed to 
establish any significant apoptotic sensitisation.
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5.2.4 Annexin V Assay Data
Figure 5.12 illustrates the results of an annexin V assay performed using PBMCs 
isolated from normal donors. The intensity of the annexin V signal, measured 
flow-cytometrically, is proportional to the number of cells having undergone 
apoptotic initiation. The cells were irradiated with 0, 10 and 20Gy and then 
incubated with and without 100nM Z.3HCL for 6h and 24hr. The purpose of the 
assay was to look for Z.3HCL mediated sensitisation to radiation induced 
apoptosis. The donor cells were also MDR profiled and all expressed P-gp 
(median MRK16 ratio 1.19, range 1.16-1.24).
The results show a progressive increase in annexin V positivity, indicating an 
increase in cells undergoing apoptosis in response to the increasing dose of 
radiation, but do not indicate any greater sensitivity to apoptosis in the +Z.3HCL 
group compared to the control group -Z.3HCL (Figure 5.12).
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Figure 5.12 Annexin V Assay with irradiated PBMCs. PBMCs isolated from 
normal donors exposed to 10Gy and 20Gy of radiation and incubated with and 
without 100nM Z.3HCL for 6hr and 24hr. Paired t-tests were performed to 
establish any significant apoptotic sensitisation.
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Figures 5.13, 5.14 and 5.15 show the annexin V assay results in CEM, CEMv 
and VLB cells, respectively, irradiated at 20Gy and 40Gy (plus a non-irradiated 
control) and incubated for 6 and 24hr in the presence and absence of 100nM 
Z.3HCL. The data represent three separate experiments for each cell type, and 
each experiment consisting of three replicates.
In Figure 5.13, it can be seen that for the P-gp negative CEM cells there is no 
sensitisation to apoptosis by addition of Z.3HCL at either 20Gy or 40y at both 
time points.
Figure 5.14 shows the results for the CEMv cells, which express an intermediate 
level of P-gp. It can be seen that at 6hr there is no sensitisation of the cells by 
blockading P-gp with Z.3HCL at 20Gy or 40Gy. However, at 24hr there does 
appear to be a slight increase in apoptosis for the cells grown in the presence of 
Z.3HCL, which is pronounced at the higher radiation level, although this 
apparent sensitisation is not statistically significant.
In Figure 5.15, the data from the highly P-gp over-expressing VLB cells shows 
an apparent sensitisation in the Z.3HCL group at 6hr for both radiation points, 
but this difference is not statistically significant. At 24hr, the levels of 
sensitisation appear more pronounced at both radiation levels than at 6hr, and 
this difference reaches statistical significance at the 40Gy point (P=0.0367), 
indicating that the P-gp modulatory effect of Z.3HCL had sensitised the VLB cells 
to apoptosis.
193
Annexin V Assay - CEM 6hr
3(H
"O<D
(A
CO
1 20H
o
CO
■{/>
O 10- 
Q.oa<
P= 0.4968
n=3
P= 0.5801
X -Z.3HCL
+Z.3HCL
0 20.0
y-lrradiation (Gy)
40.0
Annexin V Assay - CEM 24hr
15-
§ 10-
o
z
CO
'cooO 5 - 
Q.O a  <
P= 0.8342 
P= 0.1258 T  T
I— I I L
□  -Z.3HCL 
IZZI+Z.3HCL
0 20.0 40.0
n=3 y-lrradiation (Gy)
Figure 5.13 Annexin V Assay with irradiated CEM cells. CEM cells exposed 
to OGy, 20Gy and 40Gy of radiation and incubated with and without 100nM 
Z.3HCL for 6hr and 24hr. The results were normalised ratiometrically against 
the non-irradiated control. Paired statistical analysis was performed to establish 
any significant apoptotic sensitisation.
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Figure 5.14 Annexin V Assay with irradiated CEMv cells. CEMv cells 
exposed to OGy, 20Gy and 40Gy of radiation and incubated with and without 
100nM Z.3HCL for 6hr and 24hr. Paired statistical analysis was performed to 
establish any significant apoptotic sensitisation.
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Figure 5.15 Annexin V Assay with irradiated VLB cells. VLB cells exposed to 
OGy, 20Gy and 40Gy of radiation and incubated with and without 100nM Z.3HCL 
for 6hr and 24hr. Paired statistical analysis was performed to establish any 
significant apoptotic sensitisation.
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5.3 Discussion
The data presented in this chapter show the studies to recognise the anti- 
apoptotic effect of P-gp over-expression, which has been previously reported, 
and to ascertain whether P-gp inhibition with Z.3HCL would ameliorate this 
effect. Several different cell types and assays were employed with varying 
degrees of success. Ultimately the annexin V data from the CEM, CEMv, and 
VLB cell lines suggest that there may be some protective effect conferred by the 
over-expression of P-gp, at least in the very highly over expressing VLB cells. 
This was shown by the ability of Z.3HCL to induce significant sensitisation in the 
VLB cells, indicating that P-gp was in some way responsible for increasing the 
VLB cells apoptotic threshold, and that inhibiting P-gp ameliorated this effect.
Although a trend in sensitisation was observed in the intermediately over­
expressing P-gp CEMv cell line, even using the extra power available with the 
use of paired statistical analysis, this trend only approached significance for the 
higher radiation dose at 24hr. This sensitisation was not seen in the concomitant 
MTT cell viability assays for either CEMv or VLB cells, suggesting that the 
apoptotic protection provided by P-gp expression is relatively weak and its effect 
is below the detectable resolution of this assay.
For most of the experiments conducted in this chapter, ionising radiation was 
used as an inducer of apoptosis, which had its advantages and disadvantages 
when compared to the use of cytotoxic drugs. One significant advantage was 
the guarantee of null drug efflux effects causing a bias when using P-gp 
expressing cells. A disadvantage was that although y-radiation causes 
apoptosis, it also causes senescence, meaning that even though P-gp may
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protect against apoptosis the employed indicators of this, especially the cell 
viability assay, may miss it because of other forms of cell cycle arrest that 
radiation induces.332
The MTT cell viability assays conducted on the three CEM cell lines (CEM, 
CEMv, VLB) showed, contrary to initial expectation, that the P-gp over­
expressing VLB cell line was more sensitive to radiation than the P-gp negative 
parent CEM line. Earlier studies by Matarrese et al also shows that the VLB 
sub-line was more sensitive to some apoptotic stimuli, specifically TNF-a, than 
the parent CEM cell line333.
It may be hypothesised that the very high levels of P-gp expression by the VLB 
cells could in some way undermine the viability of these cells. It could be either 
through plasma membrane perturbations caused by the density of P-gp protein, 
or the metabolic cost of producing such a high level of one protein leads to a 
deficiency in other mechanism of cell fitness. This explanation would be 
concordant with the fact that radiation can also kill cells via non-apoptotic 
catastrophic cell death mechanisms, and that any disruption to the cell 
membrane could feasibly strengthen this effect332.
The Matarrese study, however, noted that there was a correlation between high
levels of P-gp expression and increased mitochondrial transport chain activity,
presumably due to the basal ATPase activity of P-gp and the high energy
requirements that would entail in a cell line such as VLB. In addition, it was also
found that the increase in mitochondrial activity was also accompanied by
perturbations in the lipid and protein composition of the mitochondrial
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membrane334. It has already been show that a reduced mitochondrial electron 
transport chain activity in leukaemic cells was associated with an apoptotic 
protective effect. It was therefore hypothesised that the converse may also be 
true, and was indeed demonstrated by the experimental use of compounds 
known to suppress electron transport chain activity333. This suggests that the 
reason for the increased sensitivity to radiation observed in the VLB may be due 
to the increased energy demands of the high P-gp phenotype, and the 
concomitant changes to the mitochondria membrane. This in turn may be 
associated with an increased sensitivity to the initiation of apoptosis via the 
release of cytochrome c from the mitochondrial membrane, in response to 
certain apoptotic stimuli, such as ionising radiation335'338.
In contrast, the CEMv cell line, which over expresses P-gp to an intermediate 
level compared to CEM and VLB cells was found to be significantly more 
resistant to the effects of y-radiation than the parent cell line CEM. Incubating 
the CEMv cells with Z.3HCL caused the cells to become more sensitive to 
radiation, suggesting that the protective effect was conferred by the expression 
of P-gp.
Western blots were used initially to probe for PARP cleavage, a well established 
method of observing apoptosis339,340. This technique is very time and labour 
intensive and we were keen to employ flow-cytometric technology, not least 
because of the rapidity of data acquisition. Ultimately, the western blot data did 
not show any evidence of apoptotic sensitisation by Z.3HCL for the CEM, CEMv 
or VLB cells.
199
The JC-1 assay was employed in an attempt to look for mitochondrial changes 
that might signify apoptotic initiation341. JC-1 has previously been investigated 
as a fluorescent probe for use in MDR profiling assays in AML cells because it is 
an avid substrate for P-gp efflux315,316. In our experience, although JC-1 proved 
itself to be extremely sensitive as an indicator of P-gp expression, the technical 
difficulties introduced by having to calibrate the flow cytometer compensation for 
a biphasic fluorophore meant that it was unsuitable for routine use, especially 
since the relatively simple and reliable calcein-AM assay was already 
established. These technical difficulties, especially that intracellular 
concentrations of JC-1 are so drastically affected by P-gp efflux, also hindered 
the studies into the role of P-gp expression in apoptosis. Until a reliable means 
of calibrating the compensation setting are established its use in this area may 
be marginalised. Repeated experiments showed that the mitochondrial 
membrane inhibitor FCCP was the most consistent means of establishing a 
baseline reading for the assay.
In the JC-1 assay, normal CD56+ cells were utilised because of their high P-gp 
status. The functional requirement of P-gp expression on haematological cells is 
uncertain and may be directly linked to a dampening effect of the apoptotic 
response as a way of protecting against bystander killing in areas of cell- 
mediated immune response. P-gp may serve to protect immune cells against 
stress-induced apoptosis or bystander lysis mediated by either the Fas or TNF 
death pathways in the hostile site of inflammation. In addition, it has been 
suggested that P-gp could play a role in the growth and/or survival of primitive 
haemopoietic stem cells180. However, this assay did not show any significant
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difference in sensitivity for NK cells incubated in the presence or absence of 
Z.3HCL.
Data from the annexin V assays (Figures 5.12 -  5.14), in conjunction with 1- 
tailed, paired analysis, at best suggested that there was a small Z.3HCL induced 
sensitisation to apoptosis in irradiated CEMv cells (approaching significance, 
P=0.0633) and VLB cells (significant, P=0.0367) which was not apparent on the 
CEM cells. This trend was not observed in the normal PBMCs, which were P- 
gp+, nor in concomitant MTT assays.
The annexin V assay was employed after the technical difficulties experienced 
with the JC-1 assay since neither the FITC-annexin V conjugate nor the PI were 
affected by P-gp expression. In addition, because the two fluorescent signals 
were generated from two different agents, the compensation procedure was 
much simplified. The annexin V assay proved itself to be extremely sensitive 
and in this study was deemed to provide the most consistent data.
In summary, the data from the CEM, CEMv and VLB cell lines suggest that P-gp 
expression has a significant (VLB) or nearing-significant (CEMv) protective effect 
upon the initiation of apoptosis, when compared to the basal level for that cell 
line, and that this effect can be ameliorated by use of the P-gp modulating agent 
Z.3HCL. This effect was not observed in the CLL cells and normal PBMCs, both 
of which over-expressed P-gp, albeit at a considerably lower level than CEMv 
and VLB.
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6. Final Discussion
6.1 Discussion
It has been shown by many studies that the over-expression of P-gp in cancer is 
an indicator of poor prognosis and chemotherapeutic treatment failure, and this 
is particularly so for the haematological tumours such as AML, ALL, MM and 
CML329,342,343. Different studies have apportioned varying levels of importance to 
what P-gp expression means to prognosis and the impact on the achievement of 
complete remission, relapse rates, and overall survival309,344.
The use of chemical adjuvants to standard chemotherapy in an attempt to 
overcome the resistance effects of P-gp have so far shown mixed results, with 
little or no obvious benefit overall, except for possibly those patients who do 
indeed over-express P-gp. These early trials have been typically conducted on 
difficult patient groups such as the elderly, relapsed and refractory, all categories 
associated with P-gp over-expression. Additionally, only first and second 
generation inhibitors whose toxicity and specificity profiles fall somewhat short of 
those exhibited by the current range of third generation compounds345,346 have 
been used.
It can be seen that the relationship between P-gp expression and MDR function
is not always a direct one. The flow cytometry data presented in chapters 3 and
4 indicate that even the measured expression of P-gp does not necessarily
indicate measurable efflux function. Neither does efflux function guarantee
measurable P-gp expression, although there is an overall correlation. The
classical model of simple P-gp upregulation in response to chemotoxic insult falls
somewhat short of the mark and must be reconsidered in light of the highly
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convoluted means of P-gp induction, activation and suppression at the nuclear, 
cytoplasmic and lipid level159,347,348. This model is further complicated in light of 
the fact that both normal and leukaemic stem cells are characterised by their 
high level of inherent MDR status349,350.
The fluorescent dye efflux data in chapters 3 and 4 show Z.3HCL to be a potent 
P-gp inhibitor in patients with AML, and other haematological malignancies. 
R123 efflux from CD56+ cells was rapidly inhibited in all of the patients studied, 
often within an hour from the start of infusion. This trend was also observed for 
the CD33+ cells in the AML clinical trial. However, CD33+ cells tend to express 
significantly less P-gp than CD56+ cells and the inhibitory effect was therefore 
less pronounced.
As the previous clinical trials of P-gp inhibitors suggest, specific targeting of only 
the P-gp over-expressing patients may be the most efficacious strategy to 
adopt264,267. In vitro assessment of the patient’s MDR status prior to treatment 
would be therefore necessary, and the assays incorporating calcein-AM and 
Z.3HCL, as shown by the data presented herein, have proved to be rapid, non- 
costly and reliable.
It is possible, by using both efflux function and expression to score semi- 
quantitatively a patient’s cells for P-gp expression based on whether they are 
double positive or negative for both measures or positive for one or the other. 
This approach can then also be augmented by considering the drug sensitivity 
profile obtainable from MTT assays. This approach, as detailed in chapter 4, 
was seen to be more successfully concordant for the AML cells than CLL cells
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and MM cells. This may be because P-gp, although often expressed on CLL 
cells, has not been shown to be a major mechanism for drug efflux resistance351, 
where in AML it has been consistently shown to be a significant factor183,352. The 
technical difficulties experienced in obtaining sufficient numbers of MM plasma 
cells ultimately curtailed the scope of the experiments that could be conducted, 
thus reducing the analytical power available.
The safety profile data, from mainly the AML trial but also contributed to by the 
two solid tumour trials, do suggest that Z.3HCL can be used along side 
conventional chemotherapy with acceptable risk. Indeed, there is evidently 
some scope for adjusting the administration regimen to minimise onset of these 
deleterious toxicities. Overall, Z.3HCL has two main advantages over previous 
modulators in that it has very little effect on the clearance of the coadministered 
drugs and their metabolites, such as daunorubicin and daunorubicinol. Also it 
does not affect the cytochome P450 isoenzymes such as CYP3A at 
administered doses, which would potentially lead to increasing the toxicity profile 
of the drug regimen318'353. However, it may also be argued that because it has 
been shown that ABC transporters can be co-expressed, and may even act in 
concert, that a new generation of inhibitor, with an inherently better safety profile, 
may have an advantage over a single specificity compound such as Z.3HCL354.
The role of P-gp in apparently protecting cells from apoptosis is still very much 
an area of ongoing research. Although several proof of principle studies have 
shown that there is an effect, including some of the data presented in Chapter 5, 
its exact mechanism of action is yet to be elucidated along with whether this 
effect is of any clinical relevance, especially since the majority of the previous
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research has been conducted on cell lines109,180,182,355’356. Pallis et al have 
shown that P-gp expression on AML blasts has a protective effect against 
spontaneous apoptosis in culture and that studies with cell lines have linked this 
to P-gp involvement with sphingomyelin and ceramide trafficking184,357.
The annexin V results from Chapter 5 suggest that Z.3HCL can be used for both 
the detection and modulation of the apoptotic effect. However, since the effect 
appears to be small, especially when compared to the drug efflux function, 
technical difficulties associated with the assays involved may conceal the effect. 
The moderate P-gp expression of the CEMv cell line did seem to offer a degree 
of apoptotic protection when compared to the CEM cells, and Z.3HCL did appear 
to be able to lessen this effect, although not to a statistically significant degree. 
Paradoxically, the very high level of P-gp expression of the VLB cells was 
associated with an increased sensitivity to ionizing radiation compared to the 
CEM, and that Z.3HCL was still associated with a further increase in apoptosis. 
Studies by Mataresse et al suggest that this effect may be linked to the high- 
energy cost of P-gp and a subsequent vulnerability to cytochrome c release 
associated with the high level of electron transport chain activity in VLB cells333.
Any future work pertaining to P-gp modulation in cancer, and in AML in 
particular, must address the concept of the leukaemic hierarchy and the 
importance of the leukaemic stem cell (LSC). In the normal haematopoietic 
system there are thought to be three distinct populations of progenitor cell: stem 
cells that have the capacity for long-term renewal; stem cells with the ability for 
short-term renewal; and multipotent progenitors, which do not have the capacity 
to renew, but can differentiate into the various cell lineages seen in the bone
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marrow349. Ultimately, a small number of haematopoietic stem cells (HSCs) 
retain a capability for self-renewal, which is only conferred to a tightly regulated 
subset of daughter progeny, whilst other products of HSC cell division 
differentiate and progress to populate the subsequent levels of the 
haematopoietic hierarchy.
It has become clear that this hierarchical architecture is paralleled in AML, and 
that the rapidly proliferating bulk cells that constitute the pathological 
manifestation of the disease arise as a consequence of the existence of a small 
number of relatively quiescent LSCs358. AML LSCs were found to exist within 
the CD34+CD38' population of malignant cells, demonstrated by leukaemia 
initiating engraftment experiments in NOD/SCID mice. These showed that only 
cells from within this compartment retained the self-renewing potential necessary 
for leukaemic engraftment294,359. These leukaemia initiating stem cells 
represents between 0.1-1.0% of the AML cell population360.
A further consideration, from the point of view of drug resistance, is that this 
population of CD34+CD38' cells, within which the HSCs and LSCs reside, is 
associated with an abundant expression of MDR associated ABC transporters, 
particularly P-gp and BCRP. These cells have previously been identified as the 
so-called side population because of their ability to extrude the fluorescent dye 
Hoechst 33342, a property exploited cytometrically to enable cell sorting 
enrichment of stem cells361,362.
The issue for the current strategy of chemotherapy and adjuvant based MDR 
modulation is that because the LSCs are both quiescent and are inherently
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multidrug resistant, agents that exert their chemotherapeutic effect by targeting 
rapidly proliferating cells are ultimately only dealing with the symptoms and not 
the cause of the malignancy. The LSC can survive chemotherapy as minimal 
residual disease and carry on to seed a new generation of malignant disease, 
which ultimately manifests as clinical relapse360,363. Future therapeutic strategies 
seeking to address this will not only have to target specifically the LSCs, but also 
to avoid undue damage to normal HSCs, since they share many phenotypical 
characteristics293.
One agent that has shown promise in this area is the sesquiterpene lactone 
parthenolide. Derived from the plant feverfew it is a potent inhibitor of NF-kB, 
which is constitutively activated in LSCs but not in HSCs. It is not a known P-gp 
substrate, and it has been shown to preferentially induce apoptosis in LSCs in 
AML, CLL and CML, whilst leaving normal HSCs intact364,365. Other, future 
compounds directed against the LSC may well also be P-gp substrates, in which 
case there will still be a role for MDR inhibitors as adjuvants to chemotherapy.
6.2 Further Work
1) Further refinement of the in vitro assays, especially the incorporation of a 
blast marker such as anti-CD45RA, to enable a more accurate assessment of 
patient tumour P-gp status. Recently, the French Drug Resistance Network 
refined and improved their standard method for P-gp detection in haematological 
malignancies. Their revised methodology claims an increased sensitivity and 
specificity for both antibody detection and functional analysis, and these 
revisions have been validated by the various laboratories that participated within
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the network366. In light of this, it could be suggested that any further investigation 
into this field, in the interest of compatibility of data, should consider the adoption 
of this methodology. However, the calcein-AM based assay employed 
throughout the bulk of this study has proved itself to have many advantages in 
terms of cost, speed, sensitivity and easy of use. It could almost certainly be 
used, in conjunction with extra cell population defining modifies such as anti- 
CD45 and propidium iodide.
2) Clinically, the administration regimen of Z.3HCL should be optimised to 
minimise the toxicity experienced without affecting its efficacy as a P-gp inhibitor. 
In light of the outcomes of the previous phase III clinical trials, a targeted 
approach should probably be adopted for the inclusion of a P-gp inhibitor, since 
data from several of the trials suggest that only patients who show an upfront 
overexpression of P-gp will gain benefit264,267. A rapid and reliable MDR status 
screening protocol would therefore be necessary for the pre-treatment 
assessment of patient samples.
3) To further elucidate the mechanism underlying the role of P-gp in protecting 
against apoptotic stimulus, and to ascertain whether this effect by itself, or in 
combination with the drug efflux function is of any clinical relevance. The 
creation of an inducible transfection cell line model would be useful for 
measuring the changes in apoptotic sensitivity at differing levels of P-gp 
expression, and measuring the cut off point, as implied by the CEMv and VLB 
cells, whereby P-gp expression ceases to exert a net protective effect and acts 
as a sensitizer to certain apoptotic stimuli. To establish the likelihood of any
208
clinical relevance, primary AML cells would have to be used in short-term culture 
in sufficient numbers to establish whether there is any statistically significant 
difference in apoptotic sensitivity between P-gp overexpressing and P-gp 
negative blast cells.
6.3 Conclusions
Z.3HCL has proved to be both potent and specific as an inhibitor of P-gp, both in 
vivo in the clinical setting, and in vitro at the bench level. It has a relatively low 
toxicity profile and has been shown to be safe to use as an adjuvant with several 
standard chemotherapy regimens. It is able to inhibit potently both the classical 
drug efflux function and possibly the proposed apoptotic suppression function of 
P-gp without itself being a substrate for efflux. These attributes recommend 
further study into its use as a targeted therapy for P-gp engendered MDR in 
haematological malignancies.
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Appendix
1. AML Patient Data
Patient Sex Age FAB P/R/T P/B %Blast (BM) WBC|MAFz MAFv |MRK16 Cyto Rx Response
1 F 59 n/a n/a BM n/a n/a 4.40 7.78 0.98 n/a n/a n/a
2 M 82 n/a n/a PB n/a 20.2 62.48 70.57 1.88 n/a n/a n/a
3 F 35 n/a P PB 98 63 6.94 525 0.93 t(11q;23) H-DAT CR
4 M 63 MDS n/a PB n/a 5.6 11.04 20.15 0.98 n/a n/a n/a
5 M 76 n/a n/a BM n/a 4.4 7.76 17.97 1.26 n/a n/a n/a
6 M 76 n/a n/a PB n/a 103.8 525 19.42 1.11 n/a n/a n/a
7 M 76 n/a n/a BM n/a 64.4 1.00 9.40 0.88 n/a n/a n/a
8 M 69 n/a n/a BM n/a 128.8 14.45 12.54 1.64 n/a n/a n/a
9 M 39 rAML T BM 31 10.8 -8.43 12.62 1.00 Failed FU G CR
10 F 44 M5a P PB 80 16.9 13.40 15.70 0.86 Complex DA/AraC/ZHCL CR
11 M 76 M5b P PB 84 242 9.42 0.00 0.91 n/a n/a n/a
12 M 31 M5 P PB 86 6.05 14.18 525 0.88 Norm DA/AraC/ZHCL CR
13 M 36 M4 P PB 98 45.4 37.90 39.60 1.36 trisomy22/inv16 DA/AraC/ZHCL CR
14 M 53 M4 R PB 36 14.6 3.53 -4.60 0.80 trisomy21 DA/AraC/ZHCL PD
15 M 62 n/a n/a PB n/a 48.7 1.78 2.66 1.02 n/a n/a n/a
16 M 81 M2 P PB 79 20.5 -3.64 26.99 1.04 n/a FU G  x2 CR
17 F 72 M0 n/a PB n/a 47 45.75 52.17 2.59 n/a n/a n/a
18 M 24 M6 P PB 45 3.5 3.53 12.62 1.08 Norm DA/AraC/ZHCL CR
19 M 54 M2 R BM 86 2.6 -1.82 1023 0.94 t(6;9) DA/AraC/ZHCL CR
20 M 56 M1 P BM 92 7.1 57.45 27.00 1.14 Norm DA/AraC/ZHCL CR
21 F 65 M7 T PB 15 56 12.62 37.36 1.02 20q HU NR
22 M 47 M5a P PB 65 5 4.40 18.69 1.07 Norm DA/AraC/ZHCL CR
23 F 53 M3 P BM 43 8.9 -6.50 1023 1.10 t(15;17) H-DAT n/a
25 M 25 M4 P
BM
BM 90 24 14.18 20.85 0.99 Abnormal
DA/AraC/ZHCL
S-DAT
CR
CR
26 M 69 M1 P PB 80 2.6 0.89 22.26 0.83 Failed DA/AraC/ZHCL n/a
27 M 52 M2 P BM 45 5.2 28.95 35.64 1.35 mono 7 DA/AraC/ZHCL PD
28 F 71 M2 P BM 50 1.8 525 18.69 1.12 trisomyl 1 /del X DA/AraC/ZHCL CR
29 M 63 M4 P PB n/a 26.8 8.60 1023 0.84 Abnormal DA/AraC NR
30 F 82 M4 T PB 50 75.09 1.78 15.71 0.90 11 q HU/Etop n/a
31 M 65 M2 P BM 82 5.3 3.53 9.42 0.75 Abnormal DA/AraC n/a
32 F 24 M5 P PB 73 0.7 10.23 11.05 1.22 Failed ADE NR
33 F 46 M4 P PB 50 9.8 47.83 48.42 0.92 Norm S-DAT CR
34 M 53 MDS R BM 45 1.1 19.41 11.20 1.05 Norm FU G NR
35 F 40 M4 P BM 56 8.8 -2.86 5.14 0.89 Norm DA/AraC CR
36 M 46 M1 R BM 86 206.4 -11.60 127 0.91 n/a FU G CR
37 M 56 M4 P BM 51 1.23 -5.19 21.81 0.96 n/a FU G NR
38 M 61 M1 P BM 91 87.8 10.56 21.76 1.06 Norm DA/AraC/Flag CR
39 M 44 M1 P BM 87 10.5 -2 12.43 0.97 Norm FU G CR
40 M 66 M1 P BM 95 98 9.45 10.46 0.93 Norm DA/AraC CR
41 M 11 M5 R BM 97 5.1 3.44 2.48 1.06 n/a FUG NR
42 M 76 M1 P PB 98 112.4 18.21 28.13 1.27 Norm DA/AraC NR
43 M 63 M2 P BM 55 n/a 27.00 30.80 1.09 Norm DA/AraC CR
43 64 M2 T BM 10 9.4 1.78 -15.48 0.78
44 F 36 M2 P BM 20 7.9 -6.50 16.46 0.91 trisomy 8 DA/AraC/ZHCL CR
44 M2 T BM 30 1.7 2.66 14.95 1.24
45 M 59 M1 P BM 100 25 51.30 58.58 1.70 Trisomy 21 DAT/FLAG CR
45 M1 T PB n/a n/a 57.83 44.77 2.33
46 M 63 M4 R BM 86 6.6 14.18 35.06 1.60 Norm DA/AraC/ZHCL PD
46 64 M4 T PB n/a 64 27.01 36.79 2.17
47 M 68 M1 P BM 84 1 43.26 4326 1.50 Norm DA/AraC/ZHCL CR
47 M1 R BM 55 2.4 13.01 20.50 1.22
48 F 77 M2 P PB 56 13.5 36.79 27.66 1.05 n/a HU n/a
48 M2 T PB n/a 17.2 19.79 27.32 1.24
48 M2 T PB n/a 15.9 30.57 33.92 1.23
Key: n/a = data not available; P = presentation; T = Treated; R = Relapsed; CR = 
Complete Response; NR = No Response; PD = Progressive Disease; DA = 
Daunorubicin. The coloured entries denote a positive MDR result.
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2. CLL Patient Data
Patient Sex Age Stage P/T/R WBC|MAF MAFv MRK16 | ZAP70 IgVh Diag Rx
1 M 70 B T 48.0 15.71 14.18 1.03 0.59 N-ID 1994 Chi x12; GR
2 M 61 A T 165.0 17.21 8.6 0.99 0.66 UM 1990 Chi; GR
3 M 73 A UnRx 37.0 19.05 -4.7 3.17 0.67 UM 1988 UnRx
4 M 79 A UnRx 35.8 18.6 22.26 6.1 0.65 N-ID 1992 UnRx
5 M 67 B UnRx 34.0 21.56 15.71 2.74 n/a n/a 1996 UnRx
6 F 71 B T 24.0 11.83 28.31 2.74 n/a n/a 1996 Chi
7 M 80 A UnRx 17.0 15.71 12.62 3.25 0.51 M 1999 UnRx
8 M 68 B T 20.0 26.35 19.42 1.01 n/a n/a n/a Chl;Flu;GR;CFM
9 M 74 B UnRx 70.0 17.4 10.06 2.04 0.57 M 1997 UnRx
10 M 57 A UnRx 100.0 37.36 35.06 2.39 0.52 M 1993 UnRx
11 M 80 n/a n/a 80.0 19.41 5.25 2.59 n/a n/a 2001 n/a
12 F 81 A UnRx 23.6 20.85 26.35 1.62 n/a n/a 2001 UnRx
13 M 63 C T 128.6 9.42 -1.8 1.3 n/a n/a n/a Chi
14 M 71 B UnRx 39.0 34.48 25.01 5.78 0.56 M 1990 UnRx
15 M 55 B T 70.0 -3.66 9.42 1.5 0.54 M 1994 Chi
16 M 68 A UnRx 32.8 14.95 18.69 2.87 0.64 M 1992 UnRx
17 M 64 A UnRx 70.0 18.69 22.26 1.23 n/a n/a 2001 UnRx
18 M 59 B UnRx 70.0 12.62 20.14 0.93 0.64 UM 1997 UnRx
19 F 68 A UnRx 30.0 0 0 0.65 0.53 M 1999 UnRx
20 M 69 A UnRx 7.0 0 4.4 1.69 n/a UM 2001 UnRx
21 M 58 A UnRx 37.0 -10.4 6.94 0.82 n/a n/a 2001 UnRx
22 M 56 A UnRx 20.0 4.4 6.1 0.88 n/a n/a 2001 UnRx
23 M 60 B T 96.0 -4.6 -10.43 0.62 0.54 M 1993 Chi x3; PR
24 M 64j A UnRx 25.0 4 7 0.92 0.65 N-ID 2001 UnRx
25 M 86 A UnRx 31.0 10.23 12.62 1.73 n/a n/a 1999 UnRx
26 F 77 C T 65.4 0 -1.82 0.77 n/a n/a 1999 n/a
27 M 75 A UnRx 35.0 16.46 14.95 1.89 0.91 UM 1997 UnRx
28 M 71 A T 104.3 35.06 24.33 2.08 0.38 N-ID 1991 Chi; PR
29 M 81 C T 48.3 12.62 11.04 2.81 0.73 UM 2000 Chi x4
30 M 64 A T 22.9 17.95 -3.66 1.86 0.54 n/a 2001 Pred/C FM; Flu ;Ri1
31 M 71 C T 34.7 17.95 14.18 0.92 0.60 n/a 1999 Chi; Flu
32 M 69 A UnRx 44.1 17.21 2.66 0.78 0.60 M 1980 UnRx
33 M 69 C T 70.0 17.21 0 0.74 n/al M 1997 Chi; GR
34 M 62 B UnRx 53.1 10.23 0 0.64 0.57 n/a 1988 UnRx
35 F 71 B T 36.3 0 0.9 0.97 1.00 M 1998 Chl;Flu;Pred;Ritn
36 F 83 A UnRx 26.0 -1.81 6.1 0.52 0.52 M 1998 UnRx
37 M 65 A T 21.1 26.68 28.31 0.92 0.43 UM 1994 Chi x2
38 M 69 B T 70.4 -4.6 -15.48 0.49 0.54 M 2002 Chi
39 M 82 n/a UnRx 34.0 6.1 9.42 12 n/a n/a 2002 UnRx
40 M 79 B T 19.3 3.53 11.04 0.84 0.61 M 1996 Chi
41 M 77 C T 52.0 2.66 18.69 0.97 n/a n/a 1993 Chi
42 F 63 C T 40.6 8.6 -7.46 0.67 0.83 UM 1990 Chi x3
43 M 55 A UnRx 37.1 -9.41 -17.47 0.47 0.66 M 1995 UnRx
44 M 72 C T 50.0 11.94 15.07 1.42 1.30 UM 1994 Chi x6
45 F 62 A T 25.0 6.94 -14.45 0.54 0.58 N-ID 1998 Chi x2
46 M 79 A UnRx n/a -1.8 11.44 0.31 1.01 n/a 2002 UnRx
47 M 72 A UnRx 31.0 15.32 16.07 2.62 1.46 UM 2002 UnRx
48 M 53 B T 75.0 10.69 -35.71 1.51 0.68 M 2000 Chl;CFM;Flu
49 F 62 B T 27.3 6.94 -2.22 0.91 n/a n/a 1997 CFM
50 F 84 B T 100.0 8.59 1.43 0.96 1.43 n/a 1983 Chl;CFM;Flu
51 F 92 A UnRx 19.5 39.59 13.43 2.35 n/a n/a 1996 UnRx
52 F 84 C T 47.0 1.78 0 1.26 n/a n/a 1994 Chi
52 n/a 0 0 1.26
52 n/a 6.1 1.78 1
52 102.0 3.83 3.03 1.98
53 M 72 A UnRx 36.1 22.97 14.95 2.18 0.40 n/a 1999 UnRx
53 29.3 15.71 5.25 1.6
54 M 58 C T 29.8 16.46 8.6 1.41 n/a n/a n/a Chi
54 30.0 0 34.45 3.16
55 M 54 A UnRx 33.2 0 0 2.11 0.58 M 1999 UnRx
55 UnRx n/a 0.9 4.4 1.31 0.58 M 1999 UnRx
56 M 74 B T 135.6 30.22 32.07 3.13 n/a n/a 1998 Chl;Flu;CFM
56 79.0 34.47 27.66 3.31
57 F 77 B T 23.4 3.53 11.04 1.26 0.95 UM 1992 Chi
57 n/a 11.45 6.94 1.12
58 M 75 A UnRx 30.0 -3.66 7.78 1.13 0.79 UM 1998 UnRx
58 115.0 16.53 -24.06 1.6
59 M 72 A T 60.0 11.83 14.18 1.63 n/a n/a 1999
59 9.0 5.24 -15.48 1.03
60 M A UnRx 20.0 15.71 25.68 1.16 UM 1999 UnRx
60 62 42.0 15.71 9.42 2.17
60 n/a 11.04 33.88 1.14
61 M 93 A UnRx 64.3 11.83 15.71 0.77 0.71 M 2001 UnRx
61 n/a -3.19 -14.98 1.38
Key: n/a = data not available; UnRx = Untreated; T = Treated; M = Mutated; UM =
Unmutated; N-ID = No clone identified. Coloured entries denote a positive MDR result.
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3. MM Patient Data
Patient Age Sex ZHCL VPM |MRK16 %PC PP type PPg/l PIT Rx Resp
1 88 F 20.14 n/a 1.00 n/a n/a n/a P Melph GR
2 n/a F 6.10 n/a 1.07 n/a n/a n/a n/a n/a n/a
3 62 F 0.00 0.00 0.97 38 IgA/k 24 P CFM; Pred PR
4 51 M 6.10 8.60 1.13 22 IgG/k 16 P CFM; Pred NR
5 49 M 14.18 n/a 1.39 80 IqD/l n/a T Thai; Dexa PR
6 n/a M 0.00 n/a 0.99 n/a n/a n/a n/a n/a n/a
7 58 M 4.40 -1.81 1.02 6 IgG/k 53 P n/a Died
8 74 M 9.83 10.63 1.01 n/a IgG/k 23 P CPM; Pred PR
9 74 M 14.95 n/a 0.90 15 IgA/k 2 P Dexa Died
10 73 M 14.18 -13.42 1.12 40 IgG/k 28 P IDEX PR
11 71 M 6.1 3.53 1.08 4 n/a n/a T CFM; Dexa; Thai; Melp n/a
12 84 F 12.22 8.6 1.18 6 IgA/k 8 T Radio NR
13 74 M 18.09 26.34 1.23 17 IgG/k 46 P Melph; Pred PR
14 67 M -3.23 -14.46 0.92 6 k n/a T Radio; CIDEX PR
15 73 F 10.03 10.77 1.53 14 IgA/k 15 T CIDEX NR
16 65 M 6.94 -2.74 1.18 80 IgG/k 73 P CFM; Thai; CIDEX PR
16 -1.81 -10.4 1.09 46 IgG/k 73 T
Key: n/a = data not available; P = presentation; T = Treated; GR = Good 
Response; NR = No Response; PR = Partial Response; PP = paraprotein; PC = 
plasma cells; Melph = Melphalan; CFM = cyclophosphamide; Pred = 
Prednisolone; Thai = Thalidomide; Dexa = Dexamethasone; CIDEX = lomustine, 
idarubicin and dexamethasone. The coloured entries denote a positive MDR 
result.
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